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Chapter	1	
General	introduction	
 
Almost two billion people are currently anaemic globally. Most live in developing countries 
such as Kenya, where anaemia, iron deficiency, and malaria co-exist. Malaria infection and 
iron deficiency are the main causes of anaemia in malaria endemic regions of the 
world(Fleming, 1982)(Clara Menendez et al., 1997)(Schellenberg et al., 1999). Severe 
anaemia is increasingly recognized as an important manifestation of severe malaria in 
young children(Newton et al., 1997)(R. W. Snow et al., 1994). The global prevalence of 
anaemia among pregnant women is 41.8%(Peña-Rosas, De-Regil, Dowswell, & Viteri, 
2012).  
Malaria and anaemia remain inextricably linked with each other, and with poverty. 
Anaemia is an almost inevitable consequence of malarial infection(Roberts, Casals-Pascual, 
& Weatherall, 2005). The highest malaria and anaemia rates are seen in countries with the 
highest rates of extreme poverty. Pregnant women and children under five years are usually 
the highest risk group possibly because they have limited protective immunity.(Mor & 
Cardenas, 2010; Stirrat, 1994)  
Since the British doctor Ronald Ross received the 1902 Nobel Prize in medicine for his 
work in malaria, more people have died from malaria than all world wars and terrorist 
attacks combined. This is in spite of the fact that the French chemists Pierre Joseph Pelletier 
and Joseph Bienaimé Caventou made quinine available from as early as 1820. According to 
the WHO, there were about 219 million cases of malaria and an estimated 660,000 deaths 
in 2010. Africa is the most affected continent: approximately 80% of cases and 90% of 
deaths are estimated to occur in the WHO African Region. However, although 40% of the 
world population is exposed to malaria parasites, malaria mortality fell 26% worldwide 
between 2000 and 2010. In the WHO African Region, the decrease was 33%. (WHO; 
World Malaria Report, 2013) 
In the recent past, a lot of research has been directed towards understanding the biological 
question whether iron deficiency in the host is detrimental or beneficial. The question has 
been whether provision of iron to the host via the various intervention vehicles such as 
supplements, sprinkles, fortified foods etc. causes a harmful effect to the host or not e.g. by 
exacerbating malaria infection. In the Pemba study carried out by Sazawal et al (2006) in 
Zanzibar and involving more than 32,000 children, it was found that supplementation with 
iron and folic acid increased severe morbidity and mortality. Similar observations in 
malaria-prone developing countries were reported by others (Sazawal et al., 2006)(Smith, 
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Hendrickse, Harrison, Hayes, & Greenwood, 1989)(Metz, 2007). However, such an effect 
was not observed in developing countries that do not have high incidences of 
malaria(Tielsch et al., 2006)(Nacher et al., 2003). Current international guidelines on iron 
supplementation are faced with uncertainties due to the observed increase in morbidity and 
mortality rates especially in malaria endemic regions. 
There have been major efforts by the global health research community to solve the 
mystery of the Pemba study. The WHO and the United Nations Children’s Fund (UNICEF) 
released a joint statement in 2006 advising that in regions where the prevalence of malaria 
and other infectious diseases was high, iron and folic acid supplementation should only be 
administered to those who are anaemic, or who are at risk of becoming iron 
deficient(WHO/UNICEF, 2006). In 2007, the WHO convened a technical consultation 
group on prevention and control of iron deficiency in infants and young children in malaria 
endemic areas. It was determined that “universal iron supplementation should not be 
implemented without the screening of individuals for iron deficiency, because this mode of 
iron administration may cause severe adverse events in iron-sufficient children”(WHO, 
2007). The report emphasised the need to determine safe, effective, and sustainable 
methods to deliver iron.  
A 2009 Cochrane review of 40 trials, involving 12,706 women, on routine antenatal iron or 
combination of iron with folic acid found insufficient data to determine if routine daily or 
intermittent iron or iron-folic acid supplementation in pregnancy improves health outcomes 
for women and babies(Peña-rosas & Viteri, 2009).  This review was updated to compare 
the daily provision of iron supplements alone or in combination with folic acid or other 
micronutrients with no intervention, placebo or versus the use of the same supplements but 
without iron (e.g. only folic acid) among pregnant women living in a variety of settings, 
including malaria-endemic areas(WHO, 2012a),(Peña-Rosas et al., 2012). The updated 
review had among others, malaria as an outcome. Although the review found no evidence 
that iron supplementation increases placental malaria, the quality of evidence presented was 
judged as low because there were few trials that assessed effects on malaria, some of the 
trials had high levels of attrition, and in various studies the method of allocation 
concealment was unclear(Peña-Rosas et al., 2012). Based on the updated review, the WHO 
issued revised iron supplementation guidelines in 2012 aimed at directing global policy on 
interventions against anaemia especially in malaria endemic regions. 
However, iron supplementation in malaria endemic regions remains controversial among 
researchers, nutritionists, and programme implementers. The safety and efficacy of daily 
oral use of iron supplements by pregnant women, as a public health intervention is still not 
clearly established despite the efforts by the WHO. Although universal iron 
supplementation continues to be recommended for women during pregnancy and three 
months postpartum, recommendations that malaria surveillance, diagnosis, and treatment be 
ensured during implementation of these programmes have been difficult to implement in 
resource poor settings.	
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Iron 
Iron is essential for biological systems such as haematopoiesis, immune function, oxygen 
delivery, neurological function, and physical development. However, it also has a critical 
role in pathogens such as bacteria, viruses, fungi, and protozoa(Drakesmith & Prentice, 
2008). The body has a highly regulated system for iron transport and storage.(Dunn, Suryo 
Rahmanto, & Richardson, 2007) Benefits of iron interventions have been demonstrated 
widely.(Lozoff, n.d.; Clara Menendez et al., 1997, 2004; Richard et al., 2006)  
Erythrocytes carry most of the body’s iron. An adult human produces approximately 200 
billion erythrocytes per day to replace an equal number of cells that that reach the end of 
their life span. The body maintains the concentration of iron at about 40 mg iron/kg in 
women and about 50 mg iron/kg in men.(Brittenham, 2000) Humans are incapable of 
excreting excess iron thus they regulate the total iron in their body by controlling iron 
absorption in the gastrointestinal tract. If iron stores increase, absorption decreases and vice 
versa.(Bothwell, Charlton, Cook, & Finch, 1979) 
A term pregnancy and delivery results in a loss of 450 – 600 mg of iron (1,200 – 1500 mL 
of blood).(Bothwell et al., 1979) Pregnant women deposit 270mg of iron in the fetus while 
an additional 90 mg is contained in the cord and placenta. 150 mg of iron are lost during 
delivery and early post natal period.   
Iron deficiency is an imbalance in total body iron that results when the supply of iron is less 
than the body requirements and losses.(Brittenham, 2000) There are three stages of iron 
deficiency: storage iron depletion, early functional iron deficiency, and established 
functional iron deficiency. Iron deficiency may cause anaemia, impaired behavioural 
development, and decreased work capacity. If severe, iron deficiency causes increased 
mortality during pregnancy, and infancy. In addition, iron deficiency can lead to clinically 
significant immune deficiency and infections in children (Cunningham-Rundles et al., 
2005). 
Iron metabolism 
Human iron metabolism is the set of chemical reactions maintaining human homeostasis of 
iron. Ferritin and haemosiderin, which are found primarily in the liver, spleen, 
reticuloendothelial cells, and bone marrow, are the major iron-storage compounds in the 
body(Usha Ramakrishnan & Semba., 2008).  
Intracellular iron is spread over three different pools: 1) the functional pool, where it is 
bound mostly to haemoglobin; 2) the storage pool, where it is bound to ferritin; and 3) the 
regulatory pool, where iron regulating proteins IRP1 (iron regulatory protein) and IRP2 
regulate transcription and translation of iron binding proteins. Serum ferritin is a good 
indicator of iron status, although its expression is up-regulated by inflammatory cytokines 
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during periods of infection. Small amounts of iron are also found in plasma(Parveen Kumar 
& Clark., 1998).  
Iron is transported in the plasma bound to transferrin, a β–globulin that is synthesized in the 
liver. Human beings normally have 40 – 50mg Fe/kg body weight(Kraemer & 
Zimmermann, 2007). About two-thirds of the total body iron is in the circulation as 
haemoglobin. 
Absorption of iron from the diet 
Iron is absorbed in the duodenum by enterocytes of the duodenal lining and the jejunum. It 
must be in its ferrous (Fe2+) form in order to be absorbed. Heme iron transporter (HCP 1) 
transports heme iron, which undergoes endocytosis after which ferrous iron (Fe2+) is 
liberated within the endosome or lysosome. Non-heme iron includes ferrous and ferric iron 
salts (Fe3+). Ferric iron is reduced to ferrous iron by ascorbic acid in the lumen or by 
membrane ferrireductases that include duodenal cytochrome B (DCYTB)(McKie et al., 
2001). Transport of non-heme iron (which is now in ferrous form) from the intestinal lumen 
into the enterocytes is facilitated by the divalent metal ion transporter 1 (DMT 1) mainly 
because  the acid microclimate at the apical membrane provides an H+ electrochemical 
gradient that drives Fe2+ transport into the enterocytes(Gunshin et al., 1997). Once inside 
the enterocyte, iron that is not directly transferred to the circulation is stored as ferritin and 
is eventually lost when the cell is exfoliated at the villus tip. At the basolateral membrane, 
iron transport to transferrin in the circulation is mediated by ferroportin 1, in association 
with hephaestin. Hepcidin, which is produced by the liver, binds to ferroportin 1 causing its 
internalization and degradation and decreasing iron transfer into the blood(Nemeth et al., 
2004)(Nemeth & Ganz, 2006). It is regulated by iron levels and erythropoiesis. In turn, it 
regulates iron uptake by enterocytes and release of iron stores from macrophages and 
hepatocytes. Ferroportin 1 also mediates export of iron from other cells, including 
macrophages(Donovan et al., 2005). 
The regulation of ferroportin is the main way of regulating the amount of iron circulating in 
the body. This is because though DCYTB and DMT1 are unique to iron transport across the 
duodenum, ferroportin is distributed throughout the body on all cells that store iron. Iron 
deficiency and hypoxia stimulate duodenal expression of DMT1, DCYTB and ferroportin 
and thereby increase iron absorption(McKie et al., 2001)(Collins, Franck, Kowdley, & 
Ghishan, 2005).  
 
Senescent red blood cells are broken down by macrophages in the spleen, bone marrow, 
and liver. The iron extracted is returned to the circulation where it binds to transferrin. 
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Figure	 1:	 Regulation	 of	 intestinal	 iron	 uptake	 [Source:	 Zimmermann	 and	 Hurrell	
2007]	
	
Transferrin binds to specific transferrin receptors on erythroid precursors in the bone 
marrow. Iron deficiency increases iron transfer to the maximum by stimulating increased 
ferroportin expression on macrophages, hepatic synthesis of transferrin and expression of 
transferrin receptors in the bone marrow and other tissues. 
	
Reasons for iron deficiency 
1. High demand for iron beyond what the diet can supply 
2. Increased iron loss usually through loss of blood 
3. Nutritional deficiency 
4. Inability to absorb iron because of damage to the intestinal lining e.g. in case of 
celiac sprue which severely reduce absorption surface area 
5. Inflammation leading to hepcidin-induced restriction on iron release from 
enterocytes 
 
Regulation of intracellular iron homeostasis 
Hepcidin is the central regulator of iron homeostasis. It is a 25-amino-acid peptide hormone 
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produced by the liver. It regulates the export of iron from cells into plasma by controlling 
absorption from the intestine, export from macrophages, and release from body 
stores.(Nemeth & Ganz, 2006)(Ganz, 2007) This is done by controlling the entry of iron 
into plasma.  
 
An increase in hepcidin synthesis causes a subsequent decrease in plasma iron and 
intestinal iron absorption. Hepcidin synthesis is increased by iron loading, inflammation, 
and infection and decreased by iron deficiency, and ineffective erythropoiesis.  
 
Iron in circulation is tightly bound to transferrin. Body cells have receptors for transferrin–
iron complexes on their surfaces. These receptors engulf and internalize both the protein 
and the iron attached to it. Once inside, the cell transfers the iron to ferritin, the internal iron 
storage molecule. The level of serum ferritin in the body is directly proportional to the 
amount of stored iron in the body. It can be determined using enzyme-linked 
immunosorbent assays (ELISAs) or two site immunoradiometric assays(Gibson & RS, 
2005). 
 
Iron absorption is influenced by dietary iron content, bioavailability of dietary iron, the 
amount of storage iron and the rate of erythrocyte production(Kraemer & Zimmermann, 
2007). In developing countries, only 5% of dietary iron is normally absorbed from the 
average daily diet. Most of the iron in the body is obtained by recycling aged red blood 
cells in the reticuloendothelial system. Iron is lost through menstruation, sweat, urine, 
breast milk, shedding of skin cells and the mucosal lining of the gastrointestinal 
tract(Parveen Kumar & Clark., 1998). Thus people must continuously absorb iron. When 
iron loss exceeds iron absorption, the iron stores become depleted and the transferrin 
saturation in the blood then falls. If this drops to below 10%, then abnormal iron deficient 
erythropoiesis occur leading to microcytic anaemia. 
 
Iron and immunity 
Iron is intricately involved in both innate and adaptive immune responses to 
infection.(Weiss, 2002) Since almost all pathogenic microorganisms require iron for 
growth, the immediate response to infection is usually to withhold iron to invading 
pathogens. Increased hepcidin synthesis restricts delivery of iron to the plasma from 
macrophages, from intestinal absorption, and from hepatocyte stores.(Ward et al., 2011)  
 
Many of the genes and proteins involved in iron homoeostasis play a vital role in 
controlling iron fluxes such that bacteria are prevented from utilising iron for growth.(Ward 
et al., 2011) Cells of the innate immune system, monocytes, macrophages, microglia and 
lymphocytes, are able to combat bacterial attacks by carefully controlling their iron fluxes, 
which are mediated by hepcidin and ferroportin. A variety of effector molecules, e.g. toll-
like receptors, NF-kB, hypoxia factor-1, haem oxygenase, orchestrate the inflammatory 
response by mobilising a variety of cytokines, neurotrophic factors, chemokines, and 
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reactive oxygen and nitrogen species.(Ward et al., 2011) Imbalances in the host iron 
availability impair the host immune system.(Weiss, 2002)  
 
The virulence of many bacteria is enhanced through exposure to iron.(Ratledge & Dover, 
2000) Some bacteria acquire iron by secreting organic iron chelators called siderophores, 
by expressing surface receptors that interact with host iron-containing proteins, or both. 
 
Anaemia  
Anaemia is defined as a haemoglobin concentration below –2 standard deviations of the 
age- and sex-specific reference mean.(Usha Ramakrishnan & Semba., 2008) The cut-off 
values most commonly used to define anaemia are haemoglobin concentrations below 110 
g/L for children under 5 years old and pregnant women, below 120 g/L for non-pregnant 
adult women, and below 130 g/L for adult men. 
 
A WHO (2001) report outlined the main causes of anaemia as: dietary iron deficiency; 
infectious diseases such as malaria, hookworm infections, or schistosomiasis infections; 
deficiencies of key micronutrients such as folate, vitamin B12, or vitamin A; and inherited 
conditions that affect cell stability such as thalassaemia and sickle cell anaemia(WHO, 
2001). The three main exogenous causes of anaemia, namely disease, blood loss and diet 
(Thurnham & Northrop-Clewes, 2007), are shown in figure 2. 
 
Although there is great variation by region, young children and women of reproductive age 
are at greatest risk of anaemia, followed by the elderly and men. Anaemia may lead to: 
fatigue, headaches, faintness, breathlessness, angina of effort, intermittent limping due to 
weakness (claudication), palpitations, pallor (extreme paleness), tachycardia, systolic flow 
murmur, cardiac failure and rarely, papillo-edema and retinal haemorrhages after an acute 
bleed (Thurnham & Northrop-Clewes, 2007). 
 
Very severe anaemia (haemoglobin < 50 gm/L) is associated with increased childhood and 
maternal mortality (Allen, 1997). In areas where severe anaemia (haemoglobin < 80 gm/L) 
is common, iron deficiency is usually one of multiple causes of anaemia (Brooker et al., 
1999).	
 
Iron deficiency anaemia (IDA)  
Anaemia is the primary sign of iron deficiency(Kraemer & Zimmermann, 2007). Stored 
iron which is physiologically bound by ferritin molecules is usually almost entirely 
depleted before the development of IDA(Usha Ramakrishnan & Semba., 2008). The causes 
of IDA include: blood loss, increased demands such as growth and pregnancy, decreased 
absorption (e.g. postgastrectomy) and poor intake. IDA develops when there is inadequate 
iron for haemoglobin synthesis(Zimmermann & Hurrell, 2007). Normal levels of 
haemoglobin are maintained for as long as possible after the iron stores are depleted; latent 
iron deficiency is said to be present during this period.  
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response to oral iron may be due to lack of compliance, continuing haemorrhage, severe 
malabsorption or another cause of the anaemia e.g. malaria infection.  
 
Although not all anaemias are caused by iron deficiency, in areas where the prevalence of 
anaemia exceeds 30–40%, most anaemia is caused largely by iron deficiency. This 
assumption may not hold in regions such as sub-Saharan Africa, where conditions such as 
thalassemia and infections such as malaria are endemic. 
 
Anaemia caused by infectious diseases and inflammation 
The infectious diseases that significantly cause anaemia are malaria, tuberculosis (TB) and 
HIV/AIDS. They act either individually or in combination and are most serious in 
developing countries.  
 
Malaria frequently causes acquired haemolytic anaemia. The anaemia of malaria has 
several causes namely: rupture of parasitized red blood cells in tissue venules, destruction 
of parasitized and unparasitized red blood cells in the reticulo-endothelial system 
(especially the spleen), haemolysis due to the presence of malaria antigen, antibodies and 
marrow suppression(Anuraj H Shankar, 2008)(Graves & Gelband, 2006). In absence of 
treatment, this cycle of invasion and destruction of red blood cells is continuous thus 
making the person more anaemic.  
 
Blood transfusion is indicated when there is acute intravascular haemolysis and when the 
haemoglobin concentration falls below critical values. It is effective in severely ill patients 
especially when more than 20% of red blood cells are parasitized(Moxham, 1994). Malaria 
not only causes blood loss leading to haemolysis but also causes inflammation leading to 
reduced iron absorption and mobilization in the gut(Kanjaksha & Kinjalka, 2007). 
 
Inflammation accounts for a substantial percentage of anaemia especially in developing 
countries. The most common cause of iron deficiency anaemia worldwide is blood loss 
from the gastrointestinal tract resulting from hook worm infestation(Ong’echa et al., 2006). 
Studies from Zanzibar and Vietnam found that hookworm infestation can account for up to 
40% of the iron deficiency anaemia in highly endemic areas. In such settings, the potential 
impact of deworming can be justified as part of the anaemia control program. 
 
The current WHO Global Malaria Control strategy is focused on four goals (Semba  Martin 
W; Piot, Peter, 2008): 
1. Provide early diagnosis and prompt treatment, 
2. Plan and implement selective and sustainable preventive measures, including 
vector control,  
3. Provide early detection to contain or prevent epidemics, and  
4. Strengthen local capacities in basic/applied research to permit the regular	
assessment of a country’s malaria situation, in particular the ecological, social, and 
economic determinants of the disease. 
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Malaria 
Malaria is an acute febrile illness characterized clinically by attacks of chills, fever and 
sweating as a consequence of asexual reproduction by species of Plasmodium within the 
red blood cells (RBC). A mosquito of the genus Anopheles transmits malaria. 
 
There are approximately 515 million reported cases of malaria in the world per year, 
resulting in death of about 1-3 million people (R. Snow, Guerra, Noor, Myint, & Hay, 
2005). Community-based intervention studies  show that malaria may account for nearly 
half of the under-5 mortality in a large part of tropical Africa(B. M. Greenwood, 
1991)(Alonso et al., 1991). A report on the global burden of disease indicates that malaria 
is responsible for 18% of all childhood deaths, 94% of which are in Africa [7, 18, 19]. 
 
Malaria is caused by five Plasmodium species:  P. vivax, P. ovale, P. falciparum, P. 
malariae and P. knowlesi (Moxham, 1994). P. vivax, P. ovale and P. malariae are 
associated with morbidity but not major mortality while P. falciparum is associated with 
both morbidity and mortality (Graves P & H., 2006). P. knowlesi is a primate malaria 
parasite that is found in some locations in Southeast Asia. 
 
The significance of malaria is region-specific e.g. nearly 90% of life-threatening P. 
falciparum-related disease continues to be in Africa, with the remaining 10% occurs 
primarily in Southeast Asia and India, followed by South America(Guinovart C, Navia 
MM, Tanner, & Alonso, 2006) (Bruce-Chwatt, 1988) (Krogstad, 1996). Studies have 
shown that malaria alone or acting in interaction with other diseases such as anaemia 
increases morbidity and mortality in a region (Fleming, 1982) (Schellenberg et al., 1999). 
 
Clinical features and presentation 
Disease processes in malaria result from the erythrocytic cycle of invasion and haemolysis 
leading to a fever, which is due to the release of pyrogens during schizont rupture. Anaemia 
is usually present and is largely the result of haemolysis (Alonso et al., 2004). Hemolysis 
liberates merozoites and releases several pyrogenic compounds from infected red blood 
cells. Febrile paroxysms, anaemia, splenomegaly and hepatomegaly are all signs of malaria 
(Anuraj H Shankar, 2008).	
 
The parasite undergoes asexual reproduction in the human host and sexual reproduction in 
the mosquito. It is transmitted to humans as a sporozoite in the saliva of an infected female 
anopheline mosquito (Gardiner, Fayer, & Dubey, 1988). Sporozoites enter the venous 
circulation through the capillary beds and invade liver cells within minutes. Over the next 
5–15 days, the sporozoite replicates to produce about 40,000 daughter parasites, called 
merozoites. In the case of P. vivax and P. ovale, dormant forms known as hypnozoites 
sometimes develop in the liver cells, remaining viable for up to 50 years (Krotoski, Collins, 
& Bray, 1982). When released from liver cells, merozoites invade erythrocytes and 
subsequently differentiate into trophozoites, which consume intracellular haemoglobin and 
give rise to 6–24 daughter merozoites. The red cell eventually ruptures, releasing these 
merozoites to invade new erythrocytes and perpetuate the cycle (Parveen Kumar & Clark., 
1998) (Moxham, 1994) (Gardiner et al., 1988). 
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Figure	3:	Life	cycle	of	Plasmodium	(Source:	CDC	2006)	
	
Vivax, ovale and malariae parasites invade 1-2% of red blood cells at most. P. falciparum 
parasites can invade higher proportions of red blood cells, accounting for the severity of 
disease and high mortality. P. vivax and P. ovale form hypnozoites within liver cells, which 
may cause relapsing malaria up to 2 – 3 years after infection. P. falciparum parasites have 
no hypnozoite form and so the infection is cured when parasites are cleared from the blood 
by treatment. P. malariae parasites lack the hypnozoite stage but can cause reappearance of 
parasitaemia (parasites in peripheral red blood cells) up to 20 or more years after infection 
(Schwartz, 1992).  
 
The current WHO Global Malaria Control Strategy is being pursued through advances in 
malaria vaccine development and provision of insecticide treated bed nets (ITNs) and 
malaria treatment kits.  Several trials (Binka et al., 1996) (Nevill et al., 1996)(D’Alessandro 
et al., 1997) demonstrated that ITNs are very effective in reducing morbidity and mortality. 
Meta-analysis of these trials indicated overall reductions in malaria morbidity by 48% and 
mortality by 20–40% (Lengeler, Armstrong-Schellenberg, D’Alessandro, Binka, & Cattani, 
1998) (Lengeler, 1998). There is progress in the fight against malaria and it is projected to 
be the worlds’ least cause of death by the year 2030 (WHO, 2008) (United Nations, 2008). 
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Iron and malaria infection 
There are complex links between body iron status, iron supplementation and susceptibility 
to malaria and other infections. Malaria causes anaemia through suppression of 
erythropoiesis, increasing gross iron deficiency and causing mal-distribution of iron in the 
body (A M Prentice, Ghattas, Doherty, & Cox, 2007) 
 
The causes of anaemia in malaria are multifactorial. They include obligatory destruction of 
red cells at merogony, accelerated destruction of non-parasitised red cells (major 
contributor in anaemia of severe malaria), bone marrow dysfunction that can persist for 
weeks, shortened red cell survival and increased splenic clearance. Massive gastrointestinal 
haemorrhage can also contribute to the anaemia of malaria.  
 
According to Prentice et al (2007), malaria-induced destruction of infected and non-
infected red blood cells both stresses and impedes the capacity of reticuloendothelial 
macrophages to recycle iron back to the bone marrow. Intravascular rupture of parasitized 
red cells, macrophagal phagocytosis of both parasitized and unparasitized red cells, and 
hypersplenism all contribute to the pathophysiology of the anaemia associated particularly 
with acute malaria (A M Prentice et al., 2007).  
 
Iron can be sequestered and trapped in reticuloendothelial macrophages as a result of both 
chronic and acute malaria and can present a picture of iron-deficient erythropoiesis 
associated with normal or increased bone marrow iron (A M Prentice et al., 2007). 
 
Observational studies linking iron status and malaria 
Early studies in famine environments showed that malaria increased when iron rich diets 
were introduced (Murray, Murray, Murray, & Murray, 1978)(Murray, Murray, Murray, & 
Murray, 1975). Since then, the association between iron status and susceptibility to malaria 
in moderately malnourished populations has been investigated in various observational 
settings. 
 
High serum ferritin was shown to be associated with high susceptibility to malaria (R. W. 
Snow et al., 1991)(Alice M. Nyakeriga  Jeffrey R. Dorfman, Neal D. Alexander, Rune 
Back, Moses Kortok, Alex K. Chemtai, Kevin Marsh, Thomas N. Williams et al., 2004). 
These studies present a conflicting picture in which higher iron status was associated 
positively (R. W. Snow et al., 1991)(Inocent et al., 2008)(Alice M. Nyakeriga  Jeffrey R. 
Dorfman, Neal D. Alexander, Rune Back, Moses Kortok, Alex K. Chemtai, Kevin Marsh, 
Thomas N. Williams et al., 2004)(S J Oppenheimer, Macfarlane, Moody, Bunari, & 
Hendrickse, 1986), negatively (Shipton, 2004), or neutrally to risk of malaria. 
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Table 1: Observational studies linking iron status and malaria 
Source Study design Findings 
Oppenheimer et al. 
1986 
(S J Oppenheimer & 
Cashin, 1986) 
 
 
 
 
Snow et al. 1991 
(R. W. Snow, Byass, 
Shenton, & 
Greenwood, 1991) 
 
 
 
 
Nyakeriga et al. 2004 
(Alice M. 
Nyakeriga  Jeffrey R. 
Dorfman, Neal D. 
Alexander, Rune 
Back, Moses Kortok, 
Alex K. Chemtai, 
Kevin Marsh, Thomas 
N. Williams et al., 
2004) 
 
 
Inocent et al. 2008 
(Inocent, Marceline, 
Bertrand, & Honore, 
2008) 
Birth–12 mo, 
subanalysis of placebo 
group of a trial of 
intramuscular iron 
dextran, Papua New 
Guinea,  
n = 212 
 
1–8 yr, observational 
study of premalaria 
season iron status and 
subsequent malaria 
morbidity, Gambia, 
n = 317 
 
 
8 mo–8 yr, 2 cross-
sectional surveys, 
Kenya, 
 n = 234 
 
 
 
 
 
 
 
 
(0 – 60 months), 
prospective,  n=163 
Infants with Hb > 13.7 g/dL and Hb > 15.7 
g/dL at birth were 2–3 times more likely to 
have a malaria-positive slide at 12 mo* (This 
population has high rates of  single deletion 
α-thalassemia, which causes anaemia and 
protects against malaria and is therefore a 
potential confounder) 
 
Susceptibility to malaria was not correlated 
with preseason serum iron, serum iron-
binding capacity, or serum ferritin. 
Children who had a clinical attack of malaria 
with high levels of parasitaemia tended to 
have higher mean serum ferritin levels at 
baseline* 
 
Incidence of clinical malaria was lower in 
iron-deficient children (IRR = 0.7)* 
IRR of malaria was associated with plasma 
ferritin* Iron status markers were associated 
with malaria- specific IgGs* No difference in 
parasite density in patients with incident 
malaria between iron-deficient and non-iron-
deficient groups 
 
 
 
 
41.7% and 63.2% of malaria patients were 
serum iron and Hb deficient respectively. 
The rates of SI, TS, Hb, HTC, MCV and 
MCH were significantly lower in malarial 
than in controls (P<0.01). Malaria negatively 
affects iron status. 
IRR, incidence-rate ratio; IgG, immunoglobulin; TS, Transferrin saturation; SI, Serum iron; 
HTC, haematocrit; MCH, mean cell haemoglobin. *Significant differences, as reported by 
the authors. 
	
Effect of iron supplementation on malaria infection 
Iron supplementation is widely used in efforts to prevent anaemia. Increases in adverse 
malarial outcomes have been seen in studies of intramuscular (S J Oppenheimer, Gibson, et 
al., 1986) and parenteral (Byles & Dsa, 1970) iron administration. 
 
Studies in East Africa (Murray et al., 1978) (Murray et al., 1975) (Keusch & Farthing, 
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1986) have provided evidence that there is an increased risk of serious infections (e.g. 
malaria and tuberculosis) when iron supplements are given to humans. These reports have 
been supported by research on animals (Keusch & Farthing, 1986). Other studies, however, 
report non-significant effects of iron supplementation on malaria outcomes (Berger et al., 
2000) (M. R. Desai et al., 2003)(Nwanyanwu et al., 1996) (Verhoef et al., 2002). Various 
authors have carried out meta-analyses and reviews of studies on the effect of iron 
supplementation on malaria infection. From the reviews, mixed observations are seen on 
the effect of iron supplementation on malaria infection and though the meta-analysis by the 
different authors has used different randomised controlled trials to a large extent, their 
conclusions are consistent. 
 
Of 15 studies reviewed by Prentice et al, (2007), six showed no effect of iron supplements 
on malaria risk, three found an increased frequency of malaria attacks in the iron-
supplemented groups and six found non-significant increases in malaria rates. It is 
important to note that all but one of the studies that found non-significant increases in 
malaria outcomes provided access to health care facilities or active follow-up and treatment 
of malaria incident cases. The detrimental effects of iron supplementation may have been 
curtailed by concurrent effective treatment of malaria infections (Andrew M Prentice, 
2008). Studies of iron supplementation of populations of anaemic children in malarious 
areas have reported both an improved haemoglobin response and decreased prevalence of 
severe anaemia(Clara Menendez et al., 1997) (M. R. Desai et al., 2003) (Verhoef et al., 
2002) (Massaga et al., 2003). In their study in Kenya, Verhoef et al (2002) showed that iron 
supplementation (twice a week at 6 mg per kg bodyweight) gives substantial health benefits 
that may outweigh the associated risk of adverse effects caused by malaria (Verhoef et al., 
2002). 
	
Table 2: Effect of iron supplementation on malaria infection 
First author Study design Findings 
Shankar A.H. 
(A H Shankar, 
2000) 
 
 
 
 
 
 
Oppenheimer S.T. 
(Stephen J 
Oppenheimer, 2001) 
 
 
Meta-analysis of 13 
RCTs of the effect of 
iron supplementation 
on malaria and iron 
status 
 
 
 
 
Review of controlled 
intervention studies 
of iron 
supplementation 
 
RR for clinical malaria attack = 1.1 (NS) 
RR for slide positive for Plasmodium 
falciparum = 1.17* 
Absolute increase in infection rate = 
5.7% (NS) 
RR for spleen enlargement = 1.12 (NS) 
Mean increase in Hb = 1.25 g/dL 
RR for anaemia = 0.5* 
 
Oral iron therapy increased clinical 
malaria in 5 out of 9 studies 
No studies of iron therapy in malarious 
areas showed benefits on infectious 
morbidity 
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Gera T. 
(Gera & Sachdev, 
2002) 
 
 
 
 
 
 
 
 
 
Prentice A.M. 
(A M Prentice et al., 
2007) 
 
 
Systematic review of 
28 RCTs of the effect 
of iron 
supplementation or 
fortification in 
children on infectious 
illness including 
8 studies of the effect 
of iron 
supplementation on 
malaria) 
 
Review of 15 RCTs 
of iron 
supplementation in 
children 
Does not report on effect on iron status 
 
Pooled OR for malaria-positive smear = 
1.43,* but OR when adjusted for baseline 
malaria smear = 1.24 (NS)  
(The treatment effect increased by 2.89 
times per unit increase in baseline 
malaria positivity; this supports the 
argument that iron supplementation of 
children with pre-existing malaria 
increases their risk of remaining malaria 
positive) 
 
 
Three trials show significant increase in 
malaria 
Six trials show non – significant increase 
Six trials show neutral findings 
* Significant differences, as reported by the authors. 
RCT, randomized, controlled trial; RR, relative risk; NS, not significant; haemoglobin, Hb; 
OR, odds ratio. 
	
In the Pemba study, children aged 1-35 months were assigned to daily oral supplementation 
with: iron (12.5 mg) and folic acid (50 μg), iron, folic acid and zinc, or placebo. The 
primary endpoints were all-cause mortality and admission to hospital. Those who received 
iron and folic acid with or without zinc were 12% (95% CI 2-23, p=0.02) more likely to die 
or need treatment in hospital for an adverse event and 11% (1-23%, p=0.03) more likely to 
be admitted to hospital. There were also 15% (-7 to 41, p=0.19) more deaths in these 
groups (Sazawal et al., 2006). The results of the Pemba study raised new concerns about 
possible serious side effects of iron supplementation in populations where the aetiology of 
anaemia is not solely attributable to iron deficiency. However, since the design of the study 
was such that there was not a group that received iron without folic acid, it was not possible 
to attribute the deleterious effect of the supplement to one or another of the components 
(Sazawal et al., 2006). Iron supplementation is now advised to be withheld until the malaria 
treatment schedule is complete, both because iron may inhibit treatment and because the 
absorption of oral iron is blocked by the inflammatory response (A M Prentice et al., 2007). 
 
There is a need to elucidate our understanding of the interactions between iron 
supplementation and infections. There is evidence to suggest that the apparent detrimental 
effect of iron supplementation may vary according to levels of antecedent iron status, the 
presence of genetic haemoglobin disorders and glucose-6-phosphate dehydrogenase 
(G6PD) deficiency, and other host genetic variants, such as haptoglobin polymorphisms (A 
M Prentice et al., 2007). 
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Effect of malaria on folate status 
Malaria infection may induce folate deficiency especially in areas where both malaria and 
malnutrition are endemic. In Nigeria, serum folate concentration fell more rapidly during 
pregnancy in women not receiving antimalarial prophylaxis than in women protected 
against malaria (Fleming, Hendrickse, & Allan, 1968). In another study, Fleming, (1981) 
found that protection against malaria alone largely prevented severe anaemia in pregnancy 
even without addition of folate supplements (Fleming, 1981). American marines in 
Vietnam showed folate-deficient megaloblastic anaemia associated with P. falciparum and 
P. vivax malaria (Strickland & Kostinas, 1970).   The cause of the folate deficiency is 
multifactorial and it includes inadequate intake, malabsorption, haemolysis and use of 
antimalarial drugs. It is thus difficult to determine the role of malaria infection in the 
genesis of folate deficiency.  
 
Iron, folate and vitamin B12 have important roles in erythropoiesis. The majority of 
nutrition-related anaemias can be attributed to deficiency of one of these nutrients 
(Hoffbrand & Herbert, 1999). Iron requirements of erythroid cells during haemoglobin 
synthesis are much greater than that of all other cell types. In addition, folate and vitamin 
B12 are both required for the extensive DNA synthesis that accompanies the production of 
hundreds of billions of new erythrocytes each day. 
 
Iron loss and/or deficiency will cause anaemia especially because of retarded RBC 
production rates characterized by smaller, less haemoglobinised erythrocytes (Bohnsack & 
Hirschi, 2004). In iron deficiency, decreased synthesis of heme results in decreased protein 
translation, especially of globins. This decreased protein translation in the iron-deficient 
erythroid cells results in impaired reticulocyte production and smaller, less 
haemoglobinised reticulocytes, leading to microcytic anaemia. During folate-deficient 
erythropoiesis, the folate-deficient erythroblasts surviving to the late stages produce fewer 
but larger reticulocytes, leading to macrocytic anaemia. The resultant anaemia induces EPO 
production, which decreases the apoptosis in the EPO-dependent cells relative to normal 
erythropoiesis. Erythroblasts require folate and vitamin B12 for proliferation during their 
differentiation. The deficiency of folate or vitamin B12 will inhibit purine and thymidylate 
syntheses, impair DNA synthesis and cause erythroblast apoptosis. This can result in 
anaemia due to ineffective erythropoiesis.  
 
Folic acid is frequently prescribed for children with malaria, on the grounds that nutritional 
folate deficiency may compromise the enhanced erythropoiesis required to restore 
haemoglobin after an episode of haemolytic anaemia (Hensbroek et al., 1995). 
 
Although some studies have supported the findings of the Pemba study (Smith et al., 1989) 
(Metz, 2007), developing countries that do not have high incidences of malaria did not 
observe the same findings (Tielsch et al., 2006) (Nacher et al., 2003). It is thus possible that 
there are interactions between iron, folate and malaria infection. However, malarial 
anaemia is responsible for the greatest amount of malaria-related morbidity and mortality 
(“WHO expert committee on malaria,” 2000) and is the most common type of anaemia in 
infants in highly endemic areas (Clara Menendez et al., 1997) (Abdulla et al., 2001). 
 
The Improved Nutrition through Staple foods for Africa (INSTAPA
The studies presented in this thesis were undertaken as part of the INSTAPA project 
(www.instapa.org). This project was financed by the 7
European Commission. Research scientists from Europe, Africa, and the United States of 
America undertook joint research in an endeavour to break the vicious cycle of poverty, 
malnutrition, and mortality currently afflicting Afri
 
The project planners recognized that poor nutritional status and limited financial resources 
often compromise individual welfare in the developing world. In combination with a 
commonly high concurrent disease load, a self
and mortality arises. This is illustrated in the figure below.
	
Figure 4:
www.instapa.org
 
 The vicious cycle of poverty, malnutrition, and poverty (adapted from
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The nutritional quality of diets in developing countries in terms of micronutrient adequacy 
was identified as a major source of ‘fuel’ for the cycle above. About one-quarter of the 
world’s population is anaemic, mainly due to iron deficiency. Because iron and zinc are 
found in many of the same foods, high rates of iron deficiency in sub-Saharan Africa 
suggest widespread occurrence of zinc deficiency in the same populations. Vitamin A 
deficiency affects an estimated 127 million preschool-age children and 7 million pregnant 
women. Approximately every third child with vitamin A deficiency lives in sub-Saharan 
Africa. The major causes of these micronutrient deficiencies comprise low intake due to 
food scarcity, unavailability of micronutrient-rich foods, poverty, or poor dietary habits; 
high demands that arise from growth spurts during infancy and adolescence, pregnancy, or 
increased blood loss as occurs with pronounced menstruation or infestation from parasites; 
and low bioavailability. 
 
The vision of the INSTAPA consortium was to improve the dietary quality of most of the 
highly consumed foods in Africa. This would result in long-term health effects, which 
would be a major step towards the realization of the Millennium Development Goals 
(MDGs), set for 2015. It was decided that ways to improve the micronutrient content of the 
major staple foods in Africa would be investigated. The identified staple foods were millet, 
sorghum, maize, and cassava.  
 
The target groups of the interventions within the consortium were women and children as 
these groups comprise the most vulnerable populations in African societies. The consortium 
focussed on three micronutrients; iron, zinc, and vitamin A. Various strategies aimed at 
boosting the micronutrient content of the identified foods with iron, zinc and vitamin A 
were investigated. This included interventions during cultivation, harvesting or post-harvest 
processing e.g. bio-fortification and post-harvest fortification. 
 
The specific objectives of the INSTAPA project were: 
1. To evaluate the genetic potential of cassava, maize, millet, and sorghum for 
increased content of provitamin A, iron and zinc and for reduced content of anti-
nutrients  
2. To determine the efficacy of fortified and biofortified cereal-based foods on 
nutritional status and health  
3. To develop improved (traditional) processing methods of millet, sorghum and 
maize enhancing iron, zinc and vitamin A bioavailability and/or reducing 
inhibitory effects of anti-nutrient factors for improvement of micronutrient status 
of young children and women  
4. To determine the safety and efficacy of iron-fortified maize to alleviate anaemia in 
malaria-endemic areas in sub-Saharan Africa  
5. To determine the effect of maize-based complementary foods fortified with iron 
and zinc on cognitive and psychomotor development of young children  
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The strategic objectives of the project were: 
1. To contribute significantly to the improvement of the dietary quality of very young 
children living in resource poor areas of developing countries resulting in long-
term health effects and a major step towards the Millennium Development Goals 
set for 2015 
2. To establish an international leading role of the consortium in the fields of 
biofortification, fortification and processing to increase the supply of bioavailable 
micronutrients from African staple foods by bringing together scientific and 
technological excellence 
3. Capacity building in knowledge and skills to solve micronutrient deficiencies in 
sub-Saharan Africa and Europe  
4. Communication within and beyond the consortium regarding the ethical and 
scientific issues of concern to the agricultural and health sectors as well as 
consumers, enabling African populations to define and choose diets for optimal 
health for their children. 
In order to design suitable interventions to the identified issues, the INSTAPA consortium 
adopted a simple yet robust approach. Seven work packages comprising of one or more 
partners were tasked with specific objectives aimed at delivering a set of outcomes. These 
were: 
1. Work package 1: Management and coordination of all other work packages 
2. Work package 2: Bio-fortification  
3. Work package 3: Post-harvest fortification 
4. Work package 4: Post-harvest processing  
5. Work package 5: Safety of food-based interventions (tasked with implementing 
the prenatal iron and malaria study – this thesis) 
6. Work package 6: Cognitive development 
7. Work package 7: Capacity building and dissemination  
 
The project framework was complex and the participating partners (research institutions) 
were many. Below is the list of all the partners (partners who were tasked with WP5 are in 
bold). 
1. Wageningen University (WU), Netherlands 
2. Swiss Federal Institute of Technology (ETH), Switzerland 
3. Institut de Recherche pour le Développement (IRD), France 
4. London School of Hygiene and Tropical Medicine (LSHTM), UK 
5. University of Kwazulu-Natal (UNSA), South-Africa 
6. Université d'Abomey Calavi (UAC), Benin 
7. International Crops Research Institute for the Semi-Arid Tropics (ICRISAT), Mali 
8. University of Nairobi (UNK), Kenya  
9. Centre National de la Recherche Scientifique et Technologique (DTA), Burkina 
Faso 
10. International Food Policy Research Institute / Harvest Plus (IFPRI/HP), USA 
11. International Institute for Tropical Agriculture (IITA), Nigeria 
12. Maseno University (MU), Kenya – was later seconded to WP5 but was not in the 
initial list of partners. 
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Aims and outline of the thesis 
The long-term aim of this study was to improve the health of pregnant women through iron 
interventions that are safe and efficacious. The new flour fortification legislation in Kenya 
now ensures that pregnant women receive iron through a combination of fortified foods and 
universal iron supplementation. In view of the findings of the Pemba trial, the current study 
aimed to assess whether the iron intake resulting from this policy is safe. We hypothesized 
that flour fortification alone would reduce the risk of Plasmodium infection in pregnant 
women as compared to combined supplementation and flour fortification. 
 
The general objective of the study was to assess the effects of combined fortification of 
whole meal maize flour with iron (NaFeEDTA) and iron supplementation on safety 
indicators, and on iron status, in pregnant women. 
 
The specific objectives were as follows: 
1. To compare the presence of malarial infection in parturient women who received a 
combination of iron-fortified foods with iron supplements versus iron-fortified foods 
only; (chapter 2) 
2. To assess intervention effects on the maternal prevalence of iron deficiency anaemia at 
1 month after delivery; (chapter 2) 
3. To assess intervention effects on neonatal iron stores at 1 month of age; (chapter 2) 
4. To assess the diagnostic utility of Zinc protoporphyrin in diagnosing iron deficiency in 
malaria endemic regions; (chapter 3) 
5. To identify baseline factors that are prognostic for the NTBI response to consumption 
of a single iron supplement; (chapter 4) 
6. To determine the factors that predict Plasmodium infection in pregnancy; (chapter 5) 
7. To identify factors associated with birth weight; (chapter 6) 
8. To to develop a methodology to predict cases of low birth weight, using a single 
prognostic score that is based on prognostic variables collected at the second trimester 
of pregnancy; (chapter 6) 
9. To develop methods for community-based flour fortification with iron;  
10. To assess intervention effects on maternal intestinal pathogens at 1 month after 
delivery. 
 
We conducted a pilot survey prior to the start of the fieldwork. This was aimed at testing 
key laboratory protocols and procedures, developing skills in collecting maternal placental 
blood, and preparing for the trial by fostering participation with local health facilities and 
research institutions. On pre-specified days of the pilot survey, parturient women with 
uncomplicated pregnancies delivering in Siaya District Hospital, Kenya, were selected 
consecutively. For all women who provided written consent (n=33), samples of cord blood 
(6 mL) were obtained after careful cleaning and by direct sampling from the umbilical vein. 
Immediately upon expulsion of the placenta, we collected (maternal) placental blood by 
puncturing the intervillous space. In addition, placental biopsies were sectioned from near 
to the centre of each placenta, adjacent to the basal plate (Bulmer, Rasheed, Francis, 
Morrison, & Greenwoods, 1993; Bulmer, Rasheed, Morrison, Francis, & Greenwoods, 
1993). These were stored in paraformaldehyde for future histological examination of tissue 
sections to detect 
development and testing of operational processes, our sample size was chosen arbitrarily, 
and a formal analysis of data was not carried out.
 
Study area and population characteristics
The fieldwork was c
province, South
shows the study area.
	
Figure 
within map; the red square on the map of Kenya shows the study area). The red place marks 
show the coordinates of the homes of study participants.  GPS data visualized at 
www.GPSVisuali
	
The area consists mainly of poor subsistence farmers. The total population based on the 
study census conducted in April 2010 was 12,202 people. According to the Kenya 
Integrated Household Budget Survey (KIHBS
(CBS, 2007). The diet of the people in the study area is mostly based on maize and has a 
low content of animal products. Maize is normally milled in the local posho (hammer) mills 
and it may be pre
living along Lake Victoria are engaged in fishing, fish is prohibitively expensive and thus 
not normally consumed in large quantities by the local community. 
 
The prevalence of anaemia in the area is high
5: Map of study area 
-West Kisumu, which is located 1350 meters above sea level. Figure 6 
zer.com
-blended with millet,
Plasmodium
onducted from September 2011 to April 2013 in Kenya, Nyanza 
 
. Map courtesy of Google ©2013.
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schistosomiasis is common (Samuels et al., 2012). Furthermore, malaria is highly endemic 
and transmission is perennial and intense, with seasonal peaks occurring during the long 
and short rains. The mean annual rainfall ranges from 800 to 1600 mm and shows a 
bimodal pattern with long rains from March to June and short rains from October to 
December. The average temperature is 26°C and the relative humidity range is between 60 
and 80%. A person living in this area is normally exposed to between 30 and 100 infectious 
mosquito bites per year (A. Noor et al., 2009), although this rate is reducing (A. Noor et al., 
2009) (Ministry of Public Health and Sanitation (MOPHS) & Ministry of Medical Services, 
2010). 
 
There are only two health centres in the area: Ober Kamoth health centre (0°6’53.197’’N, 
34°36’34.077’’E) and Rota dispensary (0°5’34.386’’N, 34°40’24.604’’E). Although either 
can offer maternal and child health care, antenatal care, immunization, and family planning 
services, only Ober Kamoth offered maternity services thus it was chosen as the study site. 
 
Study design 
The study was a double blind, randomised, placebo-controlled intervention trial with two 
parallel groups. The study was primarily designed as an explanatory trial i.e. it aimed at 
measuring potential effects when iron is administered under optimal, controlled conditions. 
The study population was relatively homogeneous, and the primary analysis was chiefly per 
protocol. To increase the relevance of trial findings for policy decisions, the interventions 
were provided under conditions of normal health care. 
 
Within or close to the study area, the prevalence of malarial infection in parturient women 
has been extensively measured (Ayisi et al., 2003; Parise et al., 2003; A M van Eijk et al., 
2004) (Parise et al., 2003) (Anna M Van Eijk et al., 2002; A M van Eijk et al., 2004, 2007; 
Anna M van Eijk et al., 2002, 2003, 2004). These studies guided sample size calculations of 
our study. 
 
Pregnant women with a gestational age of 16-23 weeks (n=470) received fortified flour and 
were randomly allocated to daily supplements with iron or placebo. Flour was fortified to a 
target level of 20 mg iron as NaFeEDTA per kg flour (FFI & report, 2008) (WHO et al., 
2009). The study (www.ClinicalTrials.gov: NCT01308112) received ethical clearance in 
Kenya and the UK. Written informed consent was sought from all study participants. 
 
Pregnant women were recruited from communities in the study area. In a census that we 
conducted in the study area, we established that there were 2,806 women of childbearing 
age (15 – 45 years). According to the Kenya Demographic and Health Survey (KDHS) 
2008-2009, fewer than 5% of women in this area make their first visit to an antenatal clinic 
in the first trimester of pregnancy (Kenya National Bureau of Statistics (KNBS) & ICF 
Macro, 2010). Elaborate methods to detect early pregnancies, before or at 20 weeks of 
gestation, were thus developed and deployed (see Annex II). Women within the study 
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communities were asked to report to the research clinic when having missed their monthly 
period twice consecutively, or when otherwise suspecting that they were pregnant. In 
addition, locally trained community health workers visited each homestead monthly to 
detect pregnancies early.  
 
Methods used to detect pregnancies included direct observation and questioning of possible 
cases, urine testing, and ultrasonography. Married women of reproductive age (15 – 45 
years) were questioned about the date of their last menstrual period. Unmarried women of 
reproductive age were requested to present themselves at the research clinic for a free 
urine-based pregnancy test (Clearblue, Unipath Ltd., Bedford, UK) once every three 
months. The date of the last menstrual period (married women) and the outcome of the 
pregnancy test (unmarried women) was entered into a pre-designed pregnancy detection 
database, which contained the area population data. For married women, the database 
automatically compared the new menstrual date with the previous menstrual date and 
calculated the elapsed period. If suspected pregnant, the entry would be highlighted and a 
community health worker would be sent to request the woman to come for a free pregnancy 
test. For all pregnant women, gestational age was established by obstetric ultrasound 
(Aloka SSD-900 ultrasound system®, Hitachi Aloka Medical Ltd., Reeuwijk, Netherlands).  
The study clinicians handled the reproductive health information of all the women 
confidentially. 
 
Women who were suspected pregnant were requested to give written informed consent for 
screening. A study questionnaire was then administered and medical examination carried 
out. Ultrasonography was carried out to confirm pregnancy, establish gestation age, and to 
establish whether the pregnancy was singleton, multiple etc. Homestead consent was sought 
from the participant’s homestead members. The head of the homestead and women of 
childbearing age living in the homestead were invited for a group meeting, where field staff 
informed them of the study goals, objectives and procedures. They were asked to consent to 
fortification of their grain with iron. The head of the homestead signed the consent forms 
on behalf of the homestead members. A homestead was excluded if written consent was not 
given or if the pregnant woman was found ineligible due to other reasons.  
 
To prevent severe anaemia, all women received chemotherapy for infections by 
Schistosoma spp. (praziquantel) and geohelminths (albendazole) at a gestation age of 13 to 
20 weeks and as per recommendations of the WHO (WHO, 2002) (WHO/FAO, 2006) . 
Written informed consent for HIV testing was sought from all the pregnant women on the 
second visit to the research clinic. 
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Chapter	2	
Antenatal	iron	supplementation	and	
Plasmodium	infection	in	Kenyan	
women:	a	randomised	trial	1	
Abstract 
Background: Whereas coverage of antenatal iron supplementation is low and benefits are 
uncertain, there is evidence that it can increase the burden of malaria. We aimed to measure 
the effect of iron supplementation during pregnancy on maternal Plasmodium infection 
assessed at delivery, birthweight, gestational duration, fetal growth and maternal and infant 
iron status. 
Methods: 470 rural Kenyan women with singleton pregnancies, gestational age 13─23 
weeks and hemoglobin concentration ≥90g/L were randomized to supervised daily 
supplementation with iron (60mg as ferrous fumarate) or placebo until 1 month postpartum. 
To prevent severe anemia, both groups additionally received 5.7mg iron/day through flour 
fortification. Intermittent preventive treatment against malaria was given as usual. 
Plasmodium infection was assessed at birth by dipstick tests, PCR and histological 
examination of placental biopsies. 
Results: We found no effect on Plasmodium infection risk (both intervention groups: 45%; 
difference, 95%CI: 0%, ─9% to 9%). Iron supplementation increased birthweight by 143g 
(95%CI: 58─228g) and reduced the prevalence of low birthweight (<2,500g) by 65% 
(95%CI: 13%─86%). The effect on birthweight was restricted to a prespecified group of 
women who were initially iron-deficient (250g; p-interaction=0.008), and seemed achieved 
mostly through better fetal growth. Iron supplementation resulted in improved maternal 
iron status at 1 month postpartum, and enhanced neonatal iron stores. 
Conclusions: In a mixed population that included women with anemia and iron deficiency 
at baseline, iron supplementation produced major gains in birth weight, with no apparent 
effect on Plasmodium infection. Coverage of universal antenatal iron supplementation must 
be increased. 
                                                           
Submitted for publication 
Chapter	2	
40 
Introduction 
Although the World Health Organization (WHO) has recommended universal iron 
supplementation throughout pregnancy since 1959 (WHO, 1959), its delivery and 
adherence have been notably poor in developing countries. (Galloway & McGuire, 
1994),(Mason, Lotfi, Dalmiya, Sethuraman, & Deitchler, 2001) Based on the association 
between anaemia and maternal mortality, iron deficiency in pregnancy has been estimated 
to cause 591,000 perinatal deaths and 115,000 maternal deaths worldwide. (Stoltzfus RJ, 
Mullany, & Black, 2004) These estimates were based on observational data, however, and 
attribution of causality is problematic because women who are anaemic are also likely to 
suffer from other disorders that cause maternal and perinatal deaths. A meta-analysis of 
randomised trials found no evidence of benefits of iron supplementation in terms of reduced 
adverse maternal and neonatal outcomes (low birth weight, delayed development, preterm 
birth, infection, postpartum haemorrhage). (Peña-rosas & Viteri, 2009) 
Added to these uncertainties, a randomised trial among children (Sazawal et al., 2006) 
reinforced earlier concerns that iron interventions can increase rates of malaria and other 
infectious diseases. (Stephen J Oppenheimer, 2001) In response to this trial, a WHO expert 
group recommended against universal iron supplementation in children living in malaria-
endemic areas, (WHO, 2004), (WHO, 2007) but antenatal iron supplementation continues 
to be recommended, despite reports from observational studies that iron deficiency is 
associated with protection against Plasmodium infection in placental blood.(Kabyemela, 
Fried, Kurtis, Mutabingwa, & Duffy, 2008), (Danquah, Bedu-Addo, & Mockenhaupt, 
2008), (Edward L Senga, Harper, Koshy, Kazembe, & Brabin, 2011) In a randomised trial, 
iron supplementation was not accompanied by increased susceptibility to Plasmodium 
infection in Gambian women; (C. Menendez et al., 1994) however, participation was 
restricted to multigravidae and the study design had several limitations. (Peña-rosas & 
Viteri, 2009) 
We aimed to measure the effect of daily supplementation with iron during pregnancy on 
maternal Plasmodium infection assessed at delivery. We anticipated that this effect may be 
influenced by iron status, gravidity, age and HIV infection at baseline. We also assessed 
intervention effects on birth weight, gestational duration and fetal growth at delivery, and 
maternal and neonatal iron status at 1 month post-partum. 
Subjects and Methods 
Area and population 
We conducted the fieldwork from October 2011 to April 2013 in the administrative areas of 
Ojolla, Kanyawegi, Osiri and Rota Sub-Locations, Nyanza Province, Kenya. The area is 
located along the shores of Lake Victoria, at around 1,234m above sea level. The 
population consists mainly of poor families from the Luo tribe who rely on subsistence 
farming, with a diet mostly based on maize and with low intake of animal products. 
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Sorghum, millet, and cassava are also consumed albeit in lower quantities. Local people 
typically bring these grains regularly and in small quantities (0.5─2 kg) to village-based 
(posho) mills, where they are ground whole or de-hulled into flour. Malaria is highly 
endemic and transmission is perennial. Local residents are exposed to 30─100 infectious 
mosquito bites per year, (A. Noor et al., 2009) although this rate has reduced in recent 
years.(A. Noor et al., 2009), (Ministry of Public Health and Sanitation (MOPHS) & 
Ministry of Medical Services, 2010)  
 
Anaemia (69%) (Ouma et al., 2007) is highly prevalent among pregnant women while 
intestinal schistosomiasis is highly prevalent in school-aged children. (Samuels et al., 2012) 
Fewer than 5% of women in these districts make their first visit to an antenatal clinic in the 
first trimester of pregnancy. (Kenya National Bureau of Statistics (KNBS) & ICF Macro, 
2010) In Nyanza Province, 55% of deliveries take place at home and 1% en route to health 
facilities. (Kenya National Bureau of Statistics (KNBS) & ICF Macro, 2010) Because this 
estimate also includes urban residents, however, who deliver much less frequently at home 
than rural residents (national estimates: 25% versus 65%, respectively); (Kenya National 
Bureau of Statistics (KNBS) & ICF Macro, 2010) it probably is a gross underestimate of 
the percentage of home deliveries in our study area. As per national and international 
guidelines,(Ministry of Public Health and Sanitation, 2008), (Ministry of Public Health and 
Sanitation (MOPHS) & Ministry of Medical Services, 2010) pregnant women should 
receive daily supplementation with iron (60 mg as ferrous sulphate from first month of 
pregnancy or first antenatal contact; if 6 months duration cannot be achieved in pregnancy, 
supplementation should continue during the postpartum period for 6 months, or the dose 
increased to 120 mg iron; treatment of anaemia also requires the dose to be increased to 120 
mg iron) and intermittent preventive treatment for malaria with 2-3 single doses of 
sulfadoxine-pyrimethamine (the first dose after quickening and subsequent doses at 
intervals of at least one month), (Ministry of Public Health and Sanitation (MOPHS) & 
Ministry of Medical Services, 2010) with delivery for both free of charge through antenatal 
services.  
 
Although national coverage of iron supplementation increased notably between 2003 and 
2008, only 54% of women in Nyanza Province reported taking iron tablets or syrup for < 
60 days during their last pregnancy, whilst 33% did not take any iron supplements. (Kenya 
National Bureau of Statistics (KNBS) & ICF Macro, 2010) Despite reports of reduced in 
vivo efficacy of sulfadoxine-pyrimethamine, (Iriemenam et al., 2012) intermittent 
preventive treatment with this combination drug remains efficacious in preventing the 
adverse consequences of Plasmodium infection on maternal and fetal outcomes. (WHO, 
2012c) Coverage nonetheless remains low: in 2008-2009, 17% of women in Nyanza 
Province received at least two doses of sulfadoxine-pyrimethamine during pregnancy, and 
35% received at least one dose. (Kenya National Bureau of Statistics (KNBS) & ICF 
Macro, 2010)  
At the time of our study, Ober Kamoth and Rota dispensaries were the only health centres 
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in the study area. We established Ober Kamoth as our study research clinic, upgraded the 
maternity ward to allow deliveries, installed an obstetric ultrasound instrument and trained 
local health staff in determination of gestational age. The study received clearance from 
ethical review committees in Kenya (Kenyatta National Hospital/University of Nairobi) and 
England (London School of Hygiene and Tropical Medicine), and was registered at 
ClinicalTrials.gov (NCT01308112). 
Study type 
The study was a double-blinded, randomised, placebo-controlled intervention trial with two 
parallel groups of pregnant women receiving daily supplementation with and without iron. 
To prevent severe anaemia, all women were dewormed before the start of the intervention, 
and received a small dose of iron through flour fortification during the intervention. 
Recruitment 
Based on community censuses that we conducted in April-May 2010 and February-March 
2011, and that was updated based on monthly reports by community health workers 
(henceforth referred to as volunteers), we listed all women aged 15–45 years in the study 
area. Meetings were held with local authorities, key persons and volunteers to discuss the 
aims and procedures of the study. As agreed in these meetings, the volunteers visited all 
homesteads to inform its members about the study aims and to enrol women in a pregnancy 
surveillance programme. Women who were married or living together were asked to record 
their menstrual period on a calendar, and to voluntarily report to research staff when having 
missed their monthly period twice consecutively, or when otherwise suspecting that they 
were pregnant. In addition, the volunteers visited each woman monthly at her homestead to 
discuss their menstrual periods. Women who reported the start of their menstrual period to 
have occurred 10 weeks earlier were invited to the research clinic for pregnancy testing. 
Because we suspected that reports of menstrual period might be unreliable in women who 
had never been married, divorced, separated or widowed, we invited them to the research 
clinic for pregnancy testing every 12 weeks. Women who were pregnant or who had 
delivered were excluded from pregnancy monitoring for the first 3 months of the neonatal 
period. Pregnancy tests were subsequently administered at 12-weekly intervals until 
menstrual periods recurred; thereafter, pregnancy detection procedures were as described 
above. Volunteers reported monthly to the research team, and data were entered into a 
database for pregnancy monitoring and tracking. 
When women attended the research clinic for pregnancy testing, we informed them again 
about study aims and procedures, and asked them to sign an informed consent form. Vital 
data and obstetric history were recorded in a standard questionnaire, a medical examination 
carried out, and a rapid test (Clearblue, Swiss Precision Diagnostics, Bedford, UK) was 
administered to detect human chorionic gonadotropin as a pregnancy marker in urine. 
Women were examined by obstetric ultrasonography (Aloka SSD-900, Hitachi Medical 
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Systems, Reeuwijk, Netherlands) to confirm pregnancy; to estimate gestation age (counted 
from first day of last menstrual period) from fetal crown-rump length, biparietal diameter, 
and head circumference; and to assess multiplicity of pregnancy. As per recommendations 
of the World Health Organization, (WHO, 2002) all eligible women received preventive 
chemotherapy with praziquantel against Schistosoma infections, and albendazole against 
geohelminth infections. They were asked to return to research clinic within 14─21 days to 
further assess eligibility. 
Within 48 h of the screening visit described in the preceding paragraph, field staff visited 
the homestead of eligible women to inform homestead members about study aims and 
procedures, to ask the head of the household to sign a form on behalf of the entire 
homestead indicating consent for their flour to be fortified. From the moment that this 
consent had been obtained, we fortified flour with iron for the pregnant woman and all her 
household members at local posho mills, until she left the study. 
We trained the operators of 45 posho millers in the study area on fortification procedures; 
three other mills in the area were excluded because they had porous sieves that prevented 
efficient homogenisation of fortificant in the flour. Research staff diluted premix containing 
highly concentrated NaFeEDTA (Fortitech, Gadstrup, Denmark) with white maize flour 
using standardized protocols. The resulting preblend was packed in 10g sachets and given 
weekly to millers, who kept them in closed plastic, opaque containers. Millers were not 
given any financial incentives but they were visited weekly to ensure their adherence to 
standard procedures. A registered member of a participating homestead brought grain to the 
mill. The mill operator sprinkled the contents of the sachets onto the grain in the feed 
hopper just before it was milled, at a target dose of one sachet (20mg iron as NaFeEDTA) 
per kg flour, as per WHO recommendations for populations with an average per capita 
consumption of wholemeal flour of 150-300g/day. (WHO et al., 2009) Arbitrarily selected 
samples of fortified flour were kept in sealed opaque containers for subsequent 
determination of fortificant iron content. Flour consumption was measured by weighed 
intake studies in 72 arbitrarily selected pregnant women.  
At the second visit to the research clinic, women were counselled and asked for consent for 
HIV testing. They were medically examined and a venous blood sample was collected in a 
tube with K2EDTA (Becton Dickinson, Nairobi, Kenya; catalogue 367863). Haemoglobin 
concentration was measured by photometer (HemoCue 301, Ängelholm, Sweden). The 
ratio of zinc protoporphyrin:haem (ZPP:H) was measured in whole blood and washed 
erythrocytes by haematofluorometer.  
Washed erythrocytes (120 µl) were stored in a DNA-stabilizing buffer (AS1, Qiagen, 
Valencia, CA, USA) with PBS, first at 2-8 °C and later at –80°C, for subsequent DNA 
extraction and detection of P. falciparum infection by PCR test. Plasma samples were 
stored for subsequent detection of Plasmodium antigens and HIV antibodies by rapid 
dipstick tests. Additional plasma samples were stored in liquid nitrogen (-196 °C) in the 
Chapter	2 
44	
field and at ─80 °C during transport and storage in The Netherlands for subsequent 
assessment of iron markers (concentrations of ferritin, soluble transferrin receptor), other 
nutritional markers (concentrations of cobalamin and folate) and inflammation markers 
(concentrations of C-reactive protein and α1-acid glycoprotein). 
Eligibility for randomisation 
Women were included when aged 15-45 years; consent had been obtained; likely to be 
available for study until 1 month after delivery and planning to deliver in the pre-designated 
health facility. They were excluded when having obvious mental retardation or a metabolic 
disorder, a medical history of sickle cell anaemia, epilepsy, diabetes, an obstetric history 
suggestive of eclampsia or pre-eclampsia; carrying multiples; gestational age at the second 
visit was below 13 weeks or exceeded 23 weeks; homestead members had not provided 
consent; no venous blood sample was collected, haemoglobin concentration was <90 g/L. 
Recruitment continued until the target sample size (n=450) had been attained. 
Randomisation and blinding 
To allow masking the organoleptic properties of supplemental iron, the supplements were 
pre-packed as opaque capsules that were identical in appearance except that the shell for 
each type (iron or placebo) was into two colours (blue and dark green for iron, white and 
buff for placebo). The code linking each colour to the type of supplement was kept in 
sealed envelopes and was not available to the research team until after the fieldwork was 
completed, preliminary statistical analyses were done to describe baseline and end-of-
intervention characteristics, and a statistical analysis plan was finalised.  
One of us (HV) not involved in the fieldwork used tables of random numbers to produce a 
list of sequential numbers linked with each of these four colours. The numbers were 
individually written on sealed, opaque envelopes, and the corresponding colour was written 
on a paper slip that was inserted in each envelope. Fieldworkers who allocated treatment 
were not allowed to open these envelopes until it was formally established that the woman 
was eligible for randomisation and registered in a central randomisation log. Each 
participating pregnant woman was then allocated in order of enrolment to the colour 
indicated in the next available envelope.  
The supplements were contained in blister packs of 10 capsules each. Each blister pack 
contained capsules of one of the four colours and had no other marks or writings on it. 
These procedures ensured that participants and field staff, including outcome assessors, 
were blinded to intervention throughout the trial until the data analysis. 
Interventions 
Women received daily supplements with either iron (60 mg as ferrous fumarate; Dr. Paul 
Lohmann, Emmertal, Germany; catalogue 500005025200) or placebo, with starch as filler. 
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We used ferrous fumarate out of concerns that ferrous sulphate, because of its hygroscopic 
properties, could react with the gelatin shells of capsules, eventually making them brittle. 
Bioavailability of iron from ferrous fumarate and ferrous sulphate is similar. (Harrington et 
al., 2011) The field team ensured that women swallowed the first dose in the presence of a 
volunteer and research assistant who were assigned during follow-up to that woman. 
Thereafter, supplementation was supervised daily by these research assistants at the 
homestead of the women or a place nearby. Women were advised not to take any other 
supplements during the remainder of the pregnancy. The research assistant recorded 
compliance and reasons for non-compliance on pre-designed forms and submitted these 
reports weekly to field research staff, who maintained these data into an electronic database 
and followed up immediately as needed. The volunteers helped to solve small problems 
such as tracking of women who were absent or missing. 
Follow-up 
As part of the consent procedure, participating women were advised to attend regular health 
services to receive antenatal care as usual or for medical care when becoming ill during the 
intervention period, except that they were instructed to not take supplements with iron 
and/or folic acid supplied by these services or from other sources. They were asked to 
ensure that all diagnoses, treatments and drugs administered were recorded in booklets that 
they were handed by the routine health services for antenatal care. As pre-agreed, we asked 
each woman for this booklet when she completed the intervention period, and entered 
relevant information into a study database. 
In preparation of deliveries that might take place before the woman reached the research 
clinic, we supplied the household of each participating women with coolers and ice packs, 
as well as delivery kits, approximately 3 weeks before she was due to deliver. Research 
assistants had been trained in advance in the collection and cold storage of blood samples 
and placentas. All participants were asked, however, to contact the volunteer or research 
assistant as soon as they went into labour, so that the field team could be alerted by mobile 
phone. An obstetric nurse was stand-by day and night to assist in the delivery and was 
dispatched immediately by ambulance to bring the woman to the research health centre. 
Complicated cases were referred and brought to Kisumu Provincial Teaching and Referral 
Hospital at a distance of 18 km from the research clinic. A laboratory technician was stand-
by to collect biological samples at delivery. In case of deliveries took place at home, 
samples were collected as soon as possible but at the latest within two hours after delivery. 
At delivery, we recorded date of birth, neonatal data (gender, anthropometric data) and 
place of delivery (home or hospital). Maternal blood (6 mL) was collected by venipuncture 
within 1 hour after delivery. Maternal placental blood (3 mL) was collected by puncturing 
the intervillous space of the placenta with a thick needle. (Othoro et al., 2006) Neonate 
blood (6 mL) was obtained after careful cleaning of the umbilical cord and by direct 
sampling from the umbilical vein. All blood samples were collected in tubes with K2EDTA 
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(Becton Dickinson). In addition, placental biopsies were collected and stored in 40% 
formaldehyde solution with PBS at pH 7.2 for subsequent histological examination. 
At delivery, we also asked each woman for her clinic attendance booklet, and extracted 
information about the number of doses received for intermittent preventive treatment 
against malaria, and whether or not they had received supplements with iron and/or folic 
acid during antenatal clinics. 
All participating women received therapeutic courses of artemether-lumefantrin,10,15 
praziquantel and albendazole9 immediately after delivery to avoid inflammation-induced 
effects on plasma iron markers at one month post-partum. We preferred potential benefits 
of the intervention to be assessed at that time point rather than at delivery because plasma 
iron markers may change rapidly perinatally independently of iron status. Thus follow-up 
and daily supplementation continued for one month after delivery, using procedures as 
described in the preceding paragraphs, and then we collected maternal blood (6 mL) by 
venipuncture in a K2EDTA tube (Becton-Dickinson) and peripheral blood from neonates 
(400-600 µL) by heel puncture in a heparin tube (Becton Dickinson, catalogue 365986). 
Plasma specimens collected during follow-up were stored as described for the baseline 
survey. 
Laboratory measurements 
The ZPP:H ratio was measured for each sample in duplicate using a haematofluorometer 
(Model ZPP 206D, Aviv Biomedical, Lakewood NJ, USA). Control samples at low, 
medium, and high levels (AVIV, catalogue 9999-40839) were run after every 30 readings 
while two level (low, high) calibration samples (AVIV, catalogue 9999-112562) were run 
twice yearly.  
Plasmodium antigenaemia was assayed by rapid dipstick tests (Access Bio Inc, Somerset, 
NJ, USA; CareStart, catalogue G0151 and G0171) that can detect P. falciparum-specific 
histidine-rich protein-2 (HRP2), Plasmodium lactate dehydrogenase (pLDH) specific to 
either P. falciparum or to non-falciparum species, i.e. P. ovale, P. malariae or P. vivax. 
Whereas HRP2-based tests detects current or recent P. falciparum infection, pLDH-based 
tests only indicate current infection.(Makler, Piper, & Milhous, 1998; Moody, 2002; Piper 
et al., 1999) 
DNA was extracted from erythrocytes (Qiagen whole blood DNA isolation protocol 
according to the manufacturer’s instructions except that DNA was eluted in 50 µl nuclease-
free water) and stored at –20°C until PCR analysis.  P. falciparum-specific DNA was 
detected as per protocol(Hermsen et al., 2001) with the following modifications: we added 
an internal amplification control detecting the human household gene GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase), using a Texas Red-labeled probe and 
GAPDH-specific primers: Fwd: 5’ GAA-GGT-GAA-GGT-CGG-AGT-C 3’;  Rev: 5’ 
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GAA-GAT-GGT-GAT-GGG-ATT-TC 3’; Probe: 5’ Texas Red CAA-GCT-TCC-CGT-
TCT-CAG-CC HBQ1 -3’.  Amplification reactions were performed in a volume of 25 µl, a 
total of 2.5 µl 1x Qiagen buffer, 6.5 mM MgCl2, 250 µM dNTPs, 400 nM of each P. 
falciparum 18S primer, 100 nM P. falciparum 18S probe, 40 nM of each GAPDH primer, 
100 nM GAPDH probe, 0.625 U HotstarTaq polymerase (Qiagen), and 2.5µl sample DNA. 
Biolegio (Nijmegen, The Netherlands) provided all primers and probes. Amplification 
comprised of 10 minutes at 95°C, followed by 45 20-second cycles at 95°C and 1 minute at 
60°C. In each PCR run, water controls, no-template controls, high and low positive controls 
were all included in duplicate. The high and low positive controls contain a known amount 
of P. falciparum; thus, the Ct values of these controls were used to determine the PCR 
amplification efficacy. The Ct values of these controls have a range between 2 SD 
(calculated by measuring the controls 12 times over several days) and the Ct values of the 
controls were required to fall within this range. 
Tissue sections of placental biopsies were examined histologically to detect Plasmodium 
infection.(Bulmer, Rasheed, Francis, et al., 1993),(Bulmer, Rasheed, Morrison, et al., 1993) 
HIV infection was assessed by rapid antibody tests (Alere™, Waltham, Massachusetts, 
USA); a positive result was confirmed using other antibody tests (Unigold; Trinity Biotech, 
Co Wicklow, Ireland and/or Bioline; Pantech, Umhlanga, Kwazulu-Natal, South Africa).  
Plasma concentrations of ferritin, soluble transferrin receptor (sTfR), transferrin, C-reactive 
protein, and α1-acid glycoprotein were measured on a Beckman Coulter UniCel DxC 880i 
analyser as per manufacturer’s instructions.  
Fortificant iron content in flour samples were analysed in duplicate, based on the principle 
that solubilized ferrous iron reacts with orthophenanthroline, a chromogenic reagent, in the 
presence of hydroxylamine hydrochloride (reducing agent), resulting in a pink-coloured 
complex. Flour samples (10 g) were mixed with 30 mL water to dissolve organic 
constituents. After shaking, centrifugation and filtration (Acrodisc LC-13 mm syringe filter, 
0.45 μm PVDF membrane), we added solutions of 0.5 mL hydroxylammonium chloride 
(500 g/L), 5 ml sodium acetate (4 M) and 2.5 mL ortho-phenthroline (2.5 g/L) to 15 g of the 
supernatant, and made up to 50 mL with water. Iron concentrations were determined 
spectrophotometrically at an absorbance of 510 nm. 
Outcomes 
The primary outcome was defined as past or present maternal Plasmodium infection 
assessed at parturition, regardless of species, as indicated by one or more positive results 
for the presence of pLDH or HRP2 in plasma (dipstick tests), Plasmodium pigment upon 
histological examination of placental biopsies), or P. falciparum DNA (PCR test). 
Secondary outcomes were: patent Plasmodium infection (similarly defined as in primary 
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outcome, but restricted to results from dipstick tests and biopsy histology); sub-patent 
Plasmodium infection (similarly as in primary outcome, but restricted to results from PCR 
tests); current or recent Plasmodium infection (similarly as in primary outcome, but 
restricted to results from dipstick tests and PCR tests); birth weight; gestational age at 
delivery; fetal weight for gestational age; and maternal and neonatal iron status at one 
month after delivery (as assessed by haemoglobin concentrations, iron deficiency anaemia, 
and iron stores). 
Statistical analysis  
We do not report sample size calculations because we interpreted a completed study; all 
information about precision is indicated by the 95% CIs of our effect estimates. 
Data cleaning and analysis was done using SPSS 21 (SPSS, Chicago, USA) and CIA 2.2.0 
(http://www.som.soton.ac.uk/research/sites/cia/). Analyses were done according to a 
statistical analysis plan that was finalised before the treatment allocation code was revealed. 
Haemoglobin concentration was calculated as the mean of duplicate measurements or 
median values if more than two recordings were available. Fetal weight-for-gestational-age 
z-scores were derived using estimated mean birth weight at 40 weeks of gestation for 
Kenyan children as a reference, (Mikolajczyk et al., 2011)and with a corresponding SD 
value of 12.8 g (estimate obtained from the population presented in this paper).  
We used the following definitions: anaemia: haemoglobin concentration <110 g/L (WHO, 
2011a); iron deficiency: plasma ferritin concentration <15 μg/L (WHO, 2011b); iron-
replete: plasma ferritin concentration ≥15 μg/L in the absence of inflammation; iron status 
uncertain: plasma ferritin concentration ≥15 μg/L in the presence of inflammation; iron 
deficiency anaemia: anaemia co-existing with iron deficiency; inflammation: plasma 
concentrations of C-reactive protein (CRP) >10 mg/L (Nielsen, Bek, Rasmussen, Qvist, & 
Tobiassen, 1990) and/or α1-acid glycoprotein >1 g/L (Filteau et al., 1993); gravidity: the 
number of times a woman reports to have been pregnant, regardless of the outcome of these 
pregnancies, with twins and other multiple births counted as 1, and including the current 
pregnancy; fetal death: occurred before birth; neonatal death: death of a live-born infant 
within the first 7 days of life (early neonatal death),  at 7 28 days of life (late neonatal 
death); small-for-gestational age: birth weight < 10-percentile of fetal weight at a particular 
gestational age; compliance: the proportion of women who consumed >90% of scheduled 
supplements. 
The full analysis population included all subjects who were randomised and who a) 
received at least one dose of the experimental supplements (iron or placebo); b) 
Plasmodium infection status could be ascertained from blood or placental samples collected 
at birth or within 48 h after birth. The per protocol population consisted of the full analysis 
set with restriction to participants who a) consumed >90% of scheduled supplements; and 
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b) had singleton pregnancies. 
Our primary analysis was restricted to the per protocol population, and concerned the 
difference between intervention groups in proportions of women with Plasmodium 
infection. Confounding was assessed by comparing odds ratios with and without adjustment 
for baseline factors known (gravidity [primigravidae, secundigravidae, multigravidae]; (M. 
Desai et al., 2007) maternal age [< 20 years and ≥ 20 years]; (M. Desai et al., 2007), (Tako 
et al., 2005) HIV infection (Kuile et al., 2004)) or suspected (Plasmodium infection status; 
iron status,  entered as haemoglobin concentration [continuous, centred around the mean] 
and plasma ferritin concentration (<12 μg/L or ≥ 12 μg/L); gestational age [continuous, 
centred around the mean]) to be prognostic for the primary outcome. We conducted an 
exploratory analysis on the full analysis set, and used stratified and direct multivariate 
analyses to explore the influence of predefined baseline factors (gravidity; (Nosten, ter 
Kuile, Maelankirri, Decludt, & White, 1991), (A. M. Greenwood, Armstrong, Byass, Snow, 
& Greenwood, 1992) maternal age; (Espinoza, Hidalgo, & Chedraui, 2005), (Leenstra et 
al., 2003), (Marques et al., 2005),  (S J Rogerson et al., 2000),  (Walker-abbey et al., 2005)  
HIV infection; (M. Desai et al., 2007)  iron status, indicated by anaemia and iron 
deficiency) on the magnitude of the intervention effect. P-values for interactions with 
binary outcomes were calculated by likelihood ratio tests. We similarly assessed to what 
extent the intervention effect is influenced by intermittent preventive treatment during the 
intervention period. 
We used multiple linear regression analysis to assess intervention effects on birth weight, 
gestational age at delivery, and maternal and infant haemoglobin concentration at 30 days 
post-partum. We conducted these analyses with and without adjustment for baseline 
haemoglobin concentration; in the analysis of the haemoglobin response to intervention, we 
also accounted for inflammation at the end survey. We used stratified analysis and 
multivariate analysis to assess effect modification by pre-specified baseline factors (iron 
status, gravidity, maternal age, Plasmodium infection, HIV infection), and by intermittent 
preventive treatment use. 
Results 
Of 2,015 women invited for screening, 470 (23%) were eligible and randomised to 
intervention (Figure 1 & Table 1).  Of these, 434 (92%) were included in the full analysis 
set, and 430 (92%) in the per protocol analysis.One woman died as a result of postpartum 
haemorrhage, and another at 2 weeks postpartum due to pneumonia and cardiac arrest. 
Adverse maternal, foetal and neonatal events are summarised in Figure 1 and table 2. 
 
Of all deliveries, 415 (88.3%) took place at the research clinic, 38 (8.1%) in referral 
hospitals and 17 (3.6%) at home. Placental biopsies were incorrectly preserved and lost for 
85 (18.1%) women, whilst 42 (8.9%) placentae were missing or poorly preserved because  
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Table 1: Baseline characteristics of study participants, by intervention group 
Characteristics High-dose iron group Low-dose iron group 
Per protocol 
analysis set 
Lost to follow-
up or excluded 
Per protocol 
analysis set 
Lost to follow-up 
or excluded 
n 215  22  212  21  
Height, cm 162.5 (5.9) 161.7 (3.9) 162.6 (6.7) 160.9 (7.2) 
Weight, kg 58.0 (7.5) 59.8 (8.7) 57.4 (7.5) 58.7 (8.5) 
Body mass index, kg/m2 22.0 (2.7) 22.9 (3.2) 21.7 (2.6) 22.7 (2.8) 
Marital status         
Married or living together 190 [88.4%] 14 [63.6%] 171 [80.7%] 13 [61.9%] 
Divorced or separated 7 [3.3%] 1 [4.5%] 9 [4.2%]  1 [4.8%] 
Never married 18 [8.4%] 7 [31.8%] 32 [15.1%]  7 [33.3%] 
Age, years 24.0 [9.0] 20.5 [7.0] 24.0 [9.0] 21.0 [10.0] 
Gestational age, weeks 1 17.4 [4.0]  18.0 [4.0] 17.3 [4.0]  18.4 [4.0] 
Gravidity         
Primigravidae 27 [12.6%]  10 [45.5%] 40 [18.9%]  8 [38.1%] 
Secundigravidae 53 [24.7%]  4 [18.2%] 32 [15.1%]  3 [14.3%] 
Multigravidae 135 [62.8%]  8 [36.4%] 140 [66.0%]  10 [47.6%] 
Plasmodium infection         
Any Plasmodium spp.2, by any dipstick or PCR 78 [36.3%] 11 [50.0%] 80 [37.7%] 6 [28.6%] 
P. falciparum, by HRP2- or LDH-based dipstick, or PCR 77 [35.8%] 11 [50.0%] 80 [37.7%] 6 [28.6%] 
Current or recent P. falciparum infection, by either 
HRP2- or LDH-based dipstick 
39 [18.1%] 8 [36.4%] 43 [20.3%] 1 [4.8%] 
P. falciparum, by PCR 70 [32.6%] 11 [50.0%] 76 [35.8%] 6 [28.6%] 
HIV infection 46 [21.4%] 2 [9.1%]5 47 [22.2%]  4 [19.0%] 
Plasma CRP concentration, mg/L 4.0 [7.3] 9.8 [25.6] 4.3 [8.5] 2.5 [10.1] 
Plasma AGP concentration, g/L 0.8 (0.3) 1.0 (0.4) 0.8 (0.3) 0.7 (0.3) 
Inflammation 3         
Plasma CRP concentration ≥10 mg/L 50 [23.3%] 11 [50.0%] 58 [27.4%] 7 [33.3%] 
Plasma AGP concentration ≥1.0 g/L 35 [16.3%] 8 [36.4%] 38 [17.9%] 4 [19.0%] 
Plasma CRP concentration ≥10 mg/L or AGP ≥1.0 g/L 63 [29.3%] 13 [59.1%] 69 [32.5%] 7 [33.3%] 
Hb concentration, g/L 113.4 (10.7) 118.2 (11.7) 112.2 (11.9) 115.1 (12.1) 
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Anemia, Hb concentration <110g/L 77 [35.8%]  5 [22.7%] 87 [41.0%]  6 [28.6%] 
Plasma ferritin concentration, µg/L 13.7 [21.0]  15.7 [41.1] 13.8 [20.4]  17.0 [21.9] 
Plasma sTfR concentration, mg/L 1.8 [1.1]  2.3 [0.8] 2.0 [1.2]  1.8 [0.8] 
Plasma transferrin concentration, g/L 3.1 (0.6) 3.0 (0.4) 3.1 (0.5) 3.0 (0.5) 
Iron deficiency, plasma ferritin concentration <15µg/L         
All women 115 [53.5%]  11 [50.0%] 112 [52.8%]  10 [47.6%]  
Those with CRP concentration <10 mg/L 94/165 [57.0%]  7/11 [63.6%] 87/154 [56.5%]  9/14 [64.3%]  
Those with AGP concentration <1.0g/L 105/180 [58.3%]  9/14 [64.3%] 97/174 [55.7%]  9/17 [52.9%]  
Those with concentrations of CRP <10mg/L or AGP <1.0 
g/L 
109/152 [71.7%]  8/9 [88.9%] 100/143 [69.9%]  1/14 [7.1%]  
Whole blood ZPP:heme ratio, µmol/mol 89.5 [53.0]  85.3 [28.1] 90.8 [62.8]  86.0 [39.3]  
Erythrocyte ZPP:heme ratio, µmol/mol 37.5 [44.5] 34.3 [38.8] 36.0 [57.8] 32.5 [35.5]  
Erythrocyte FEP concentration, µg/dl 4 22.2 [31.1]  15.0 [15.5] 19.4 [31.9]  16.2 [60.3]  
 
Mean (SD), Median [IQR], n [%] or n/n [%] 
AGP: α1-acid glycoprotein; CRP: C-reactive protein; FEP: free erythrocyte protoporphyrin; HRP2: P. falciparum-specific histidine-rich 
protein-2); LDH: P. falciparum-specific lactate dehydrogenase; sTfR: soluble transferrin receptor; ZPP: zinc protoporphyrin 
1 All women except one were in the 2nd trimester of pregnancy; 2 Only one participant (high-dose iron group) had infection by a Plasmodium 
species other than P. falciparum; 3 Only one participant (high-dose iron group) had current fever defined as axillary temperature ≥ 37.5 °C; 
4 One missing value in the per protocol analysis dataset; 5 HIV status of two participants was not determined 
delivery took place at home or in referral hospitals. Two mothers refused consent for neonatal blood collection at 1-month post-
partum. Samples from two babies in the control group were inadequate to perform all the biochemical tests. 
 
Analysis of flour samples showed an average iron content of 18.0 mg/kg (SD: 2.2 mg/kg). Pregnant women had an average daily 
intake of flour and fortificant iron of 286 g and 5.7 mg, respectively. 
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Table 2: Frequency of adverse events in mothers and children 
Adverse events High–dose iron group Low–dose iron group 
Maternal events   
Maternal death 0 2 1 
Hospital admissions 1 4 
Pre-eclampsia 0 1 
Atonic uterine contraction 0 1 
General sickness (self-reported) 4 3 
Malaria 1 1 
Pneumonia 1 0 
Meningitis 1 0 
Breech delivery 1 0 
Total 9 12 
Fetal and neonatal events   
Fetal death 3 3 
Early neonatal death 2 2 2 
Late neonatal death 3 2 2 
Infant death after 28 days of life 1 1 
Neural tube defect 0 2 
Neonatal sepsis 1 1 
Total 9 11 
 
1 One woman died due to postpartum hemorrhage, and another at 2weeks postpartum due to 
pneumonia and cardiac arrest. 2 Early neonatal death: death of a live-born infant within the 
first week of life; 3 Late neonatal death: death of a live-born infant at 7 28 days of life 
	
 
Except for some mild imbalance in marital status and gravidity, intervention groups were 
similar regarding baseline characteristics (Table 1). Compliance in the high-dose and low-
dose iron groups was 100% and 99.1%, respectively. Records from clinic attendance 
booklets indicated that women in high-dose iron and low-dose iron groups were similar 
regarding the percentage who received iron supplements from external sources in addition 
to supplements administered by the study (9.3% versus 9.9%), and who received 
insecticide-treated bed nets (15.2% versus 15.9%).	
	
PP: Per protocol; High-dose iron: daily supplementation with iron (60 mg as ferrous fumarate) plus 
fortified flour throughout the intervention period; low-dose iron: fortified flour throughout the 
intervention period. Percentages reported between parentheses are calculated with the number 
randomised to intervention as the denominator 
Maternal outcomes at delivery: We found no effect of iron on Plasmodium infection, 
however defined (Table 3); crude and adjusted odds ratios were 1.05 and 0.97, 
respectively, indicating no evidence for confounding by baseline factors (gravidity, HIV 
infection status, maternal age, gestation age, Plasmodium infection, haemoglobin 
concentration, plasma ferritin concentration, marital status). There was weak evidence that 
Chapter	2 
54	
iron increased the risk of Plasmodium infection in women who were anaemic or iron 
deficient at baseline (Figure 2). 
Iron supplementation increased haemoglobin concentrations by 9.4 g/L, reduced the 
prevalence of anaemia by 29.8% and reduced ZPP:haem ratios in whole blood and 
erythrocytes (Table 2). 
Neonatal outcomes at delivery: Iron supplementation increased birth weight by 143 g 
(Table 2), and reduced the prevalence of low birth weight by 65% (3.1% versus 8.8%; ratio, 
95%CI: 0.35, 14.1─87.2). The effect of iron on birth weight seemed larger in women with 
iron deficiency at baseline than in their peers who were initially iron-replete (249 g versus 
─14 g; difference, 95% CI: 263 g, 136 362 g; Figure 2). 
Iron increased foetal-weight z-score at delivery by 0.27 SD, and neonatal length by 1.0 cm. 
There was no evidence that iron increased gestational age at delivery, but there was weak 
evidence that it reduced the proportion of neonates that were born prematurely by 6.3% 
(Table 2). We did not find an effect of iron on neonate iron markers (haemoglobin 
concentration, ZPP:haem ratios). 
Outcomes at 1 month postpartum: Iron supplementation improved maternal iron status at 
1 month postpartum, as shown by increased haemoglobin concentrations plasma ferritin 
concentrations, as well as reductions in the prevalence of anaemia, iron deficiency and 
plasma transferrin receptor concentration (Table 4).  
In the analysis of haemoglobin concentration, adjustment for baseline haemoglobin, ferritin 
concentration, maternal age, gravidity, marital status, and HIV infection status, as well as 
for time between delivery and blood collection one month post-partum, led to similar effect 
estimates. Beneficial gains in iron status were greater in women with poor iron status at 
baseline. For example, iron supplementation increased haemoglobin concentration by 15.6 
g/L in women who were initially anaemic, as compared to a gain of 3.7 g/L in those who 
were initially non-anaemic (Figure 2). 
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Table 3: Effect of iron on maternal and neonatal outcomes at delivery, per protocol analysis 
Indicator High-dose iron Low-dose iron Difference or per cent change 
(95% CI) 
Maternal outcomes        
n 
215 [90.7%] 215 [92.3%]   
Plasmodium infection (see text for definitions)       
Patent and sub-patent infections (primary outcome) 96 [44.7%] 96 [44.7%] 0.0% (─9.3% to 9.3%) 
Patent infections 84 [39.1%] 81 [37.7%] 1.4% (─7.7% to 10.5%) 
Sub-patent infections 49 [22.8%] 52 [24.2%] ─1.4% (─9.4% to 6.6%) 
Current or recent infection 60 [27.9%] 66 [30.7%] ─2.8% (─11.3% to 5.8%) 
Hb concentration, g/L 120.7 (16.4) 111.6 (18.9) 9.1 (5.7 to 12.4) 
High Hb concentration (>130) g/L 66 [30.7%] 371 [17.3%] 13.4% (5.3% to 21.3%) 
Anemia (Hb concentration <110 g/L) 46 [21.4%] 108 1 [50.5%] ─ 29.1% (─37.3% to ─20.1%) 
Severe anemia (Hb concentration <70 g/L) 3 [1.4%] 11 [0.5%] 0.9% (─1.4% to 3.6%) 
ZPP in maternal venous blood, µmol:mol heme 103.2 [63.0, 126.5 ] 155.6 [87.0, 207.5] ─33.7% (─40.1% to ─26.5%) 
ZPP in maternal erythrocytes, µmol:mol heme 27.7 [10.5, 43.0] 65.8 [25.0, 110.0] ─57.9% (─64.9% to ─49.7%) 
Neonatal outcomes       
n 220  218    
Sex, male:female 109:111 [49.5%, 50.5%] 109:109 [50.0%, 50.0%]   
Birthweight, g 2 3,191 (441) 3,048 (410) 143 (58 to 228) 
Low birthweight (<2,500 g) 6/194 [3.1%] 17/196 [8.7%] ─5.6% (─10.6% to ─0.9%) 
Fetal weight z-score at delivery, SD 3 0.70 (1.17) 0.42 (1.11) 0.27 (0.04 to 0.50) 
Small-for-gestational age  5/194 (2.6%) 8/195 (4.1%) ─1.5% (─5.6% to 2.3%) 
Length, cm 50.6 (4.2) 49.6 (4.3) 1.0 (0.1 to 1.8) 
Head circumference, cm 35.0 [33.5, 35.5] 34.6 [33.5, 35.5] 0.9% (─0.2% to 2.0%) 
Gestational age at delivery, weeks 38.6 (1.9) 38.4 (1.9) 0.2 (─0.2 to 0.6) 
Premature birth (< 37 weeks gestation) 32 [14.9%] 45 [20.9%] ─6.0% (─13.3% to 1.2%) 
Hb concentration in cord blood, g/L 153.6 (21.5) 150.5 (21.1) 3.1 (─1.0 to 7.2) 
ZPP in cord blood, µmol:mol heme 137.4 [113.0, 162.5] 139.5 [110.5, 170.0 ] ─1.5% (─7.4% to 4.7%) 
ZPP in cord erythrocytes, µmol:mol heme 55.0 [42.0, 75.0] 55.7 [37.0, 79.5] ─1.3% (─10.5% to 8.9%) 
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Table 4: Effect of iron on maternal and neonatal iron status at 1 month post-partum 
Indicator High-dose iron Low-dose iron Difference or per cent change 
(95% CI) 
Maternal outcomes       
n  214 [90.3%] 213 [91.4%]   
Hb concentration, g/L 129.0 (13.9) 120.1 (16.5) 8.9 (6.0 to 11.8) 
Anemia (Hb concentration <120 g/L ) 52/214 [24.3%] 96/213 [45.1%] ─20.8% (─29.3% to ─11.8%) 
Plasma ferritin concentration, µg/L 32.7 [19.5, 58.7] 14.6 [6.9, 29.8] 124.1% (87.3% to 168.1%) 
Iron deficiency (plasma ferritin concentration <15 
µg/L)       
All persons 40/214 [18.7%] 118/212 [55.7%] ─37.0% (─45.0% to ─28.1%) 
Those without inflammation 1 26/133 [19.5%] 80/135 [59.3%] ─39.7% (─49.6% to ─28.4%) 
Iron deficiency anemia 2 10/214 [4.7%] 46/212 [21.7%] ─17.0% (─23.4% to ─10.8%) 
Plasma transferrin concentration, g/L  2.65 (0.50) 3.07 (0.52) ─0.42 (─0.52 to ─0.32) 
Plasma transferrin receptor concentration, mg/L 1.78 [1.24, 2.32] 2.52 [1.72, 3.64] ─29.4% (─36.1% to ─22.1%) 
Neonatal outcomes       
n 202 [85.2%] 206 [88.4%] ─3.2%  
Hb concentration, g/L 131.4 [111.5, 144.0] 129.6 [114.5, 147.5] 1.3% (─2.9% to 5.7%) 
Plasma ferritin concentration, µg/L 163.0 [110.0, 268.9] 139.2 [93.2, 212.0] 17.1% (2.1% to 34.3%) 
Plasma transferrin receptor concentration, mg/L 1.2 [1.0, 1.5] 1.3 [1.0, 1.5] ─4.9% (─ 11.5% to 2.1%) 
Current or recent Plasmodium infection  3/200 [1.5%]  3/197 [1.5%]  0.0% (─ 0.03 to 0.03) 
Mean (SD), geometric mean [25th, 75th percentiles], n [%] or n/n [%], *Geometric mean, **median 
1 Concentrations of C-reactive protein <10 mg/L or α1-acid glycoprotein <1.0 g/L; 
2Presence of both anemia and iron deficiency;  
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Supplementary Figure 2: Effect 
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improved maternal and neonatal iron stores at 1 month postpartum. 
 
Although P. falciparum infection in pregnancy is usually asymptomatic, it may cause 
adverse birth outcomes (reduced birth weight, intrauterine growth retardation, preterm 
delivery, increased neonatal mortality) and adverse maternal outcomes (increased risk of 
severe anaemia and death). (M. Desai et al., 2007) We found no effect of iron on 
Plasmodium infection, however, regardless of pre-specified case definitions, and the upper 
limit of the 95% CI was consistent with a 9% increase only in the cumulative incidence of 
infection (Table 1; primary outcome).  
 
A unique aspect of this study is the ethical licence, created by the concern about the 
potential risk of malaria, to assess the benefits of iron supplementation in a mixed 
population that included women with anaemia and iron deficiency at baseline. Recent meta-
analyses, (Peña-Rosas et al., 2012), (Vucic et al., 2013), (Haider et al., 2013) published 
after we started our trial, found no (Vucic et al., 2013) or only small effects (31g, 95%CI: 
6–56g, (Peña-Rosas et al., 2012) and 40.8g, 0.97–80.6g) (Haider et al., 2013) of antenatal 
iron supplementation on birth weight. All but three of the studies (Preziosi et al., 1997), 
(Christian et al., 2003), (Zeng et al., 2008) reviewed, however, excluded women who were 
initially iron deficient or anaemic, and most reported good iron status at baseline. Our data 
show no evident effect on birth weight of iron supplementation in iron-replete women 
(Figure 3). Pena-Rosas et al. could not conduct subgroup analysis by initial anaemia status, 
because there was not a single woman who was reported to be initially anaemic in the 
studies reviewed. (Peña-Rosas et al., 2012) 
 
The large benefit on birth weight in our study may also be explained by a superior 
compliance compared to all studies reviewed. (Peña-Rosas et al., 2012), (Vucic et al., 
2013), (Haider et al., 2013) Whereas we observed daily throughout the intervention period 
if women swallowed supplements, supervision was unclear in other studies, or contact with 
participants was limited to repeated visits or phone calls in the period until delivery. 
Although several studies used capsules or coated tablets, (Cogswell, Parvanta, Ickes, Yip, 
& Brittenham, 2003), (Zeng et al., 2008), (Falahi, Akbari, Ebrahimzade, & Gargari) iron 
was mostly given as tablets with ferrous salts, which produce a strong and unpleasant taste 
that may have discouraged adherence. Attrition was high in many studies, although it is 
unclear whether this occurred selectively in the iron groups. Although supplement use was 
assessed in most studies by tablet counts or self-reports, such methods tend to overestimate 
adherence. (Cramer, 1989), (Olivieri, Matsui, Hermann, & Koren, 1991), (Shalansky, Levy, 
& Ignaszewski, 2004), (Grosset, Bone, Reid, & Grosset, 2006) With few exceptions, 
however, adherence was not reported or poor. 
 
The gain in birth weight seemed achieved mostly through improved fetal growth (as evident 
by an increased fetal weight-for-gestational-age and body length), and perhaps to some 
extent by a reduction in premature births. Consistent with and supportive of our finding of 
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the selective effect of iron on birth weight, the haemoglobin response to iron was larger in 
women who were initially iron deficient as compared to those who were iron replete.  
 
Low birthweight is the primary determinant of neonatal and post-neonatal mortality, and is 
believed to be an important cause of neonatal morbidity, inhibited growth and cognitive 
development, and chronic diseases later in life.  
 
Our finding that infants whose mothers received iron had elevated plasma ferritin 
concentrations at 1 month post-partum adds to growing evidence, (Scholl, 2011) so far 
confirmed only in a single trial, (Preziosi et al., 1997) that antenatal iron supplementation 
improves neonatal iron stores, thus delaying the age at which iron deficiency is likely to 
develop during infancy. 
 
The main limitation of our study is that Plasmodium infection was determined in samples 
collected at delivery, which may not have captured all infections experienced during the 
intervention period. To avoid ethical dilemmas, we did not collect blood samples between 
enrolment and delivery, and referred women for antenatal care after enrolment to the 
regular health services, where they received standard service. Our inability to assess 
infection in this period was compensated by histological assessment of Plasmodium 
pigment in placental biopsies, (Bulmer, Rasheed, Francis, et al., 1993; Bulmer, Rasheed, 
Morrison, et al., 1993) which probably captures the vast majority of past infections. 
Our results cannot be extrapolated to children, for whom there is substantial evidence that 
iron supplementation can increase malaria rates. (Andrew M Prentice & Cox, 2012) 
 
Concluding remarks 
Antenatal iron supplementation leads to large improvements of birth weight, fetal growth 
and infant iron stores, with potentially immense benefits for infant survival and health that 
should outweigh any possible concerns about risks of malaria. Scaling up universal iron 
supplementation in pregnancy in developing countries is likely to generate major public 
health gains. 
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Chapter	3	
Diagnostic	utility	of	zinc	
protoporphyrin	to	detect	iron	
deficiency	in	Kenyan	pregnant	women2	
Abstract 
Zinc protoporphyrin (ZPP) indicates iron-deficient erythropoiesis and is a screening marker 
of iron deficiency (ID) in pregnant women and children. There are concerns about gross 
discrepancies of reported prevalence estimates for ID obtained by ZPP and circulating 
ferritin concentrations.  
We used baseline samples collected from a randomized controlled trial involving 470 rural 
Kenyan women with singleton pregnancies, gestational age 13─23 weeks and haemoglobin 
concentration ≥ 90 g/L, to examine associations between ZPP and Plasmodium infection, 
HIV, and α+-thalassemia. We assessed the diagnostic utility of ZPP (measured in whole 
blood and erythrocytes) and Erythrocyte Protoporphyrin(EP), either alone or in 
combination with haemoglobin, in detecting ID (plasma ferritin <15μg/L).  
Individually, whole blood ZPP (WB-ZPP), erythrocyte ZPP (E-ZPP) and EP had limited 
ability to discriminate between women with and without ID. Combining each of these 
markers with haemoglobin had no additional diagnostic value. Conventional cutpoints for 
WB-ZPP (>70 μmol/mol heme) resulted in gross estimates of the prevalence of ID. E-ZPP 
may have limited value to rule out ID when used for screening in conditions with a low 
prevalence (e.g. 10%). ZPP is of unreliable diagnostic utility when discriminating between 
pregnant women with and without ID. ZPP measurements in washed erythrocytes are best. 
 
  
                                                           
2Submitted for publication 
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Introduction 
Zinc protoporphyrin (ZPP) indicates iron-deficient erythropoiesis. It can be measured 
instantly and at low assay cost using portable hematofluorometers, and it has been used as a 
screening marker to manage iron deficiency in children and pregnant women, (NCCLS, 
1996), (WHO/CDC, 2007) with the advantage that values remain stable throughout 
gestation in women with adequate iron nutrition. (Ron B. Schifman, Thomasson, & Evers, 
1987), (Romslo, Haram, Sagen, & Augensen, 1983), (Harthoorn-Lasthuizen, Lindemans, & 
Langenhuijsen, 2000) ZPP has also been recommended to be used in combination with 
haemoglobin concentration in surveys to assess population iron status. (NCCLS, 1996) 
However, we have concerns about gross discrepancies of reported prevalence estimates for 
iron deficiency obtained by ZPP and circulating ferritin concentrations. For example, in 
Kenyan children, this prevalence was 80% versus 41% (after correction for inflammation) 
for ZPP >80 μmol/mol heme and ferritin concentration <12 μg/L, respectively,(Grant et al., 
2012) whilst corresponding values were 56% versus 40% for Tanzanian  children without 
Plasmodium infection. (Rebecca J. Stoltzfus et al., 1997) 
Non-heme protoporphyrin includes both ZPP and free erythrocyte protoporphyrin (FEP, i.e. 
the metal-free form that occurs naturally in erythrocytes). If the supply of iron is 
insufficient or when iron utilization is impaired (e.g. anemia of chronic disease), zinc is 
used in the biosynthetic pathway of heme instead of iron, resulting in the formation of ZPP. 
Thus increased ZPP concentrations in whole blood or erythrocytes reflect depleted iron 
stores and a decrease in circulating iron in the bone marrow. (NCCLS, 1996) (WHO/CDC, 
2007) Contrary to heme, ZPP and FEP fluoresce at 555-780 nm when exited at 408 nm. 
Because the intensity of the fluorescent signal is proportional to the molar ratio of ZPP to 
haemoglobin, hematofluorometer measurements should theoretically not be influenced by 
volume of the blood sample, pregnancy-induced hemodilution or whether it is determined 
in fresh whole blood or in erythrocytes. In practice, however, measurement in washed 
erythrocytes yields more valid results because washing removes haemoglobin breakdown 
products such as bilirubin or other serum constituents (e.g. riboflavin) that fluoresce at the 
same wavelength as the porphyrins. (Hastka, Lasserre, Schwarzbeck, Strauch, & 
Hehlmann, 1992) 
In addition to being raised in iron deficiency, ZPP can be elevated by other factors causing 
an inadequate supply of iron to erythroblasts (inflammation), increased erythropoiesis 
(hemolysis, sickle cell anemia, thalassemia), or disturbances in the heme synthetic pathway 
(lead poisoning). (NCCLS, 1996) 
ZPP is the predominant form of non-heme protoporphyrin in normal erythrocytes. 
(WHO/CDC, 2007)In many disorders, however, the ratio of ZPP and FEP is highly variable 
because of the high FEP content in reticulocytes. Using acid extraction, chelated zinc can 
be liberated from ZPP, yielding a larger pool of metal-free erythrocyte protoporphyrin 
(henceforth referred to as erythrocyte protoporphyrin, EP). (NCCLS, 1996) 
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We conducted a study in pregnant women, with the aim to examine associations between 
ZPP and disorders that are common in Africa (Plasmodium infection, HIV infection, α+-
thalassemia). In addition, we assessed the diagnostic utility of ZPP (measured in whole 
blood and erythrocytes) and EP, either alone or in combination with haemoglobin 
concentration, in detecting iron deficiency defined as plasma ferritin <15 μg/L. 
Subjects and Methods 
Study population: For this study, we used samples collected at baseline for a randomized 
controlled trial to investigate the safety and efficacy of iron supplementation in Kenyan 
pregnant women (Chapter 2). The study (www.ClinicalTrials.gov:NCT01308112) received 
ethical clearance in Kenya and England; written consent was obtained from all participating 
women. Fieldwork was conducted from October 2011 to October 2012 in a rural area 
highly endemic for malaria in western Kenya. A surveillance system was set up to detect 
pregnancies in the late stage of the first trimester to early stage of second trimester. 
Pregnancy was confirmed and gestational age was determined by urine test and ultrasound 
examination respectively. Immediately upon confirmation of pregnancy, women received 
preventive chemotherapy with albendazole and praziquantel against helminth infections and 
intestinal schistosomiasis to prevent severe anaemia.  
At the second visit to the research clinic, 14─21 days after the initial visit, we collected a 
venous blood sample to measure haemoglobin concentrations (HemoCue301, Ängelholm, 
Sweden), and ZPP in whole blood and washed erythrocytes (both in duplicate; Aviv 206D, 
Lakewood NJ, USA). Erythrocytes were stored in DNA-stabilizing buffer (AS1, Qiagen, 
Valencia, CA) and plasma in liquid nitrogen and dry ice until analysis.  
Women were included when aged 15─45 years; consent had been obtained; likely to be 
available for study until 1 month after delivery and planning to deliver in the pre-designated 
health facility. They were excluded when having obvious mental retardation or a metabolic 
disorder, a medical history of sickle cell anemia, epilepsy, diabetes, an obstetric history 
suggestive of eclampsia or pre-eclampsia; carrying multiples; gestational age at the second 
visit was <13weeks or >23weeks; no venous blood was collected, or haemoglobin 
concentration was <90g/L. 
To wash erythrocytes, blood samples were centrifuged (8min, 600xg), plasma was removed 
and replaced with an equal volume of phosphate buffered saline (Medicago, Uppsala, 
Sweden; catalogue no. 09-2051-100) in 100 mL deionized water. Following renewed 
centrifugation (8min, 600×g), the supernatant and buffy coat were discarded. ZPP was 
measured in the washed erythrocytes. 
Washed erythrocytes (20μL) were transferred to 2mL cryotubes prefilled with 0.3mL 
solution 0.9% saline and 50% Celite (Sigma-Aldrich, catalogue 525235, St. Louis, MO). 
Aliquots were stored in liquid nitrogen and dry ice until analysis for EP concentration in 
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The Netherlands.  
Laboratory analyses: ZPP content was measured by hematofluorometer (Aviv 206D, 
Lakewood Township, NJ, USA). Control samples at low, medium, and high levels (AVIV) 
were run after every 30 readings while two level calibration (Aviv; low, high) samples were 
run twice per year. To measure EP, washed erythrocytes (20μL) were transferred to 2mL 
cryotubes prefilled with 0.3mL solution 0.9% saline and 50% Celite (Sigma-Aldrich, 
catalogue 525235, St. Louis, MO). Protoporphyrins were extracted and separated from 
heme as described (Piomelli, 1977) and determined quantitatively by a spectrofluorometer 
using a protoporphyrin IX standard (Sigma-Aldrich, catalogue 282820). 
We measured iron markers (plasma concentrations of ferritin, soluble transferrin receptor, 
and transferrin), inflammation markers (plasma concentrations of C-reactive protein [CRP] 
and α1-acid glycoprotein [AGP]), vitamins (plasma concentrations of folate and vitamin 
B12) and a marker of hemolysis (plasma lactate dehydrogenase concentration) on a 
Beckman Coulter UniCel DxC 880i analyzer as per manufacturer’s instructions. 
Plasmodium antigenaemia was assayed by dipstick tests (Access Bio Inc., Somerset, NJ, 
USA; CareStart, catalogue G0151 and G0171) that can detect P. falciparum-specific 
histidine-rich protein-2 (HRP2), Plasmodium lactate dehydrogenase (pLDH) specific to 
either P. falciparum or to non-falciparum species, i.e. P. ovale, P. malariae or P. vivax. 
Whereas HRP2-based tests detects current or recent P. falciparum infection, pLDH-based 
tests only indicate current infection.(Makler et al., 1998)(Piper et al., 1999)(Moody, 2002) 
HIV infection was assayed using antibody tests (Alere, Waltham, MA; confirmed by 
Unigold; Trinity Biotech, Bray, Ireland and/or Bioline; Pantech, Umhlanga, South Africa). 
We determined α+-thalassaemia genotype by polymerase chain reaction;(Veenemans et al., 
2008)(Veenemans, Jansen, et al., 2011) because of practical reasons, we could perform this 
analysis only in the first 213 successively recruited women. 
Definitions: We used the following definitions: anemia: haemoglobin concentration <110 
g/L;(WHO, 2011a) iron deficiency: plasma ferritin concentration <15 µg/L;(WHO, 2011b) 
inflammation: plasma concentrations of CRP >10 mg/L(Nielsen et al., 1990) and/or AGP 
>1 g/L;(Filteau et al., 1993) gravidity: the number of times a woman reports to have been 
pregnant, regardless of the outcome of these pregnancies, with twins and other multiple 
births counted as 1, and including the current pregnancy; Plasmodium infection was defined 
as any infection: one or more positive results for the presence of pLDH or HRP2 in plasma 
(dipstick tests), Plasmodium pigment upon histological examination of placental biopsies), 
or P. falciparum DNA (PCR test); current or recent P. falciparum infection (similarly, but 
restricted to results from dipstick tests and PCR tests); or current infection (similarly, but 
restricted to results from PCR tests).  
Statistical analysis: Data were analyzed using SPSS version 22 (IBM, Armonk, NY). Data 
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were described as means (SDs), medians (25th- and 75th-percentiles) or prevalence values 
in the overall population, or in women without inflammation (plasma concentrations CRP 
≥10 mg/L or AGP ≥1.0 g/L), HIV infection or Plasmodium infection. 
Univariate linear analysis was used to explore associations between ZPP (log-transformed) 
and iron markers (including anemia), factors known or suspected to be associated with iron 
status (age, gestational age, gravidity, plasma concentrations of folate and vitamin B12), 
inflammation markers, infections (Plasmodium infection, HIV infection) and other 
disorders suspected to be associated with ZPP (α+-thalassemia, plasma concentrations of 
bilirubin and LDH). Multivariate linear analysis with a backward elimination procedure 
was used to derive a parsimonious model of factors that were independently associated with 
ZPP. 
We assessed the diagnostic performance of ZPP (both in whole blood and erythrocytes) in 
detecting iron deficiency (plasma ferritin concentration <15 μg/L). Because plasma ferritin 
concentration reacts as an acute phase protein, we restricted these analyses to women 
without inflammation, Plasmodium infection or HIV infection.  
Combinations of ZPP and haemoglobin concentration may have better ability than single 
markers to distinguish between children with and without iron deficiency. Thus we used 
scatter plots and logistic discriminant analysis to assess the diagnostic performance of ZPP 
combined with haemoglobin concentration. Receiver Operating Characteristics (ROC) 
curves were produce using the probability of iron deficiency as a function of ZPP and 
haemoglobin concentration as a quantitative test outcome. Diagnostic performance was 
assessed by visual inspection of these curves and by assessing differences in the Area-
Under-the-Curve (AUC) with corresponding p-values. Similar analyses were performed for 
EP concentration. 
We subsequently assessed the diagnostic performance of ZPP as a dichotomized variable, 
with various thresholds. First, we used threshold values for ZPP of 70 μmol/mol and 40 
μmol/mol heme (NCCLS, 1996), (WHO/CDC, 2007), depending on whether the assay is 
conducted in whole blood or washed erythrocytes. The whole blood ZPP value of 70 
μmol/mol heme (NCCLS, 1996), (WHO/CDC, 2007), (WHO, UNICEF, & UNU, 2001) 
(2.7 μg/g Hb) was derived from the 95% upper limit of the reference values for women and 
children participating in the US National Health and Nutrition Examination Survey 
(NHANES) II, after excluding individuals with anemia, low transferrin saturation and 
elevated blood lead concentrations. The cut-point for erythrocyte ZPP of 40 μmol/mol 
heme is based on several small studies comparing iron-deficient and iron-replete 
individuals. (Hastka et al., 1992), (Hastka, Lasserre, Schwarzbeck, & Hehlmann, 1994) 
Lastly, we calibrated ZPP cutpoints to produce unbiased estimates of the prevalence of iron 
deficiency using methods described elsewhere (Talsma, Verhoef, Brouwer, Mburu-de 
Wagt, Hulshof and Melse-Boonstra: submitted). 
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Results  
Plasmodium infection was highly prevalent but contained, as judged by low plasma 
concentrations of inflammation markers, LDH and bilirubin (Table 1). One-fifth of women 
had HIV infection, and one-third had inflammation. They had poor iron status, with 37% 
being anemic, 53% being iron deficient and 27% being iron replete. Iron status was 
uncertain in 20% of women because they had inflammation with plasma ferritin 
concentrations in the normal range, which indicates either iron repletion or iron deficiency 
with elevated ferritin concentrations due to inflammation.  
The prevalence of iron deficiency as defined by whole blood ZPP >70 μmol/mol heme, 
erythrocyte ZPP >70 μmol/mol heme and erythrocyte ZPP >40 μmol/mol heme was 73%, 
23.4% and 46.4%, respectively. 
α+-thalassemia was common, with 41% and 8% of women being heterozygous and 
homozygous, respectively.  
Both in univariate and multivariate analysis, whole blood and erythrocyte ZPP were 
associated with iron deficiency, plasma concentrations of soluble transferrin receptor and 
folate (Table 2). For example, in univariate analysis, each increment in plasma 
concentrations of soluble transferrin receptor by 1 mg/L was associated with a 32% 
increase in whole blood ZPP. Although whole blood ZPP seemed associated with 
gestational age in multivariate analysis, such an association was not found for erythrocyte 
ZPP. Being multigravid was independently associated with ZPP. Both univariate and 
multivariate analysis suggested that bilirubin concentration was associated with reduced 
erythrocyte ZPP. Neither Plasmodium infection nor inflammation were associate with ZPP, 
regardless of the case definition for Plasmodium infection, whether assessed in whole blood 
or erythrocytes, or whether examined by univariate or multivariate analysis. We also found 
no evidence that ZPP was associated with α+-thalassemia genotype. In univariate analysis, 
ZPP was associated with plasma vitamin B12 concentration, but this association 
disappeared in multivariate analysis. 
In the restricted population (i.e. women without inflammation, Plasmodium infection or 
HIV infection), whole blood ZPP, erythrocyte ZPP and EP concentration had only modest 
ability to discriminate between women with and without iron deficiency (Figure 1, panels A 
and B). Erythrocyte ZPP scored best of these three markers, with an AUC of 0.73 (Figure 
1, footnote). Haemoglobin concentration also performed poorly when used individually, 
and had no added diagnostic value when used in combination with whole blood ZPP, 
erythrocyte ZPP or EP concentration (Figure 1, panels C-H). 
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Table 1: Characteristics of the populations studied 
Characteristic All women Women without either 
inflammation, any 
Plasmodium infection or 
HIV infection 
n  470  175 
Age     
< 20 years 20.6% (97) 17.1% (30) 
≥ 20 years 79.4% (373) 82.9% (145) 
Gestational age     
13-14 weeks 9.1% (43) 6.3% (11) 
15–16 weeks 25.7% (121) 25.1% (44) 
17–18 weeks 29.6% (139) 26.3% (46) 
19–21 weeks 24.5% (115) 30.3% (53) 
22–25 weeks 11.1% (52) 12.0% (21) 
Gravidity     
Primigravidae 18.1% (85) 17.7% (31) 
Secundigravidae 19.6% (92) 16.0% (28) 
Multigravidae 62.3% (293) 66.3% (116) 
Plasma CRP concentration, mg/L 4.3 [2.1–10.4] 0  
Plasma AGP concentration, g/L 0.72 [0.60–0.93] 0  
Inflammation     
Plasma CRP concentration ≥ 10 mg/L 26.8% (126) 0  
Plasma AGP concentration ≥ 1 g/L 18.1% (85) 0  
Plasma concentrations of CRP ≥10 mg/L or AGP ≥ 1.0 g/L 32.3% (152) 0  
HIV infection 21.1% (99) 2 0  
Plasmodium infection     
Any Plasmodium infection, 3 by dipstick or PCR 37.2% (175) 0  
Chapter	3 
74	
Table 1: Characteristics of the populations studied 
Current or recent P. falciparum infection, by either HRP2- or LDH-based 
dipstick 
19.5% (91) 3 0  
P. falciparum, by PCR 34.7% (163) 0  
Hb concentration, g/L 113.2 (11.4) 115.7 (10.8) 
Anemia (haemoglobin concentration <110 g/L) 37.2% (175) 25.7% (45) 
Plasma ferritin concentration, μg/L 13.9 [8.2–29.2] 10.6 [7.0–18.5] 
Iron status     
Iron deficient (plasma ferritin concentration <12 μg/L) 52.8% (248) 64.6% (113) 
Iron replete (plasma ferritin concentration ≥12 μg/L, without 
inflammation) 
27.2% (128) 35.4% (62) 
Uncertain (plasma ferritin concentration ≥12 μg/L, with inflammation) 20.0% (94) 0  
Whole blood ZPP, μmol/mol heme 90 [68–121] 87 [63–121] 
Whole blood ZPP > 70 μmol/mol heme 73.4% (345) 69.1% (121) 
Erythrocyte ZPP, μmol/mol heme 36 [20–66] 42 [20–74] 
Erythrocyte ZPP > 70 μmol/mol heme 23.4% (110) 28.6% (50) 
Erythrocyte ZPP > 40 μmol/mol heme 46.4% (218) 52.6% (92) 
EP concentration, µg/L 203 [117–428] 2 224 [130–476] 4 
Plasma sTfR concentration, mg/L 1.94 [1.48–2.63] 1.87 [1.36–2.62] 
Plasma transferrin concentration, g/L 3.12 (0.56) 3.21 (0.54) 
Plasma folate concentration, μg/L 6.91 [5.45–9.39] 3 6.55 [5.21–8.87] 4 
Plasma vitamin B12 concentration, pmol/L 425 [311–651]
 3 413 [307–638] 4 
Plasma bilirubin concentration, μmol/L 6.9 [4.9–9.4] 3 7.1 [4.8–9.4] 4 
α+-thalassemia genotype     
Normal 51.2% [109/213] 5 48.4% [44] 6 
Heterozygote 41.3% [88/213] 5 42.9% [39] 6 
Homozygote 7.5% [16/213] 5 8.8% [8] 6 
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Table 1: Characteristics of the populations studied 
Values indicate mean (SD), median [25th- and 75th-percentile] or % (n) 
AGP: α1-acid glycoprotein protein; CRP: C-reactive protein; EP: erythrocyte protoporphyrin; HRP2: P. falciparum-specific 
histidine-rich protein-2; LDH: P. falciparum-specific lactate dehydrogenase; sTfR: soluble transferrin receptor; ZPP:H: zinc 
protoporphyrin:haem 
1 Only one participant had infection by a Plasmodium species other than P. falciparum; missing values resulted in n=468, 2 n=466, 3 
n=174, 4 213 5 and n=91 6 
	
TABLE 2: Factors associated with ZPP measured in whole blood or erythrocytes 
 Univariate analysis Multivariate analysis 
Difference (95% CI) p Difference (95% CI) p 
Whole blood ZPP 
Gravidity   0.68   0.04 
Primigravidae [Reference]  [Reference]  
Secundigravidae –2.3% (–15.6% to 13.1%)  0.5% (–9.6% to 11.8%)  
Multigravidae 2.7% (–8.9% to 15.7%)  9.4% (0.1% to 19.6%)  
Gestational age   0.87   0.008 
13–14 weeks [Reference]  [Reference]  
15–16 weeks 5.4% (–11.3% to 25.3%)  6.7% (–5.6% to 20.7%)  
16–18 weeks 6.1% (–10.4% to 25.7%)  –4.0% (–14.9% to 8.3%)  
19–21 weeks 2.0% (–14.3% to 21.3%)  –7.3% (–18.2% to 5.1%)  
22–25 weeks –1.0% (–19.0% to 20.9%)  –11.0% (–23.0% to –2.8%)  
Anaemia 64% (51.2% to 77.8%) <0.001 33.5% (23.9% to 43.9%) <0.001 
Iron deficiency (plasma ferritin concentration <15 μg/L) 26.3% (15.8% to 37.8%) <0.001 16.6% (9.1% to 24.6%) <0.001 
Plasma sTfR concentration, mg/L 31.9% (28.1% to 35.9%) <0.001 24.5% (20.6% to 28.5%) <0.001 
Plasma transferrin concentration, g/L 30.9% (21.4% to 41.2%) <0.001 –   
Plasma folate concentration, 10 μg/L 6.1% (–7.2% to 21.4%) 0.39 13.5% (3.0% to 25.2%) 0.01 
Plasma vitamin B12 concentration, 100 pmol/L –1.8% (–3.4% to –0.2%) 0.03 –   
Plasma total bilirubin concentration, μmol/L 0.7% (–0.4% to 1.8%) 0.20 –   
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TABLE 2: Factors associated with ZPP measured in whole blood or erythrocytes 
α+-thalassemia genotype   0.67    
Normal [Reference]    
Heterozygote –3.8% (–16.1% to 10.2%)  –   
Homozygote –10.0% (–30.2% to 16.1%)  –   
Plasmodium infection       
Any Plasmodium spp., by any dipstick or PCR 8.0% (–1.6% to 18.4%) 0.10 –   
Current or recent P. falciparum infection 1 5.1% (–6.2% to 17.8%) 0.39 –   
P. falciparum, by dipstick 1 or PCR 8.1% (–1.4% to 18.6%) 0.10 –   
P. falciparum, by PCR 9.9% (0.1% to 20.7%) 0.05 –   
HIV infection 5.2% (–14.9% to 6.2%) 0.37 –   
Plasma CRP concentration, mg/L 0.2% (–0.1% to 0.5%) 0.27 –   
Plasma AGP concentration, g/L 21.5% (3.2% to 43.0%) 0.02 –   
Inflammation 3       
Plasma CRP concentration ≥10 mg/L 5.0% (–5.1% to 16.1%) 0.34 –   
Plasma AGP concentration ≥1.0 g/L 14.0% (–1.5% to 27.9%) 0.03 –   
Plasma CRP concentration ≥10 mg/L or AGP ≥1.0 g/L 6.6% (–3.1% to 17.2%) 0.19 –   
Erythrocyte ZPP 1 
Gravidity   0.13   0.007 
Primigravidae [Reference]  [Reference]  
Secundigravidae 23.4% (–4.3% to 59.2%)  21.7% (–0.5% to 49.0%)  
Multigravidae 23.2% (0.0% to 51.7%)  31.8% (–11.0% to 56.6%)  
Gestational age   0.48    
13–14 weeks [Reference]    
15–16 weeks –4.6% (–29.4% to 29.0%)  –   
16–18 weeks 13.9% (–15.3% to 53.2%)  –   
19–21 weeks 6.1% (–21.6% to 43.8%)  –   
22–25 weeks –5.0% (–33.1% to 34.8%)  –   
Anaemia 94.6% (–67.5% to 126.2%) <0.001 47.1% (27.5% to 69.7%) <0.001 
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TABLE 2: Factors associated with ZPP measured in whole blood or erythrocytes 
Iron deficiency (plasma ferritin concentration <15 μg/L) 87.6% (–62.1% to 117.1%) <0.001 53.4% (34.8% to 74.6%) <0.001 
Plasma sTfR concentration, mg/L 48.3% (–40.0% to 57.1%) <0.001 35.1% (27.2% to 43.6%) <0.001 
Plasma transferrin concentration, g/L 85.3% (–63.2% to 110.4%) <0.001    
Plasma folate concentration, 10 μg/L 0.6% (–1.8% to 2.9%) 0.64 24.0% (3.0% to 49.3%) 0.02 
Plasma vitamin B12 concentration, 100 pmol/L –4.4% (–9.0% to 0.5%) 0.08 –   
Plasma total bilirubin concentration, μmol/L –3.0% (–4.8% to –1.1%) 0.002 –3.2% (–4.7% to –1.7%) <0.001 
α+-thalassemia genotype   0.87    
Normal [Reference]    
Heterozygote –5.9% (–25.2% to 18.3%)  –   
Homozygote –4.7% (–37.9% to 46.2%)  –   
Plasmodium infection       
Any Plasmodium spp., by any dipstick or PCR –3.0% (–17.5% to 14.1%) 0.71 –   
Current or recent P. falciparum infection 1 –10.2% (–26.3% to 9.5%) 0.29 –   
P. falciparum, by dipstick, 1 or PCR –3.0% (–17.5% to 14.1%) 0.71 –   
P. falciparum, by PCR –1.4% (–16.3% to 16.3%) 0.87 –   
HIV infection –8.5% (–24.6% to 11.0%) 0.37 –17.9% (–29.9% to –4.0%) 0.01 
Plasma CRP concentration, mg/L –0.1% (–0.6% to 0.5%) 0.82 –   
Plasma AGP concentration, g/L 1.4% (–24.0% to 35.2%) 0.92 –   
Inflammation 3       
Plasma CRP concentration ≥10 mg/L –2.1% (–18.0% to 16.8%) 0.81 –   
Plasma AGP concentration ≥1.0 g/L 3.2% (–15.8% to 26.5%) 0.76 –   
Plasma CRP concentration ≥10 mg/L or AGP ≥1.0 g/L –4.2% (–19.0% to 13.2%) 0.61 –   
AGP: α1-acid glycoprotein; CRP: C-reactive protein; HRP2: P. falciparum-specific histidine-rich protein-2; LDH: P. falciparum-specific 
lactate dehydrogenase; sTfR: soluble transferrin receptor; ZPP: zinc protoporphyrin 
1 Either HRP2- or LDH-based dipstick  
	Figure
concentration, to discriminate between pregnant women with and without iron deficiency (see 
next page for details of panels A to H).
 1: Ability of erythrocyte protoporphyrin, either alone or combined
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Panel A: Receiver operating characteristics (ROC) curve for various blood markers, used 
alone, to discriminate between iron-deficient and iron-replete women. Area-under-the-
curve, AUC (95% CI): whole blood ZPP: 0.66 (0.57–0.74); erythrocyte ZPP: 0.73 (0.65–
0.80); EP: 0.59 (0.50–0.68); Haemoglobin concentration: 0.61 (0.52–0.70). 
Panel B: Cumulative relative frequency distribution of erythrocyte ZPP, the best indicator 
when used as a single test (Panel A), to discriminate between iron-deficient and iron-replete 
women. 
The black circle in Panel A and the dotted black line in Panel B indicate the erythrocyte 
PP:heme ratio of 34 μmol/mol whereby the total diagnostic error is minimized at a 
prevalence of iron deficiency of 50%. 
Panels C, E and G: ROC curves for whole blood ZPP, erythrocyte ZPP and EP, either 
alone or each in combination with haemoglobin concentration. AUC (95%CI): combined 
whole blood ZPP with haemoglobin concentration: 0.64 (0.56–0.73); combined erythrocyte 
ZPP with haemoglobin concentration: 0.72 (0.64–0.80); combined EP with haemoglobin 
concentration: 0.64 (0.55–0.73). 
Panel D: bivariate scatterplot for whole blood protoporphyrin and haemoglobin 
concentration, by iron status;  
Panel F: bivariate scatterplot for erythrocyte protoporphyrin and haemoglobin 
concentration, by iron status;  
Panel H: bivariate scatterplot for free erythrocyte protoporphyrin and haemoglobin 
concentration, by iron status. 
Grey dashed lines in ROC curves indicate a ‘worst’ possible test, which has no 
discriminatory value and an area-under-the-curve (AUC) of 0.5. An ideal marker would 
have a curve that runs from the lower-left via the upper-left to the upper-right corner, 
yielding an AUC of 1.0. 
At a cut-point of 70 μmol/mol heme, whole blood ZPP had sensitivity and specificity of 
78% and 47%, respectively, of detecting iron deficiency (Table 3). This low specificity 
results in low positive predictive values (i.e. the probability of a test result correctly 
indicating iron deficiency) and gross overestimates of the prevalence of iron deficiency, 
particularly when the true prevalence is low. For example, at a hypothetical prevalence of 
10%, the positive predictive value would be 14%, and the estimated prevalence would be 
56% (Table 3).  
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Table 3: Diagnostic performance of ZPP, measured in whole blood or erythrocytes, in detecting iron deficiency 1 at hypothetical 
prevalence values (50%, 30% and 10%) for iron deficiency 2 
Cut-
point 
Justification Sensitivity Specificity True 
prevalence 
PPV NPV Estimated 
prevalence 
Whole blood ZPP, μmol/mol heme 
>70 
Cutpoint corresponding to 2.7 μg/g, which has 
been selected to define the presence of iron-
deficient erythropoiesis(E. L. Senga, Koshy, & 
Brabin, 2012) 
78% 47% 
50% 59% 68% 66% 
30% 39% 83% 61% 
10% 14% 95% 56% 
>49 
Cutpoint selected for screening, with a sensitivity 
of 95%  
95% 3.2% 
50% 50% 39% 96% 
30% 30% 60% 96% 
10% 10% 85% 97% 
>85 Cutpoints selected to yield unbiased estimates of 
the prevalence of iron deficiency (Figure 2; top 
panels) 
63% 63% 50% 63% 63% 50% 
>102 43% 76% 30% 43% 76% 30% 
>160 13% 90% 10% 13% 90% 10% 
Erythrocyte ZPP, μmol/mol heme 
>70 
Recommended range to indicate iron deficiency 
in the absence of infection(WHO, 2001) 38% 87% 
50% 75% 58% 26% 
30% 56% 77% 21% 
10% 25% 93% 16% 
>40 
Cutpoint recommended to distinguish between 
iron deficient erythropoiesis and iron sufficient 
erythropoiesis(WHO/CDC, 2007) 
64% 68% 
50% 66% 65% 48% 
30% 46% 81% 42% 
10% 18% 94% 35% 
>11 
Cutpoint selected for screening, with a sensitivity 
of 95% 95% 19% 
50% 54% 80% 88% 
30% 34% 90% 85% 
10% 12% 97% 82% 
>34 Cutpoints selected to yield unbiased estimates of 
the prevalence of iron deficiency (Figure 2; top 
panels) 
67% 67% 50% 67% 67% 50% 
>52 48% 77% 30% 48% 77% 30% 
>81 27% 92% 10% 27% 92% 10% 
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Table 3: Diagnostic performance of ZPP, measured in whole blood or erythrocytes, in detecting iron deficiency 1 at hypothetical 
prevalence values (50%, 30% and 10%) for iron deficiency 2 
PPV: positive predictive value; NA: not applicable; NPV: negative predictive value. Cutpoint values for ZPP (column 1) 
expressed as μmol/mol heme. 
1 Defined as serum ferritin concentration <15 μg/L; 2 analysis restricted to women without inflammation, Plasmodium infection 
or HIV infection 
	
Erythrocyte ZPP >70 μmol/mol heme had much better specificity (87%) but a low sensitivity (38%), whilst values >40 μmol/mol 
heme yielded intermediate values for sensitivity and specificity (64% and 68%, respectively; values obtained from ROC curve 
analysis, Figure 1). With our sensitivity and specificity values, unbiased estimates for hypothetical prevalence values of 50%, 30% 
or 10% would be produced at whole blood ZPP cutpoints of 85 μmol/mol heme, 102 μmol/mol heme and 160 μmol/mol heme, 
respectively. Corresponding cutpoints for erythrocyte ZPP would be 34 μmol/mol heme, 52 μmol/mol heme and 81 μmol/mol 
heme. 
 
Even at a sensitivity of 95%, as may be applied for screening purposes, a negative test result obtained as whole blood ZPP ≤ 49 
μmol/mol heme would be insufficient to rule out iron deficiency, because negative predictive values (i.e. the probability of a test 
result correctly indicating absence of iron deficiency) would only be 63%, 76% and 85% at prevalence values of 50%, 30% or 
10%, respectively (Table 3). 
 
At a prevalence of 19%, erythrocyte ZPP ≤ 11 μmol/mol heme (corresponding to a sensitivity of 95%) would yield 97% probability 
of ruling out iron deficiency, resulting in iron deficiency being excluded in 18% (=100%–82%; Table 3) of women. At higher 
prevalence values, this sensitivity is insufficient to rule out iron deficiency as judged by negative predictive values. 
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Discussion 
In the population studied, both whole blood ZPP and erythrocyte ZPP were mostly 
determined by iron markers including anemia, whilst inflammation, Plasmodium infection 
and HIV infection played only minor roles. When used individually, whole blood ZPP, 
erythrocyte ZPP and EP had limited ability to discriminate between women with and 
without iron deficiency, whilst combining each of these markers with haemoglobin 
concentration had no additional diagnostic value. This limited diagnostic value was also 
apparent when using dichotomized variables for whole blood ZPP and erythrocyte ZPP. 
Conventional cut off points for whole blood ZPP (>70 μmol/mol heme) can result in gross 
estimates of the prevalence of iron deficiency, particularly when the true prevalence is low. 
Erythrocyte ZPP may have limited value to rule out iron deficiency when used for 
screening in conditions with a low prevalence (e.g. 10%). 
 
Our study was designed to investigate the diagnostic utility of ZPP in a malaria endemic, 
resource-poor setting that has a high prevalence of α+-thalassemia and other haemoglobin 
disorders. This is particularly relevant because the World Health Organization (WHO) no 
longer recommends that children in malaria-endemic areas should receive universal iron 
supplementation; instead, children should be screened and supplementation should be 
restricted to those with iron deficiency. (WHO, 2007) Unfortunately, however, there are no 
simple, rapid tests available to implement this recommendation under field conditions. The 
WHO has pointed to the need to validate ZPP in malarious areas. (WHO, 2007) 
 
Iron status is commonly monitored by haemoglobin concentration, hematocrit, and plasma 
ferritin concentration. (Romslo et al., 1983) Whereas cutpoints for these markers have been 
established in non-pregnant individuals, they are probably unreliable in pregnancy because 
these markers are affected by plasma expansion. By contrast, ZPP content can be expressed 
as a molar ratio to heme, which should theoretically be independent of hemodilution. Thus 
ZPP has been proposed as a preferred marker for iron status in pregnancy. (Ron B. 
Schifman et al., 1987) Furthermore, erythrocyte ZPP was reported to be a sensitive and 
specific indicator in the detection of iron deficiency in non-pregnant women and young 
children aged 1-5 years in the United States and in areas where the prevalence of elevated 
blood lead concentration is not high. (Mei, Parvanta, Cogswell, Gunter, & Grummer-
Strawn, 2003) 
 
A strong point in our study was ZPP measured both in whole blood and in washed 
erythrocytes. We strictly adhered to protocol, conducted measurements in duplicate, and 
ran control samples as per instructions by the manufacturer. Lead exposure in our study 
population was probably very low. We ensured comprehensive assessment of iron status in 
all the participants using different markers as recommended by various guidelines. 
(WHO/CDC, 2007), (British Committee for Standards in Haematology, 2011) The iron 
markers, inflammation markers, and hemolysis markers reported in this study, as well as EP 
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concentrations, were assessed independently by laboratories that were not involved in the 
fieldwork. Further, were probably detected most asymptomatic Plasmodium infections 
using most of the known methods of assessing Plasmodium infection during pregnancy 
(dipsticks, PCR, and histopathology of placental biopsies). The high acceptance rate for 
HIV testing (98%) enabled us to study the diagnostic performance of ZPP in the presence 
of HIV as a chronic disease. We also performed statistical analyses restricted to women 
without inflammation, Plasmodium infection or HIV infection because plasma ferritin 
concentration reacts as an acute phase protein. 
 
Our study had several limitations. First, we could not assess α+-thalassemia status of all the 
participants due to practical reasons. However, we found no associations between ZPP and 
α+-thalassemia in the women in whom α+-thalassemia genotype was established. Secondly, 
we studied pregnant women. Although we do not expect that the diagnostic performance of 
ZPP is better in children, we cannot exclude this possibility. In addition, other conditions 
and genetic disorders such as sickle cell anemia and G6PD that may influence the 
diagnostic utility of ZPP were not studied.  
 
Several other studies also found that detection of iron deficiency by ZPP leads to marked 
overestimates of the prevalence of iron deficiency. (Grant et al., 2012), (Rebecca J. 
Stoltzfus et al., 1997), (Asobayire, Adou, Davidsson, Cook, & Hurrell, 2001), (Crowell, 
Ferris, Wood, Joyce, & Slivka, 2006) This may have been due at least in part to 
inflammation or infection. (WHO/CDC, 2007), (WHO, 2007) Several studies have shown 
that ZPP content in whole blood can be markedly higher than values measured in washed 
erythrocytes. Various reasons including interference by bilirubin have been cited. (Hastka 
et al., 1992), (Hastka et al., 1994), (R B Schifman & Finley, 1981), (Janousek, Rosa, Jirova, 
& Kejlova, 2010), (Buhrmann, Mentzer, & Lubin, 1978) Our findings show, however, that 
this overestimation is also in large part due to low specificity to ZPP at conventionally used 
cutpoints, whether measured in whole blood or in erythrocytes. Selection of cut-points for 
dichotomized diagnostic tests should depend on the diagnostic aims. When used as an 
initial screening marker to manage iron deficiency, ZPP should be highly sensitive, with a 
view to rule out iron deficiency (i.e. a high negative predictive value, no longer needing 
work-up) or to identify individuals who are iron deficient or who need further diagnostic 
work-up. Our findings show, however, that a high sensitivity will inevitably be 
accompanied by a low specificity, and thus an unacceptably low negative predictive value. 
For example, in Table 3, we have shown that for whole blood ZPP, a sensitivity of 95% can 
be obtained with a cutpoint of 49 μmol/mol heme. However, the corresponding specificity 
is 3.5%, resulting in negative predictive values that will be unacceptably low with true 
prevalence values for iron deficiency in most conditions. As an exception, erythrocyte ZPP 
may have limited value to rule out iron deficiency in populations with low prevalence of 
iron deficiency (Table 3). These results were obtained in a restricted dataset, with exclusion 
of women with inflammation, Plasmodium infection or HIV infection. The diagnostic 
performance of ZPP in an unrestricted dataset would presumably have been even worse. 
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When applied to estimate the prevalence of iron deficiency, ZPP cutpoints can be calibrated 
to produce unbiased estimates. 
 
In this population, both whole blood ZPP and erythrocyte ZPP have little diagnostic utility 
as a screening marker to manage iron deficiency, whether used as single tests or combined 
with haemoglobin concentration. When used to estimate the prevalence of iron deficiency, 
conventional cutpoints for whole blood ZPP can result in marked overestimates. 
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Chapter	4	
Antenatal	iron	supplementation	and	serum	
concentrations	of	non-transferrin	bound	iron	in	
pregnant	women	in	a	malaria-endemic	region	of	Kenya:	a	
randomised	controlled	trial	3	
Abstract	
Background: Iron supplementation can lead to increased incidence of malaria and other 
infectious diseases in children, possibly because of non-transferrin bound iron (NTBI). We 
aimed to measure the influence of ingestion of a supplement with iron (60 mg, as ferrous 
fumarate) on serum NTBI concentrations in pregnant Kenyan women. We also assessed the 
influence of iron status, gravidity, maternal age, Plasmodium infection, HIV infection and 
α+-thalassemia genotype on the serum NTBI response to oral iron supplementation. 
Design and methods: Double-blind, randomised intervention trial comparing 
supplementation with iron versus placebo. Pregnant women (gestation age 13-23 weeks, 
haemoglobin >90 g/L) ingested the iron supplement. They were offered an optional non-
standardized lunch meal approximately 1.5 hours after ingestion. At 3 hours after ingesting 
the iron supplement, blood was collected in trace elements free tubes. Serum NTBI, iron, 
and inflammation markers were then assessed. Statistical analysis was done according to a 
pre-defined plan. 
Results: 379 women participated in the study. Compliance was 100%. Intervention groups 
were similar at baseline except for mild imbalances. NTBI concentrations were similar 
between groups (mean for both: 0.18 µmol/L; difference, 95%CI: 0.01 µmol/L, –0.03 
µmol/L to 0.05 µmol/L). NTBI was present (values ≥0.18µmol/L) in 40.9% (76/186) and 
46.1% (89/193) of women in high-dose iron versus low-dose iron groups (difference: 5.3%, 
–15.0% to 4.7%). 
Conclusion: There was no effect of oral ingestion of 60 mg ferrous fumarate on serum 
NTBI concentration three hours after ingestion; the NTBI response to iron was also not 
influenced by Plasmodium infection, iron deficiency, iron deficiency anaemia or α-
thalassaemia. In addition, the effect was not substantially changed by other covariates such 
as gravidity, maternal age, and HIV infection status. 
                                                           
3Submitted for publication 
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Introduction 
Supplementation with ferrous iron salts can lead to an increased incidence of malaria and 
other infectious diseases in children, (Sazawal et al., 2006) which is possibly mediated by 
non-transferrin bound iron (NTBI). (WHO, 2007)  NTBI does not normally occur in 
healthy individuals. (Espósito, Epsztejn, Breuer, & Cabantchik, 2002) Supplementation 
with ferrous salts can transiently produce NTBI (Table 1), although the supportive 
evidence was obtained from small, mostly non-randomised studies using volunteers with 
adequate iron status. Although transferrin-mediated uptake is the major route of iron 
delivery to erythroblasts, reticulocytes and mature erythrocytes can take up NTBI via 
transferrin-independent mechanisms. (Morgan, 1988) (Egyed, 1988) (Kovar et al., 2006) 
(Valis et al., 2008) (Sanchez-Lopez & Haldar, 1992) Thus, it would seem likely that 
Plasmodium parasites can access NTBI as a nutritional source of iron for their development 
and propagation (R J Stoltzfus, 2008; WHO, 2007). Elimination of NTBI is also a 
therapeutic goal (Brissot, Ropert, Le Lan, Loréal, & Loreal, 2012) because it is thought to 
play a role in various pathological conditions and also in the production of reactive oxygen 
species which may contribute to tissue damage. 
Little is known about factors that influence the magnitude of the serum NTBI response to 
iron ingestion. It is plausible that these factors include determinants of iron absorption, 
since NTBI production probably occurs when the absorption rate of iron and its release into 
circulation exceeds the rate of iron binding to transferrin. Thus, women may be particularly 
vulnerable in the second trimester of pregnancy, when iron deficiency is common and non-
haem iron absorption may be as high as 25%. (Barrett, Whittaker, Williams, & Lind, 1994) 
In pregnancy, iron status is also known to be related to gestational age, (Leif Hallberg, 
2001) gravidity, and maternal age. Plasmodium infection (de Mast, Nadjm, et al., 2009; 
Andrew M Prentice et al., 2012) and HIV infection can lead to decreased iron absorption, 
and thus perhaps to a reduced NTBI response. Thalassaemia is characterised by ineffective 
erythropoiesis and increased plasma iron turnover. (Gafter-Gvili, Prokocimer, Breuer, 
Cabantchik, & Hershko, 2004) When extreme, this can lead to excessively low hepcidin 
production, resulting in iron being absorbed at a faster rate than being used for 
erythropoiesis. Although this is the case in severe forms of β-thalassemia, even without 
transfusions, (Gardenghi et al., 2007; Musallam, Taher, & Rachmilewitz, 2012) it remains 
to be established for α+-thalassaemia, which does not result in manifestations other than 
mild anaemia in homozygotes. 
Our main aim was to measure the influence of ingestion of a supplement with iron (60 mg, 
as ferrous fumarate) on serum NTBI concentrations in pregnant Kenyan women. 
Additionally, we assessed the influence of iron status, gravidity, maternal age, Plasmodium 
infection, HIV infection and α+-thalassemia genotype on the serum NTBI response to oral 
iron supplementation.  
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Table 1: Summary of studies into effect of iron interventions on non-transferrin bound iron (NTBI) concentrations 
Reference Population  
(sample size) 
Intervention Follow-
up/measurements 
Key findings Comments 
Hutchinso
n et al. 
2004 
UK adult women with 
anaemia (n=7) 
65mg iron as ferrous 
sulphate given with or 
without test meal low in 
inhibitors of iron 
absorption (white bread, 
margarine, honey and 
dilute orange cordial) 
Serial collection of serum 
samples at 30min-
intervals for 4hrs 
NTBI measurement: 
Gosriwatana et al. with 
detection by HPLC 
NTBI increased over 
time relative to 
baseline, whether 
taken with or without 
food (both p<0.001) 
No evidence that food 
had an effect  
Absence of detectable 
effect of food may be 
because the meal 
was low in compounds 
that inhibit iron 
absorption, or due to 
small sample size 
Hutchinso
n et al. 
2008 
UK males with HH (HFE 
C282Y+/+; n=5) versus 
iron-replete male controls 
(n=6) 
Test meal with 10mg 
extrinsically added ferric 
iron as enriched 58FeCl3 
Serum samples collected 
at baseline and at 0.5h 
and 3h thereafter 
NTBI measurement: 
Gosriwatana et al. (Anal 
Biochem 
1999;273:212e20) with 
detection by ICP-MS 
HH: NTBI seemed 
increased at 3h after 
baseline, p=0.06 
Controls: no 
postprandial increase 
in NTBI 
None 
Baron et 
al. 2008 
Pregnant Israeli women 
(n=57) 
100mg oral iron as 
ferrous calcium citrate 
(n=35) versus iv 100mg 
iron as ferric hydroxide 
sucrose (n=22) 
None of the patients had 
fasted overnight 
Blood samples collected 
at baseline and at 1hr 
thereafter 
NTBI measurement: 
Breuer, Cabntchik (Anal 
Biochem 2001;299:194–
202) 
No NTBI detectable 
at baseline 
NTBI concentration 
at 1hr: 0.8091 μM 
versus 0.0743 μM, 
p<0.01 
Non-randomised study 
(iv iron given to those 
with severe anaemia 
unresponsive to oral 
iron treatment or 
because they could not 
tolerate oral iron 
treatment due to severe 
side effects) 
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Table 1: Summary of studies into effect of iron interventions on non-transferrin bound iron (NTBI) concentrations 
Reference Population  
(sample size) 
Intervention Follow-
up/measurements 
Key findings Comments 
Dresow et 
al. 2008 
German healthy adult 
volunteers 1 or patients 
with IDA (n=2) 
Healthy volunteers: 10– 
150 mg iron in various 
formulations 1 
Patients with IDA: 
100mg ferrous iron as 
ascorbate 
Plasma samples collected 
at baseline and at 1–8h 
thereafter 
NTBI measurement: 
Singh et al. (Anal 
Biochem 186:320–323) 
with modification of 
using atomic absorption 
spectroscopy 
Peak NTBI 
concentration at 1–
8h: 6–12 μM, p<0.01 
 
Schümann 
et al. 2012a 
Fasted non-anaemic iron-
replete Guatemalan adult 
men (n=8) 
0, 15mg, 30mg, 60mg, 
120mg and 240mg iron 
as ferrous sulphate 
Serum samples collected 
at baseline and at 1h, 2h 
and 3h thereafter 
NTBI measurement: 
Breuer, Cabntchik (Anal 
Biochem 2001;299:194–
202) 
Iron resulted in  a 
dose-dependent 
increase in NTBI 
Cross-over trial with 
incremental doses and a 
7-day or 14-day 
washout period 
between testing, 
depending on dose 
Schümann 
et al. 
2012b 
Fasted non-anaemic 
healthy adult Guatemalan 
men without 
inflammation (n=10) 
100mg ferrous iron as 
sulphate versus 100mg 
ferric iron as NaFeEDTA 
versus 100mg ferric iron 
in polymaltose complex 
versus placebo, with a 
light snack 
(pancakes/fruit) after 
180min 
Plasma samples collected 
at baseline and at 90min, 
180min and 270min 
thereafter 
NTBI measurement: 
Breuer, Cabntchik (Anal 
Biochem 2001;299:194–
202) 
Increase in NTBI 
with FeSO4 was 
significantly greater 
than that with water, 
NaFeEDTA, or IPM, 
with no differences 
among the latter three 
Randomised cross-over 
trial with a 7-day 
washout period 
between testing 
Schümann 
et al. 2013 
Apparently healthy, 
fasted  non-pregnant 
adult Guatemalan women 
100mg iron as ferrous 
sulphate versus 100mg 
iron as NaFeEDTA 
Serum samples collected 
at baseline and at 90min, 
180min and 270min 
Increase in NTBI 
with FeSO4 was 
significantly greater 
Trial with parallel 
groups; however, report 
that intervention was 
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Table 1: Summary of studies into effect of iron interventions on non-transferrin bound iron (NTBI) concentrations 
Reference Population  
(sample size) 
Intervention Follow-
up/measurements 
Key findings Comments 
without inflammation, 
with ferritin 
concentration 
<30μg/L and Hb 
concentration ≥112g/L 
(n=40) 
versus 100mg iron in 
polymaltose complex 
versus placebo, with a 
light snack 
(pancakes/fruit) after 
180min 
thereafter 
NTBI measurement: 
Breuer, Cabntchik (Anal 
Biochem 2001;299:194–
202) 
than that with water, 
NaFeEDTA, or IPM, 
with no differences 
among the latter three 
randomly allocation 
seems contradicted by 
equal sample size per 
group 
HH: hereditary haemochromatosis; IDA: iron deficiency anaemia 
1 Iron dosage: 10mg as ferrous ascorbate (n=6), 100mg as ferrous ascorbate (n=8); 100mg as ferrous sulphate (n=6); 50mg as 
ferrous glycine sulphate (n=4); 100mg as ferrous glycine sulphate (n=7); 80.5mg as ferrous gluconate (n=5); 150mg ferric 
polysaccharide complex (n=5) 
	
Subjects and Methods 
This study was part of a randomised controlled trial to assess the effect of iron supplementation in Kenyan women. Details about 
study design and main results will be reported elsewhere. The trial received ethical clearance from ethical review committees in 
Kenya (Kenyatta National Hospital/University of Nairobi) and England (London School of Hygiene and Tropical Medicine), and 
was registered at www.ClinicalTrials.gov (NCT01308112). Written informed consent was obtained from all study participants. 
Study area and population 
The study was conducted (October 2011–April 2013) in the administrative areas of Kanyawegi, Osiri and Ojolla, Nyanza Province, 
Kenya, where malaria is highly endemic and transmission is perennial. Anaemia is highly prevalent (69%)(Ouma et al., 2007) and 
intestinal schistosomiasis is common(Samuels et al., 2012). The population consists mainly of poor families from the Luo tribe, 
and has a diet mostly based on maize and with a low content of animal products, with sorghum, millet, and cassava being 
consumed in smaller quantities. 
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Study design 
The study was a double blind, randomised intervention trial comparing supplementation 
with iron versus placebo. To prevent severe anemia, all women were dewormed, and all 
received a small daily dose of iron through flour fortification in the 2–3-week period before 
randomisation.   
Recruitment and eligibility criteria 
Local women aged 15–45 years who were married or cohabitating were invited for 
pregnancy testing when having missed their menstrual period for 10 weeks. Those who 
were not in stable relationships were invited for pregnancy testing every 12 weeks. In 
consenting women, we administered a urine pregnancy test, a medical examination 
including obstetric ultrasonography, and preventive antihelminth chemotherapy with 
praziquantel and albendazole.  
Local mill operators added fortificant iron (target dose: 20mg/kg as NaFeEDTA) (WHO et 
al., 2009) to grain routinely brought by a member of a participating homestead from 
screening until women left the study. Based on weighed intake studies, we estimate that 
fortification supplied on average 5.7mg fortificant iron daily in pregnant women 
(unpublished data). 
At the second visit to the research clinic (14 to 21 days after initial visit), we collected 
venous blood in K2EDTA tubes, and measured haemoglobin concentration (HemoCue301, 
Ängelholm, Sweden) and zinc protoporphyrin (Aviv 206d, Lakewood, NJ). Buffy coat and 
erythrocyte sediment were stored separately in DNA-stabilizing buffer (AS1, Qiagen, 
Valencia, CA) at 2–8˚C in the field and subsequently at–80˚C until polymerase chain 
reaction (PCR) assays. Plasma was stored at –196˚C in the field and subsequently at–80˚C 
until analysis. 
Women were included when aged 15-45 years; consent had been obtained; likely to be 
available for study until 1 month after delivery and planning to deliver in the pre-designated 
health facility. They were excluded when having obvious mental retardation or a metabolic 
disorder, a medical history of sickle cell anemia, epilepsy, diabetes, an obstetric history 
suggestive of eclampsia or pre-eclampsia; carrying multiples; gestational age at the second 
visit was <13weeks or >23weeks; no venous blood was collected, haemoglobin 
concentration was <90g/L. 
Randomisation, interventions and blinding 
Supplements comprised capsules with starch as filler that were identical in appearance 
except that the shell for each type was into two colors (blue and dark green for iron, white 
and buff for placebo). Iron supplements contained 60 mg iron as ferrous fumarate (Dr. Paul 
Lohmann®, CAT No.500005025200). Ferrous fumarate was used for practical reasons, 
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knowing that it has similar iron bioavailability as ferrous sulfate. (Harrington et al., 2011) 
The code linking each color to the type of supplement was kept in sealed envelopes. One of 
us (HV) not involved in the fieldwork used tables with random numbers to produce 
sequentially numbered sealed, opaque envelopes containing the code. Eligible women were 
allocated in order of enrolment to the color indicated in the next available envelope. 
Participants and field staff were blinded to intervention until data analysis. To ensure 
adherence, women were observed when swallowing the capsule. 
Follow-up of study participants  
Approximately 1.5h after ingesting the first supplement, the participant was offered a non-
standardised lunch that could include fish, omena (Rastrineobola argentea), beef, beans, 
green grams (Vigna radiata), bread, ugali (stiff maize porridge), rice, and chapati 
(unleavened flat-bread made from wheat flour), vegetables (mostly kale) and drinking 
water. We did not keep records of what was consumed by each participant.  
 At 3h after ingesting the first supplement, blood was collected in trace elements free tubes 
(Becton-Dickinson, Franklin Lakes, NJ, USA; catalogue 368380). Serum was stored at –
196˚C in the field and subsequently at –80˚C during transport and storage until assessment 
of NTBI concentration in the UK. Although women were retained for further study, this is 
outside the scope of this paper, and will not be described here. 
Laboratory analysis 
Serum NTBI concentration was measured at King’s College, London, UK, using a flow 
cytometry-based assay. This assay allows for accurate detection of NTBI concentrations 
down to 0.1µM. (Hider, Silva, Podinovskaia, & Ma, 2010) The detailed procedure can also 
be found in a patent application which was published in 2010, UK Patent Application 
number 1007209.8. For practical reasons, NTBI concentration was determined in the first 
379 consecutively randomised women. 
Haemoglobin concentrations were measured using a photometer (HemoCue model 301, 
Ängelholm, Sweden). The molar ratio of zinc protoporphyrin to haemoglobin (ZPP:H) in 
whole blood and washed erythrocytes was measured in duplicate for each sample using a 
haematofluorometer (Model ZPP 206D, AVIV Biomedical, Lakewood, NJ, USA). Control 
samples at low, medium, and high levels (AVIV) were run after every 30 readings while 
two level (low, high) calibration samples (AVIV) were run twice per year.  
Iron markers (plasma concentrations of ferritin, soluble transferrin receptor, transferrin), 
and inflammation markers (plasma concentrations of C-reactive protein [CRP] and α1-acid 
glycoprotein) were measured on a Beckman Coulter UniCel DxC 880i analyser as per 
manufacturer’s instructions. 
HIV infection was determined using rapid antibody tests (Alere Determine™, Alere™, 
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Waltham, Massachusetts, USA); a positive result was confirmed using other antibody tests 
(Unigold™, Trinity Biotech PLC™, Co Wicklow, Ireland, and/or Bioline™, Pantech, 
Umhlanga, Kwazulu-Natal, South Africa).  
Plasmodium antigenaemia was assayed by rapid dipstick tests (Access Bio Inc, Somerset, 
NJ, USA; CareStart, catalogue G0151 and G0171) that can detect P. falciparum-specific 
histidine-rich protein-2 (HRP2), Plasmodium lactate dehydrogenase (pLDH) specific to 
either P. falciparum or to non-falciparum species, i.e. P. ovale, P. malariae or P. vivax. 
Whereas HRP2-based tests detects current or recent P. falciparum infection, pLDH-based 
tests only indicate current infection.(Makler et al., 1998; Moody, 2002; Piper et al., 1999) 
DNA was extracted from buffy coats and erythrocytes with a QIAamp DNA blood Mini Kit 
(Qiagen, Hilden, Germany). The –α3.7 deletion type of α+-thalassemia and P. falciparum 
infection were detected by separate PCRs.(Liu et al., 2000)(Hermsen et al., 2001) Due to 
practical constraints, α+-thalassemia genotype was assessed for the first 216 consecutively 
randomised women only. 
Definitions 
We used the following definitions: gravidity: the number of times a woman reported to 
have been pregnant, regardless of the outcome of those pregnancies, with twins and other 
multiple births counted as 1, and including the current pregnancy; compliance: percentage 
of participants who consumed the iron supplement or placebo and for whom a venous blood 
sample was obtained at 3h thereafter; Plasmodium infection: positive result for a pLDH-
based dipstick test, a HRP2-based dipstick test or PCR test; anaemia: haemoglobin 
concentration <110 g/L;(WHO, 2011a) iron deficiency: plasma ferritin concentration <15 
µg/L; (WHO, 2011b) iron deficiency anaemia: concurrent anaemia and iron deficiency; 
iron-deficient erythropoiesis: erythrocyte ZPP:haem molar ratio >40 µmol/mol; 
(Zimmermann, 2008) (Hastka et al., 1992) (Hastka et al., 1994) inflammation: either C-
reactive protein (CRP) >10 mg/L (Nielsen et al., 1990) or α1-acid glycoprotein (AGP) >1 
g/L (Filteau et al., 1993). 
Statistical methods 
Haemoglobin concentration and ZPP:haem molar ration were calculated as the mean of 
duplicate measurements, or as median values if more than two recordings were available. 
Data analysis was done using IBM-SPSS Version 21 (SPSS, Chicago, USA) and CIA 2.2.0 
(http://www.som.soton.ac.uk/research/sites/cia/). The primary analysis concerned the 
relative difference in serum NTBI concentrations at 3h after ingestion of the first 
supplement between groups that received iron or placebo. Serum NTBI concentrations were 
normalised by log-transformation. We considered NTBI to be present at values exceeding 
0.18 µmol/L (Robert Hider, unpublished results). All analyses were by intention-to-treat. 
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Using linear regression analysis, we assessed confounding by comparing effects with and 
without adjustment for baseline factors suspected to be prognostic for the primary outcome 
(iron status, indicated by haemoglobin concentration, plasma ferritin concentration [<12 
μg/L or ≥ 12 μg/L], gestational age, gravidity [primigravidae, secundigravidae, 
multigravidae] and maternal age [< 20 years and ≥ 20 years]); HIV infection; Plasmodium 
infection status; and α+-thalassemia genotype. We used stratified analysis and multivariate 
analysis to explore effect modification by baseline factors. 
Results  
Of 2,015 women invited for screening, we randomised 470 (23%) to intervention (Figure 
1), and included 379 women in this paper. Compliance was 100%.  
Regarding baseline characteristics, intervention groups were similar except for mild 
imbalances in marital status, gravidity, anaemia and the prevalence of iron deficiency 
anaemia (Table 2). 99% of participants who tested positive for Plasmodium infection had 
P. falciparum while only one participant (1%) was infected with other Plasmodium species. 
At 3h after ingesting the supplement, NTBI concentrations were similar between groups 
(mean for both: 0.18 µmol/L; difference, 95%CI: 0.01µmol/L, –0.03 µmol/L to 0.05 
µmol/L). NTBI was present (values ≥0.18µmol/L) in 40.9% (76/186) and 46.1% (89/193) 
of women in high-dose iron versus low-dose iron groups (difference: 5.3%, –15.0% to 
4.7%).  
Adjustment for possible confounders did not substantially change the effect estimate; 
neither was any of these factors independently associated with NTBI concentrations (not 
shown). 
There was no evidence that NTBI response was dependent on Plasmodium infection status 
at baseline (difference, 0.01 µmol/L in groups with and without infection; 95% CI: 0.01 
µmol/L, -0.06 to 0.04) (Figure 2). There was also no evidence that NTBI response to iron 
depended on initial haemoglobin concentrations. Similarly, given placebo or iron, a 10-fold 
increase in the zinc protoporphyrin:haem ratio was associated with a 0.04 and 0.07 µmol/L 
decrease in NTBI concentrations respectively	(difference, 95% CI: 0.03 µmol/L, -0.124 to 
0.064, p=0.53). NTBI values seemed slightly reduced in participants with iron deficiency 
anaemia as compared to iron-replete individuals (95% CI: -0.04 to 0.06, p=0.11), 
irrespective of intervention group.  
We found no evidence for an effect of normal (mean, 95% CI: -0.02 µmol/L, -0.09 to 0.04), 
heterozygous (0.04 µmol/L, -0.01 to 0.09) or homozygous (0.04 µmol/L, -0.07 to 0.16) α-
thalassaemia genotypes in the serum NTBI response to ferrous fumarate. The effect of iron 
on NTBI concentrations is found to be -0.02 µmol/L in the normal genotype and equal in 
both the heterozygous and homozygous genotypes (0.04 µmol/L, difference 0.06 µmol/L) 
T
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n
Height, cm
Weight, kg
Body mass index, kg/m
Marital status
Married or living together
Divorced or separated
Never married
Age, years
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High-dose iron
186
162.5
58.3
22.1
162
25.3
5
19
  
 (6.0)
 (8.0)
 (2.8)
  
 [87.1%]
 [2.7%]
 [10.2%]
 (6.2)
 
 
 
 
 
 
 
 
 
Low
162.3
-
193
57.5
21.8
157
29
24.5
dose iron
  
 (6.8)
 (7.8)
 (2.6)
  
 [81.3%]
7 [3.6%]
 [15.0%]
 (5.9)
 
 
 
 
 
 
 
 
	
Antenatal	iron	supplementation	and	serum		NTBI	in	pregnant	women	in	a	malaria-endemic	region	of	Kenya	
97	
Table 2: Characteristics of study participants, by intervention group 
Characteristics High-dose iron Low-dose iron 
Gestational age, weeks 1 17.8 (2.5)  17.8 (2.5)  
Gravidity     
Primigravidae 26 [14.0%]  38 [19.7%]  
Secundigravidae 42 [22.6%] 33 [17.1%] 
Multigravidae 118 [63.4%] 122 [63.2%] 
Plasmodium infection 2 60 [32.3%] 67 [34.7%] 
HIV infection4 33 [17.9%] 42 [21.8%] 
Plasma CRP concentration, mg/L 4.32 [7.3] 4.39 [9.2] 
Plasma AGP concentration, g/L 0.76 (0.25) 0.78 (0.26) 
Inflammation 3     
Plasma CRP concentration ≥10 mg/L 45 [24.2%] 55 [28.5%] 
Plasma AGP concentration ≥1.0 g/L 28 [15.1%] 33 [17.1%] 
Plasma concentrations of CRP ≥10 mg/L or AGP 
≥1.0 g/L 
56 [30.1%] 62 [32.1%] 
Haemoglobin concentration, g/L 113.9 (11.2) 112.3 (11.6) 
Anaemia, haemoglobin concentration <110g/L 63 [33.9%]  79 [40.9%]  
Iron deficiency, plasma ferritin concentration 
<15µg/L 
    
All women 103 [55.4%]  102 [52.8%]  
Those with CRP concentration <10 mg/L 82 [44.1%]  79 [40.9%]  
Those with AGP concentration <1.0g/L 93 [50.0%]  88 [45.6%]  
Those with concentrations of CRP <10mg/L or AGP 
<1.0 g/L 
97 [52.2%]  91 [47.2%]  
Iron deficiency anaemia 31 [16.7%] 43 [22.3%] 
Plasma ferritin concentration, µg/L 15.4 [20.3]  15.9 [19.9]  
Plasma sTfR concentration, mg/L 1.90 [1.09]  2.09 [1.16]  
Plasma transferrin concentration, g/L 3.1 (0.6) 3.1 (0.5) 
Whole blood ZPP:haem molar ratio, µmol/mol 94.7 [53.1]  98.4 [57.1]  
Erythrocyte ZPP:haem molar ratio, µmol/mol 38.3 [48.3] 41.1 [55.8] 
Plasma folate concentration, nmol/L 16.85 (6.88) 17.27 (7.33) 
Plasma vitamin B12 concentration, pmol/L 497.9 (266.2) 499.3 (274.8) 
α+-thalassaemia genotype 5     
Normal 54/ 105 51.4% 57/ 111 51.4% 
Heterozygote 45/ 105 42.9% 44/ 111 39.6% 
Homozygote 6/ 105 5.7% 10/ 111 9.0% 
Values indicate mean (SD), geometric mean [IQR], n [%] or n/n [%]. AGP: α1-acid glycoprotein; CRP: C-
reactive protein; FEP: free erythrocyte protoporphyrin; HRP2: P. falciparum-specific histidine-rich protein-
2; LDH: P. falciparum-specific lactate dehydrogenase; sTfR: soluble transferrin receptor; ZPP: zinc 
protoporphyrin. 
1 All participants were in the second trimester of pregnancy except for one who was in the first trimester; 2 
Any species, by any dipstick or PCR; only one participant (high-dose iron group) had infection by a 
Plasmodium species other than P. falciparum; 3 Only one participant (high-dose iron group) had current fever 
defined as axillary temperature ≥ 37.5 °C; 4 HIV infection status was not determined for two participants; 5 
Determined in 216 women only. 
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Discussion
We found no effect of oral ingestion of 60 mg ferrous fumarate on serum NTBI 
concentration three hours after ingestion; the NTBI response to iron was also not influenced 
by 
addition, the effect was not substantially changed by other covariates such as gravidity, 
maternal age, and HIV infection status.
 
This was despite the fact that iron deficiency anaemia leads to increased iron absorption
(Leif Hallberg & Hulthén, 2002) 
(Chung & Wessling
absorption as a result of ineffective erythropoiesis, and increased plasma iron turnover
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-Resnick, 2003) Thalassaemias are associated with increased iron 
which would lead to higher serum NTBI concentrations.
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(Gafter-Gvili et al., 2004), thus NTBI concentration is expected to be higher in individuals 
with thalassaemia disorders. However, Plasmodium-induced inflammation has been shown 
to lead to a decreased iron absorption (de Mast, van Dongen-Lases, et al., 2009) and is 
therefore likely to result in a reduced NTBI concentration.  
 
To our knowledge, this is the first study on the effect of iron supplementation on serum 
NTBI involving pregnant African women living in a region of high malaria endemicity. 
Compliance was 100%, and there was no attrition during follow-up. Blinding was highly 
effective because the taste of the iron and placebo supplements was masked by the 
capsules. Malaria rates in Kenya have been declining, (A. Noor et al., 2009) (Ministry of 
Public Health and Sanitation (MOPHS) & Ministry of Medical Services, 2010) thus in 
order to quantify the total malaria burden on the participants, we assessed all asymptomatic 
Plasmodium infection using combinations of dipstick tests and Plasmodium falciparum 
specific PCR. PCR tests for other Plasmodium species were not done because results of 
dipstick tests showed that all infections except one were due to P. falciparum. Assessment 
of inflammation by combinations of C-reactive protein and α1-acid glycoprotein allowed us 
to determine iron status in the study population. All analyses were done according to a pre-
specified plan.  
 
Our study had some limitations. A meal was consumed by most of the study participants 
during the three-hour waiting period, especially if the intervention period occurred during 
lunchtime. Ideally, participants should not have ingested anything else apart from the study 
supplement during this period. For ethical reasons and in the hope to boost compliance, 
however, we decided to offer an optional meal during the intervention. We did not control 
or record amounts or types of food eaten after ingestion of the supplement. Generally, 
meals contained relatively high concentrations of iron inhibitors, such as phytates from 
maize flour, which may have reduced iron absorption and thus NTBI production. This is 
strengthened by the recommendation of the WHO to take iron supplements with food, to 
avoid a rapid increase of serum iron concentrations and transferrin saturation, exceeding the 
binding capacity of transferrin and leading to the production of NTBI. (Hurrell, 2011) 
(WHO, 2007) A study that compared the NTBI response in participants with and without 
taking a meal (Hutchinson et al., 2004), found no difference between NTBI concentrations. 
The meal served in that study was however low in iron inhibitors, and the sample size (n=7) 
was small, which made it unlikely to detect a difference if it existed. 
 
The nature of NTBI is still largely unknown, resulting in little consensus on its true levels 
and how it should be measured. Research groups throughout the world use a variety of test 
principles to measure NTBI. A round robin compared NTBI measurements from twelve 
serum samples in six laboratories; five laboratories (including ours) used chelation methods 
and one a bleomycin assay. This round robin showed considerable inter- and intra-method 
variation between serum NTBI levels (Jacobs et al., 2005). None of the methods thus far 
has however shown to be clearly superior. There is need of additional information on the 
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nature and relevance of NTBI and the development of more robust quantification methods 
before introducing it into clinical practice.  
 
Increased concentrations of transferrin receptor indicate an increased erythropoiesis or 
tissue iron deficiency, and thus possibly with an enhanced response in NTBI concentration 
to oral ferrous iron. NTBI samples were obtained in the second trimester, between 13 and 
23 weeks of pregnancy. Transferrin receptor levels are lowest around 13-20 weeks of 
pregnancy and far lower than in non-pregnant women (4.5 and 7.0 mg/L respectively). 
(Beguin, Lipscei, Thoumsin, & Fillet, 1991) This implies that iron uptake for erythropoiesis 
was likely to be down regulated at the moment of sample collection for NTBI analysis, 
which may be a contributing factor for not finding a difference in NTBI response between 
the intervention and placebo group. 
 
Little is known about factors that determine the magnitude of serum NTBI concentration. It 
is assumed that factors leading to increased iron absorption from gut enterocytes positively 
affect the amount of NTBI released into the circulation. (Chung & Wessling-Resnick, 
2003) The relatively high levels of NTBI in iron replete subjects as compared to iron 
deficient women are possibly caused by higher levels of apotransferrin circulating in people 
with iron deficiency anaemia, whereby the binding capacity of transferrin is increased and 
less NTBI is formed (Dresow, Petersen, Fischer, & Nielsen, 2008). 
 
Ineffective erythropoiesis in severe forms of β-thalassaemia can lead to excessively low 
hepcidin production, resulting in iron being absorbed at a faster rate than being used for 
erythropoiesis, which likely leads to NTBI production (Musallam, Cappellini, Wood, & 
Taher, 2012). Unlike severe β-thalassaemia, α+-thalassaemia causes only minor symptoms 
and has not shown to be associated with iron loading. (Veenemans et al., 2008) 
(Veenemans, Milligan, et al., 2011) This can possibly explain the absence of an evident 
difference in NTBI production between normal and α+-thalassaemia genotypes (Figure 4), 
although a slightly positive effect on the NTBI concentration of heterozygous and 
homozygous genotypes was observed as compared to the normal genotype (Figure 4 and 5). 
 
Our findings are in contrast with other studies, which found NTBI production upon 
ingestion of iron supplements. (Schuemann et al., 2012) (Hutchinson et al., 2004) (Dresow 
et al., 2008) These studies issued 10-240 mg ferrous iron to participants and all observed 
NTBI after three hours, even when unsaturated transferrin was still present. This probably 
occurs when the iron influx exceeds the rate of iron uptake by transferrin, a process that 
may be enhanced by the relatively slow binding between iron and transferrin (Aisen, 1974). 
Healthy Guatemalan males (n=8), anaemic British women (n=7) and a combination of 
healthy and anaemic German participants (n=43) were included in the respective studies, 
indicating that NTBI after the ingestion of ferrous iron occurs in iron replete as well as 
anaemic subjects. 
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Conclusions 
We found no effect of oral iron supplementation on NTBI concentrations when the 
supplement was given with food to women in their second trimester of pregnancy. This 
study does not support changing existing policies for daily supplementation with 60 mg 
iron as ferrous salts.  Further studies are needed to determine the effect of iron 
supplementation on NTBI in pregnant women in a fasting state in various stages of 
pregnancy, especially the third trimester of pregnancy when transferrin receptor 
concentrations are highest. 
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Chapter	5	
Factors	that	predict	Plasmodium	
infection	in	pregnancy	4	
	
Introduction 
Malaria prevalence among pregnant women and their offspring has declined in various 
malaria endemic regions. (Kalayjian, Malhotra, Mungai, Holding, & King, 2013)  Emphasis 
on asymptomatic malaria is increasingly common especially because of the observed 
detrimental effects during pregnancy. Several studies have found that sub-patent infections 
(i.e. low parasitaemias that are detected by PCR but not by microscopy or dipstick tests) are 
associated with reduced birth, intrauterine growth retardation, preterm delivery, and 
increased neonatal mortality. (Malhotra, Dent, Mungai, Muchiri, & King, 2005), (Adegnika 
et al., 2006), (Arango, Maestre, & Carmona-Fonseca, 2010), (Mohammed et al., 2013)  The 
pathological consequences of maternal infection are possibly dependent on population-
specific factors such as immunity, transmission intensity, parity, maternal age, access to 
treatment, coverage and quality of antenatal services.  
Prompt diagnosis of malaria is vital for reduction of malaria morbidity and mortality. 
Laboratories in most resource-poor malaria regions are not equipped to effectively detect 
asymptomatic Plasmodium infection. Doctors and other clinical care specialists often make 
critical diagnostic decisions on clinical grounds alone using very limited information. 
Commonly used symptoms to diagnose malaria, e.g. fever, can be a result of a myriad other 
causes.  Over-prescription of malaria treatment drugs is therefore common. As a result, 
resistance to existing drugs is on the rise and global efforts to contain the resistance have 
been initiated. (WHO Global Malaria Programme, 2010, 2011) 
Malaria rarely occurs in isolation. Usually, other co-morbidities co-exist. In addition to 
malaria, other diseases such as anaemia, HIV infection, tuberculosis, bilharzia, and 
helminthic infections are also common. (Stevens, 2004) Drug supply to counter these 
diseases in resource-poor countries is not always adequate. (Thiam, Kimotho, & Gatonga, 
2013) The social cultural environment also plays a role in hindering the elimination of these 
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diseases. A poor social economic status has been attributed to disease burden in sub-
Saharan Africa. (Stevens, 2004) Currently, scenarios of low coverage of micronutrient 
supplementation and inadequate health care access and coverage manifests in many 
countries. (Anna Maria van Eijk et al., 2011) Problems of coverage of known interventions 
such as intermittent preventive treatment (IPT), (Thiam et al., 2013) and bed nets have been 
reported. (Malhotra et al., 2009)  
Global and national maps of malaria risk have been important tools in targeting of malaria 
control interventions (A. M. Noor et al., 2008). Spatial prediction of malaria prevalence has 
enabled researchers and program implementers to map out high-risk zones in most 
geographical areas. (Haque et al., 2010; A. M. Noor et al., 2008) At patient level, the World 
Health Organisation has guidelines for the identification of severe malaria. (WHO, 2010) 
Decision-making tools such as the malaria severity score (MSA) and the Glasgow coma 
score (GCS) exist and are a great aid to medical practitioners. (Mishra, Panigrahi, Mishra, 
& Mohanty, 2007) Predictive scores are now widely used in the management of various 
clinical conditions in resource-rich countries. (Antman et al., 2000; Fine et al., 1997) 
However, there is no guideline for the prediction of asymptomatic Plasmodium infection 
especially in pregnancy, in resource-poor settings. 
The new challenge in resource-poor countries involve targeting interventions to the most at 
risk persons in groups that are already living in malaria hot-spots. Medical practitioners are 
increasingly faced with the dilemma of how to diagnose asymptomatic Plasmodium 
infection. In the future, resource-poor malaria endemic countries will probably result to 
dipstick tests to diagnose asymptomatic infection. These tests will most likely be selected 
based on cost, ease of use, storage stability under field conditions, sensitivity and/or 
specificity of the selected test. In our previous work, we combined two types of dipstick 
tests that detected current and recent Plasmodium infection. They were only able to detect 
50% of the asymptomatic infection when compared to quantitative PCR. Doctors need to 
correctly predict the remaining 50% as adverse outcomes are also existent in these persons. 
There has been few assessments of the combinations of prognostic factors that best predict 
asymptomatic Plasmodium infection during pregnancy. The effectiveness of interventions 
given by program implementers and clinicians could be boosted by tools that enable them 
predict the most at-risk individuals within population groups. We therefore sought to 
identify factors that predict Plasmodium infection during pregnancy. We also aimed to 
develop a prediction model that can reliably predict asymptomatic Plasmodium infection 
during pregnancy, in women who are Plasmodium-negative by dipstick tests but 
Plasmodium-positive by PCR. To do this, we examined the sensitivity and specificity of the 
predictive variables in order to derive simple models to identify pregnant women at risk of 
asymptomatic Plasmodium infection. 
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Methods 
Study background  
The data for this study was obtained from the main study (Chapter 2 of this thesis). The 
fieldwork was conducted from October 2011 to April 2013 in the administrative area of 
South-West Kisumu county, formerly Kisumu district, Kenya. This area is along the shores 
of Lake Victoria, at around 1234m above sea level. Malaria is endemic and transmission is 
perennial. People living in the area are exposed to 30─100 infectious mosquito bites per 
year, (A. Noor et al., 2009) although this rate is reducing. (Ministry of Public Health and 
Sanitation (MOPHS) & Ministry of Medical Services, 2010) Anaemia (69%) (Ouma et al., 
2007) is highly prevalent among pregnant women while intestinal schistosomiasis is highly 
prevalent in school-aged children.(Samuels et al., 2012) Coverage of intermittent 
preventive treatment is low: in 2008-2009, 17% of women in Nyanza Province received at 
least two doses of sulfadoxine-pyrimethamine during pregnancy, and 35% received at least 
one dose. (Kenya National Bureau of Statistics (KNBS) & ICF Macro, 2010)  
An obstetric ultrasound instrument to enable accurate determination of gestational age was 
installed in one of the two health facilities in the study area, Ober Kamoth health centre. 
The study received clearance from ethical review committees in Kenya (Kenyatta National 
Hospital/University of Nairobi) and England (London School of Hygiene and Tropical 
Medicine), and was registered at ClinicalTrials.gov (NCT01308112). 
Study design and data collection 
The parent study was a double blind, randomised, placebo-controlled intervention trial with 
two parallel groups. Pregnant women received daily supplementation with iron or placebo. 
To prevent severe anaemia, all women were dewormed before the start of the intervention, 
and received a small dose of iron through flour fortification during the intervention. 
However, a cross-sectional design was used for the analysis of the results presented in this 
chapter. Baseline data from the two arms of the randomised trial was pooled and used for 
the cross-sectional analysis. All Plasmodium positive cases were identified by various 
methods (see table 2) and used in this analysis. 
The data analysed according to pre-defined statistical plan. We validated the obtained 
results with data obtained at delivery from all the clients who provided Plasmodium 
infection data at delivery.  
Detailed recruitment procedures are reported elsewhere (chapter 2 of this thesis). We re-
describe some of the procedures that were relevant to this study. At baseline, women were 
counselled and asked for consent for HIV testing. Following medical examination, a venous 
blood sample was collected in a tube with K2EDTA (Becton Dickinson, Nairobi, Kenya; 
catalogue 367863). Haemoglobin concentration was measured by photometer (HemoCue 
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301, Ängelholm, Sweden). The ratio of zinc protoporphyrin:haem (ZPP:H) was measured 
in whole blood and washed erythrocytes by haematofluorometer (see section Laboratory 
analyses). Washed erythrocytes were stored in a DNA-stabilizing buffer (AS1, Qiagen, 
Valencia, CA, USA) at 2 – 8 °C for subsequent DNA extraction and detection of 
Plasmodium infection by PCR test. Plasma samples were stored for subsequent detection of 
Plasmodium antigens and HIV antibodies by rapid dipstick tests. Additional plasma 
samples were stored in liquid nitrogen (-196 °C) in the field and at –80 °C during transport 
and storage for subsequent assessment of iron markers (concentrations of ferritin, soluble 
transferrin receptor, transferrin), C-reactive protein, α1-acid glycoprotein, bilirubin, vitamin 
B12, lactate dehydrogenase, haptoglobin, folate, pre-albumin, and albumin. 
Women were included when aged 15–45 years; consent had been obtained; and likely to be 
available for larger study until 1 month after delivery. They were excluded when having 
obvious mental retardation or a metabolic disorder, a medical history of sickle cell anaemia, 
epilepsy, diabetes, an obstetric history suggestive of eclampsia or pre-eclampsia; carrying 
multiples; gestational age at the second visit was below 13 weeks or exceeded 23 weeks; 
homestead members had not provided consent; no venous blood sample was collected, 
haemoglobin concentration was <90 g/L. Recruitment continued until the target sample size 
(470) had been attained. 
As per procedures of the main study, maternal blood (6 mL) was collected by venipuncture 
in tubes containing K2EDTA tubes (Becton Dickinson) within 1 hour after delivery. Each 
woman was requested for her clinic attendance booklet, and information regarding the 
number of doses received for intermittent preventive treatment against malaria was 
recorded. 
Laboratory analysis 
ZPP:H ratio was measured for each sample in duplicate using a haematofluorometer 
(Model ZPP 206D, Aviv Biomedical, Lakewood NJ, USA). Control samples at low, 
medium, and high levels (AVIV, catalogue 9999-40839) were run after every 30 readings 
while two level (low, high) calibration samples were run twice per year (AVIV, catalogue 
9999-112562). Plasmodium antigenaemia was assayed by rapid dipstick tests (Access Bio 
Inc, Somerset, NJ, USA; CareStart, catalogue G0151 and G0171) that can detect P. 
falciparum-specific histidine-rich protein-2 (HRP2), Plasmodium lactate dehydrogenase 
(pLDH) specific to either P. falciparum or to non-falciparum species, i.e. P. ovale, P. 
malariae or P. vivax. Whereas HRP2-based tests detect current or recent P. falciparum 
infection, pLDH-based tests only indicate current infection. (Makler et al., 1998; Moody, 
2002; Piper et al., 1999) 
In order to detect of Plasmodium infection by PCR, blood samples were centrifuged (8min 
@ 600g), and 120 µl red blood cells were transferred to 0.5 mL tubes prefilled with 120 µl 
PBS and 140µl DNA-stabilizing buffer AS1. They were then mixed, and stored at -196°C 
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for subsequent shipment to the Netherlands for further laboratory analysis. Nucleic acid 
isolation was performed and DNA was extracted using Qiagen whole blood DNA isolation 
protocol according to the manufacturer’s instructions. However, DNA was eluted in 50 µl 
nuclease free water. The extracted DNA was stored in -20°C until PCR analysis.  Analysis 
of samples for the presence of P. falciparum DNA was done according to the protocol of 
Hermsen et al(Hermsen et al., 2001) with the following modifications: An internal 
amplification control detecting the human household gene GAPDH (Glyceraldehyde 3-
phosphate dehydrogenase) was added to the protocol by using a Texas Red labeled probe 
and Gapdh specific primers: Fwd: 5` GAA-GGT-GAA-GGT-CGG-AGT-C  `3;  Rev: 5` 
GAA-GAT-GGT-GAT-GGG-ATT-TC  `3; Probe: 5` Texas Red CAA-GCT-TCC-CGT-
TCT-CAG-CC  HBQ1 -`3.  Amplification reactions were performed in a volume of 25 µl, a 
total of 2.5 µl 1x Qiagen buffer, 6.5 mM MgCl2, 250 µM dNTP’s, 400 nM of each P. 
falciparum 18S primer, 100 nM P. falciparum 18S probe, 40 nM of each GAPDH primer, 
100 nM GAPDH probe, 0.625 U HotstarTaq polymerase Qiagen, and 2.5µl DNA sample. 
The primers and probes were all provided by Biolegio. Amplification comprised of 10 
minutes at 95°C, followed by 45 cycles of 20 seconds at 95°C and 1 minute at 60°C. In 
each PCR run, water controls, no-template controls, high and low positive controls were all 
included in duplicate. The high and low positive controls contain a known amount of P. 
falciparum; thus, the Ct values of these controls were used to determine the PCR 
amplification efficacy. The Ct values of these controls have a range between 2x the 
standard deviation (which was calculated by measuring the controls 12 times over several 
days) and the Ct values of the controls were required to fall within this range. 
HIV infection was assessed by rapid antibody tests (Alere™, Waltham, Massachusetts, 
USA); a positive result was confirmed using other antibody tests (Unigold; Trinity Biotech, 
Co Wicklow, Ireland and/or Bioline; Pantech, Umhlanga, Kwazulu-Natal, South Africa).  
Plasma concentrations of ferritin, soluble transferrin receptor (sTfR), transferrin, C-reactive 
protein, and α1-acid glycoprotein were measured on a Beckman Coulter UniCel DxC 880i 
analyser according to the manufacturer’s instructions.  
Statistical analyses 
Statistical analyses were done using SPSS version 21.0 (SPSS, Chicago, USA). We 
described Plasmodium infection as assessed by HRP-2, LDH, HRP-2 and LDH, and PCR. 
The primary outcome, which was adopted as the gold standard in this analyses, was defined 
as the presence of maternal Plasmodium infection in samples collected at baseline, 
regardless of species, as indicated by one or more positive results for the presence of 
parasite-derived LDH or HRP2 in plasma (dipstick tests),  or Plasmodium DNA (any 
species, by PCR test). Results of microscopy were excluded from this case definition as 
they would be considered incorrect if discordant with results from PCR tests.  
The following definitions were used: anaemia: haemoglobin concentration <110 g/L 
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(WHO, 2011a); iron deficiency: plasma ferritin concentration <15 µg/L (WHO, 2011b); 
iron-replete: plasma ferritin concentration ≥15 g/L in the absence of inflammation; iron 
status uncertain: plasma ferritin concentration ≥15 g/L in the presence of inflammation; 
iron deficiency anaemia: anaemia co-existing with iron deficiency; inflammation: plasma 
concentrations of C-reactive protein (CRP) >10 mg/L (Nielsen et al., 1990) and/or α1-acid 
glycoprotein >1 g/L (Filteau et al., 1993); gravidity: the number of times a woman reported 
to have been pregnant, regardless of the outcome of these pregnancies, with twins and other 
multiple births counted as 1, and including the current pregnancy. 
Since the outcome was dichotomous (yes/no Plasmodium infection), a logistic regression 
was used.  Logistic regression does not make assumptions of linearity, normality and 
homogeneity of variance for the independent variable.  We assessed the contribution of 
individual determinants to the overall effect estimate. A stepwise forward multivariate 
analysis was then fitted and the weight of the determinants was estimated using estimations 
of the maximum likelihood ratio. We checked for multi-colinearity and estimated accuracy 
of the effect estimate by visual assessment of the calibration plots.  
Receiver operating characteristics (ROC) curves and area under the curve (AUC) estimates 
were generated. We used the following criteria to judge the quality of the AUC estimates: 
0.90 to 1.0 = excellent (A); 0.80 to 0.90 = Good (B); 0.70 to 0.80 = Fair (C); 0.60 to 0.70 = 
Poor (D); 0.50 to 0.60 = Fail (F) 
 
Finally, we checked for internal validation of the selected model(s) using data collected at 
parturition from women who completed the follow-up period. 
Results 
Out of the 2,015 women invited for screening, 470 (23%) were randomised to intervention 
and included in the main analysis for this study.  Table 1 and Figure 1 contains the 
characteristics of study subjects.  
Table 1: Characteristics of study participants 
Characteristics 
n 470  
Height, cm 162.4 (6.2) 
Weight, kg 57.9 (7.6) 
Body mass index, kg/m2 21.9 (2.7) 
Marital status   
Married or living together 388 [82.6%] 
Divorced or separated 18 [3.8%] 
Never married 64 [13.6%] 
Age, years 24.8 (6.1) 
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Table 1: Characteristics of study participants 
Gestational age, weeks 1 17.8 (2.6) 
Gravidity   
Primigravidae 85 [18.1%] 
Secundigravidae 92 [19.6%] 
Multigravidae 293 [62.3%] 
Plasmodium infection   
Current Plasmodium infection (pLDH) 31 [6.6%] 
Current or recent Plasmodium infection (pLDH + HRP2) 90 [19.1%] 
Current Plasmodium infection (q-PCR) 163 [34.7%] 
Current or recent Plasmodium infection (pLDH + HRP2 + Pf-PCR)2 175 [37.2%] 
HIV infection 99 [21.1%] 
Plasma CRP concentration, mg/L 4.3 [8.3] 
Plasma AGP concentration, g/L 0.78 (0.27) 
Inflammation 3   
Plasma CRP concentration ≥10 mg/L 126 [26.8%] 
Plasma AGP concentration ≥1.0 g/L 85 [18.1%] 
Plasma CRP concentration ≥10 mg/L or AGP ≥1.0 g/L 152 [32.3%] 
Haemoglobin concentration, g/L 113.2 (11.4) 
Anaemia, haemoglobin concentration <110g/L 175 [37.2%] 
Plasma ferritin concentration, µg/L 13.9 [20.9] 
Plasma sTfR concentration, mg/L 1.94 [1.15] 
Plasma transferrin concentration, g/L 3.1 (0.6) 
Iron deficiency, plasma ferritin concentration <15µg/L   
All women 248 [52.8%] 
Those with CRP concentration <10 mg/L 197 [41.9%] 
Those with AGP concentration <1.0g/L 221 [47.0%] 
Those with concentrations of CRP <10mg/L or AGP <1.0 g/L 228 [48.5%] 
Whole blood ZPP:haem ratio, µmol/mol 89.5 [52.8] 
Erythrocyte ZPP:haem ratio, µmol/mol 36.5 [46.9] 
Mean (SD), Median [IQR], n [%]  
 
AGP: α1-acid glycoprotein; CRP: C-reactive protein;HRP2: P. falciparum-specific 
histidine-rich protein-2); LDH: P. falciparum-specific lactate dehydrogenase; sTfR: 
soluble transferrin receptor; ZPP: zinc protoporphyrin 
 
1. All women except one were in the 2nd trimester of pregnancy; 2. Only one 
participant (high-dose iron group) had infection by a Plasmodium species other than 
P. falciparum; 3. Only one participant (high-dose iron group) had current fever 
defined as axillary temperature ≥ 37.5 °C; 4. One missing value in the per protocol 
analysis dataset; 5. HIV status of two participants was not determined 
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Table 2 describes the different type of tests used to assess Plasmodium infection and the 
number of positive cases. Majority of the Plasmodium infected women were detected by 
PCR (93.1%), followed by a combination of HRP2 and pLDH dipsticks (51.4%) . pLDH, 
which detects only current infection, detected only 17.7% of positive cases when used 
independently. 
Table 2: Prevalence of asymptomatic Plasmodium infection at baseline, by various test 
methods 
Type of Plasmodium infection Type of test Number infected, 
n/n (%) 
Current infection pLDH 31/ 175 (17.7) 
Current or recent infection pLDH + HRP2 90/ 175 (51.4) 
Current infection P. falciparum PCR 163/ 175 (93.1) 
Current and recent infection [AND] All (pLDH & HRP2 & 
PCR) 
27/ 175 (15.4) 
Current and recent infection [OR] All (pLDH or HRP2 or 
PCR) 
175/ 175 (100) 
	
We developed seven models (A to G) to predict asymptomatic Plasmodium infection 
during pregnancy in women who are Plasmodium-negative by dipstick tests but 
Plasmodium-positive by PCR. Table 3 is a list of the various determinants used to obtain 
models A to G. 
Table 3: Determinants in the various models* 
Model A: Plasma α1-acid glycoprotein + Number of live children + HIV infection + 
Plasma pre-albumin + Plasma haptoglobin + Plasma lactate dehydrogenase + 
Plasma bilirubin + Plasma ferritin + Hb concentration +Maternal age + Blood 
group + Systolic blood pressure + parity 
Model D: Number of live children + HIV infection + Hb concentration + Blood group + 
Plasma α1-acid glycoprotein + Plasma haptoglobin + Plasma pre-albumin + 
Plasma lactate dehydrogenase + Plasma bilirubin 
Model B: Plasma α1-acid glycoprotein + Plasma pre-albumin + Plasma haptoglobin + 
Plasma lactate dehydrogenase + Plasma bilirubin + Plasma ferritin concentration 
Model C: Number of live children + HIV infection + Hb concentration + Blood group 
Model E: 
N Number of live children + HIV infection + Hb concentration + Blood group + 
Plasma α1-acid glycoprotein + Plasma haptoglobin + Plasma pre-albumin 
Model F: 
Number of live children + HIV infection + Hb concentration + Blood group + 
Plasma α1-acid glycoprotein + Plasma lactate dehydrogenase + Plasma bilirubin 
Model G: Number of live children + HIV infection + Hb concentration + Blood group + 
Plasma α1-acid glycoprotein 
*Models arranged in order of appearance in the ROC curves 
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We assessed the potential of various baseline determinants to predict  asymptomatic 
Plasmodium infection as assessed by q-PCR. Figure 2 shows the obtained ROC curves and 
the criteria used to build the final models.   Model A and D had the best area under the 
curve (AUC) (0.82 and 0.80). Model C which was composed of easy to assess 
determinants, had an AUC of 0.68. 
 
Based on our pre-specified criteria, the models were judged as follows: Model A = Good; 
Model B = Fair; Model C = Poor; Model D = Good; Model E = Fair; Model F = Fair; 
Model G = Fair 
	
Figure 1: Prevalence of asymptomatic Plasmodium infection at baseline, by various 
test methods 
 
Two best models (A and D) were judged as “good”  as they had an area under the curve 
above 0.80.  All the remaining models except one were judged as “fair”. We made a model 
(model C) composed of easy to measure determinants in resource-poor settings (number of 
live children + HIV infection + Haemoglobin + Blood group). Addition of an extra 
determinant to this model (α1-acid glycoprotein) improved its AUC  from 0.68 to 0.72 thus 
it was judged as fair (model G). 
 
The best predictors of asymptomatic Plasmodium infection were: α1-acid glycoprotein, 
number of live children, HIV infection, pre-albumin, haptoglobin, lactate dehydrogenase, 
bilirubin, ferritin, haemoglobin, age, blood group, systolic blood pressure, and parity. 
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Discussion 
The factors that were best in predicting asymptomatic Plasmodium infection were HIV 
infection, plasma haemoglobin concentration, number of live children, blood group, plasma 
α1-acid glycoprotein concentration, plasma haptoglobin concentration, plasma pre-albumin 
concentration, plasma lactate dehydrogenase concentration, and plasma bilirubin 
concentration. Out of these, four (HIV infection, plasma haemoglobin concentration, 
number of live children, blood group) are routinely assessed in most resource-poor settings. 
The other predictive determinants are assessed in more specialised laboratories in larger 
medical and research institutions. 
 
Out of the seven models developed to predict asymptomatic Plasmodium infection during 
pregnancy in women who are Plasmodium-negative by dipstick tests but Plasmodium-
positive by PCR, Model A was best with an AUC of 0.82 (“good”). However, it was 
composed of many determinants (12) and was thus not easy to apply it under conditions of 
usual healthcare. Model C, which was composed of determinants that are easy to assess in 
resource poor settings, was judged as “poor”. Although addition of α1-acid glycoprotein to 
this model improved its AUC to 0.72 (“fair” – model G), a predictive curve of above 0.9 
(“excellent”) would have been the best predictor.  
 
Our study had various strengths. First, as a gold standard, we assessed Plasmodium 
infection by PCR. Compared to the two dipstick tests used in this study (pLDH and HRP2), 
PCR detected many more Plasmodium-infected subjects (34.7% versus 19.1%). Secondly, 
because all the PCR analysis was performed by the same lab, there was no verification bias 
of the gold standard as PCR analysis for all subjects was done in the same laboratory using 
the same protocol. Lastly, the number of responders (Plasmodium positive cases) was large 
enough to allow us to assess the predictive ability of the determinants. According to Harrell 
and Peduzzi et al, 1996, for each determinant studied in multivariate prediction research, at 
least 10 individuals with the disease are needed in the smallest category of the outcome 
variable to allow proper statistical modelling. [Harrell et al., 1996; Peduzzi et al., 1996].    
 
Our participants were part of a randomised controlled trial which was conducted in a 
malaria endemic area. The data used in this study was obtained after the participants were 
randomised into the trial thus no selection bias could be associated with the subjects 
selection criteria. Furthermore, we were able to study the discriminatory ability  of many 
determinants to correctly pick up Plasmodium-infected and non-infected subjects in one 
population. We were also able to compare the predictive reliability of different 
determinants whether independently or in combination with others (interaction). The 
assumptions of binary logistic regression made it possible to study multiple determinants 
and derive their probabilities which could be used to plot the ROC curves.  
 
Our study had some limitations. In the studied population, multiple morbidities exist thus it 
is reasonable to expect some co-morbidity bias because known or unknown diseases may 
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affect the positivity or negativity of test. Secondly, some determinants e.g. past 
miscarriages, past still births, use of insecticide treated nets, and  use of insecticide sprays 
although possibly of high predictive value, were not assessed because of unavailability of 
data. Lastly, other area-specific demographic and geographic determinants such as house-
type and distance from known water masses were not used despite the fact that spatial 
prediction of malaria risk zones has been done elsewhere. (Haque et al., 2010; A. M. Noor 
et al., 2008)   
 
Various studies have explained the association between Plasmodium and most of the 
determinants outlined in this study.  Silamut et al found that plasma α1-acid glycoprotein 
concentrations were consistently raised in acute malaria.(Silamut, Molunto, Ho, Davis, & 
White, 1991) The association between Plasmodium falciparum and HIV infection has been 
shown by others. (Kuile et al., 2004) We expected that due to compromised malarial 
immunity, women that were HIV infected would be more susceptible to Plasmodium 
infection. Steketee et al found that HIV infection diminishes a pregnant woman's capacity 
to control P. falciparum parasitaemia. (Steketee et al., 1996)  
 
Cserti et al studied the association between blood group and Plasmodium falciparum 
infection and found that the worldwide prevalence of blood group O parallels malarial 
regions suggesting that survival from malaria is associated with group O, and mortality is 
associated with group A. (Cserti & Dzik, 2007).  Gravidity, (M. Desai et al., 2007)  and 
maternal age, (Tako et al., 2005) are also associated with Plasmodium infection. In highly 
endemic areas, primigravidae are at greater risk of malarial infection (Nosten et al., 1991) 
(A. M. Greenwood et al., 1992), probably because they have a reduced immunity.  Young 
primigravidae and multigravidae are at greater risk of malaria and its adverse effects than 
older primigravidae or multigravidae, respectively (Espinoza et al., 2005; Leenstra et al., 
2003; Marques et al., 2005) (S J Rogerson et al., 2000) (Walker-abbey et al., 2005). 
Furthermore, it is conceivable that a subject with many live children in a resource-poor 
setting may be immune-compromised due to excessive workload, poor dietary intake, and 
cumulative poor health.  
 
To the best of our knowledge, no other studies have investigated the reliability of multiple 
determinants to predict asymptomatic Plasmodium infection even though scoring methods 
exist for prediction of fatality from other clinical conditions such as burn injuries, (Ryan et 
al., 1998) stroke, (Poungvarin, Viriyavejakul, & Komontri, 1991) acute pancreatitis 
(Wilson, Heath, & Imrie, 1990) etc. In a study in Lagos, Nigeria, young maternal age, and 
use of insecticide spray was associated with increased risk of malaria infection in pregnant 
women. (Agomo & Oyibo, 2013) However, the authors did not study more determinants or 
combinations of determinants. According to Cottrell et al, although an infection during late 
pregnancy (after 28 weeks of pregnancy) was found to be strongly related to the presence of 
a placental infection, the best predictive model was given by taking into account 
parasitological information during whole pregnancy. (Cottrell et al., 2006) Such 
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information is seldom available in resource-poor settings. Although investigators frequently 
use ROC curves to assess diagnostic tests, this method  is also appropriate for prognostic 
prediction using probabilistic estimates from logistic regression. (Levi, 1985) Medical 
decision making is then made easier by enabling the physicians' probabilistic judgments 
using predictive models. 
 
Conclusions 
This study identified the best predictive factors for asymptomatic Plasmodium infection. 
The study also confirmed that the number of live children that a subject has, coupled with 
HIV infection, low haemoglobin concentration levels, and elevated inflammation are fair 
predictors of asymptomatic Plasmodium infection. However, despite the potential benefits 
of combining different determinants to arrive at a set of predictive criteria that can be used 
to judge whether a subject may or may not be having asymptomatic Plasmodium infection, 
a highly predictive field-friendly predictive model was not plausible. For future research, 
plasma α1-acid glycoprotein concentration deserves further investigation as it was highly 
predictive of Plasmodium infection. Similarly, there is need to investigate the predictive 
reliability of plasma haptoglobin concentration, plasma pre-albumin concentration, plasma 
lactate dehydrogenase concentration, and plasma bilirubin concentration whether 
independently or in combinations with each other. 
 
Acknowledgements 
 
We would like to acknowledge all the study participants who gave data including blood 
samples for this work. Further, we acknowledge the staff of the specialised laboratories in 
the Netherlands (Meander Medical Centre – Amersfoort, and the Royal Tropical Institute – 
Amsterdam) who carried out the biochemical analysis of the samples and the PCR analysis 
respectively. We also thank Sofie Terwel and Elise Talsma for lively discussions on this 
subject during data analysis. 
 
References 
1. Adegnika, A. a, Verweij, J. J., Agnandji, S. T., Chai, S. K., Breitling, L. P., Ramharter, M., … 
Yazdanbakhsh, M. (2006). Microscopic and sub-microscopic Plasmodium falciparum infection, 
but not inflammation caused by infection, is associated with low birth weight. The American 
Journal of Tropical Medicine and Hygiene, 75(5), 798–803.  
2. Agomo, C. O., & Oyibo, W. a. (2013). Factors associated with risk of malaria infection among 
pregnant women in Lagos, Nigeria. Infectious Diseases of Poverty, 2(1), 19.  
3. Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., … 
Braunwald, E. (2000). The TIMI risk Score for unstable Angina/Non–ST elevation MI: A Method 
for prognostication and therapeutic decision making. JAMA, 284(7), 835 – 842.  
Chapter	5	
118	
4. Arango, E., Maestre, A., & Carmona-Fonseca, J. (2010). Efecto de la infección submicroscópica 
o policlonal de Plasmodium falciparum sobre la madre y el producto de la gestación: revisión 
sistemática. Revista Brasileira de Epidemiologia, 13(3), 373–386.  
5. Cottrell, G., Deloron, P., Fievet, N., Sow, S., Gaye, O., & Le Hesran, J.-Y. (2006). Prediction of 
Plasmodium falciparum placental infection according to the time of infection during pregnancy. 
Acta Tropica, 98(3), 255–60.  
6. Cserti, C. M., & Dzik, W. H. (2007). The ABO blood group system and Plasmodium falciparum 
malaria. Blood, 110(7), 2250–8.  
7. Desai, M., Kuile, F. O. ter, Nosten, F., McGready, R., Asamoa, K., Brabin, B., & Newman, R. D. 
(2007). Epidemiology and burden of malaria in pregnancy. The Lancet Infectious Diseases, 7(2), 
93–104.  
8. Espinoza, E., Hidalgo, L., & Chedraui, P. (2005). The effect of malarial infection on maternal-
fetal outcome in Ecuador. The Journal of Maternal-Fetal & Neonatal Medicine : The Official 
Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania 
Perinatal Societies, the International Society of Perinatal Obstetricians, 18(2), 101–5.  
9. Filteau, S., Morris, S., Abbott, R., Tomkins, A., Kirkwood, B., Arthur, P., … Raynes, J. (1993). 
Influence of morbidity on serum retinol of children in a community- based study in northern 
Ghana. Am J Clin Nutr, 58(2), 192–197.  
10. Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E., … 
Kapoor, W. N. (1997). A prediction rule to identify low-risk patients with community acquired 
pneumonia. The New England Journal of Medicine, 336(4), 243–250. 
11. Greenwood, A. M., Armstrong, J. R. M., Byass, P., Snow, R. W., & Greenwood, B. M. (1992). 
Malaria chemoprophylaxis, birth weight and child survival. Transactions of the Royal Society of 
Tropical Medicine and Hygiene.  
12. Haque, U., Magalhães, R. J. S., Reid, H. L., Clements, A. C. a, Ahmed, S. M., Islam, A., … 
Glass, G. E. (2010). Spatial prediction of malaria prevalence in an endemic area of Bangladesh. 
Malaria Journal, 9, 120.  
13. Hermsen, C. C., Telgt, D. S. C., Linders, E. H. P., van de Locht, L. A. T. F., Eling, W. M. C., 
Mensink, E. J. B. M., & Sauerwein, R. W. (2001). Detection of Plasmodium falciparum malaria 
parasites in vivo by real-time quantitative PCR. Molecular and Biochemical Parasitology.  
14. Kalayjian, B. C., Malhotra, I., Mungai, P., Holding, P., & King, C. L. (2013). Marked Decline in 
Malaria Prevalence among Pregnant Women and Their Offspring from 1996 to 2010 on the South 
Kenyan Coast. The American Journal of Tropical Medicine and Hygiene, 89(6), 1129–1134.  
15. Kenya National Bureau of Statistics (KNBS), & ICF Macro. (2010). Kenya Demographic and 
Health Survey 2008-09. (K. N. B. of S. (KNBS) & I. C. F. Macro, Eds.). Calverton, Maryland: 
KNBS and ICF Macro. 
16. Kuile, F. O. ter, Parise, M. E., Verhoeff, F. H., Udhayakumar, V., Newman, R. D., Eijk, A. M. 
van, … Steketee, R. W. (2004). The Burden of Co-Infection with Human Immunodeficiency 
Virus Type 1 and Malaria in Pregnant Women in Sub-Saharan Africa. American Journal of 
Tropical Medicine and Hygiene, 71(2), 41–54.  
17. Leenstra, T., Phillips-Howard, P. A., Kariuki, S. K., Hawley, W. A., Alaii, J. A., Rosen, D. H., … 
Ter Kuile, F. O. (2003). Permethrin-treated bed nets in the prevention of malaria and anaemia in 
adolescent school girls in Western Kenya. Am J Trop Med Hyg, 68(90040), 86–93.  
18. Levi, K. (1985). A signal detection framework for the evaluation of probabilistic forecasts. 
Factors	that	predict	Plasmodium infection	in	pregnancy 
119	
Organizational Behavior and Human Decision Processes, 36(2), 143–166.  
19. Makler, M. T., Piper, R. C., & Milhous, W. K. (1998). Lactate Dehydrogenase and the Diagnosis 
of Malaria. Parasitology Today, 14(9), 376–377.  
20. Malhotra, I., Dent, A., Mungai, P., Muchiri, E., & King, C. L. (2005). Real-time quantitative PCR 
for determining the burden of Plasmodium falciparum parasites during pregnancy and infancy. 
Journal of Clinical Microbiology, 43(8), 3630–5.  
21. Malhotra, I., Dent, A., Mungai, P., Wamachi, A., Ouma, J. H., Narum, D. L., … King, C. L. 
(2009). Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective 
birth cohort study in Kenya. PLoS Medicine, 6(7), e1000116.  
22. Marques, P. X., Saúte, F., Pinto, V. V, Cardoso, S., Pinto, J., Alonso, P. L., … Arez, A. P. (2005). 
Plasmodium species mixed infections in two areas of Manhiça district, Mozambique. 
International Journal of Biological Sciences, 1(3), 96–102.  
23. Ministry of Public Health and Sanitation (MOPHS), & Ministry of Medical Services. (2010). 
National guidelines for the diagnosis, treatment and prevention of malaria in Kenya. (D. of M. 
Control, Ed.). Nairobi: Ministry of Public Health and Sanitation (MOPHS). 
24. Mishra, S. K., Panigrahi, P., Mishra, R., & Mohanty, S. (2007). Prediction of outcome in adults 
with severe falciparum malaria: a new scoring system. Malaria Journal, 6, 24.  
25. Mohammed, A. H., Salih, M. M., Elhassan, E. M., Mohmmed, A. a, Elzaki, S. E., El-Sayed, B. 
B., & Adam, I. (2013). Submicroscopic Plasmodium falciparum malaria and low birth weight in 
an area of unstable malaria transmission in Central Sudan. Malaria Journal, 12(1), 172.  
26. Moody, A. (2002). Rapid Diagnostic Tests for Malaria Parasites. Clinical Microbiology Reviews, 
15(1), 66–78.  
27. Nielsen, F. R., Bek, K. M., Rasmussen, P. E., Qvist, I., & Tobiassen, M. (1990). C-reactive 
protein during normal pregnancy. European Journal of Obstetrics & Gynecology and 
Reproductive Biology, 35(1), 23–27.  
28. Noor, A., Gething, P., Alegana, V., Patil, A., Hay, S., Muchiri, E., … Snow, R. (2009). The risks 
of malaria infection in Kenya in 2009. BMC Infectious Diseases, 9(1), 180.  
29. Noor, A. M., Clements, A. C. a, Gething, P. W., Moloney, G., Borle, M., Shewchuk, T., … Snow, 
R. W. (2008). Spatial prediction of Plasmodium falciparum prevalence in Somalia. Malaria 
Journal, 7, 159.  
30. Nosten, F., ter Kuile, F., Maelankirri, L., Decludt, B., & White, N. J. (1991). Malaria during 
pregnancy in an area of unstable endemicity. Transactions of the Royal Society of Tropical 
Medicine and Hygiene, 85(4), 424–429.  
31. Ouma, P., Van Eijk, A. M., Hamel, M. J., Parise, M., Ayisi, J. G., Otieno, K., … Slutsker, L. 
(2007). Malaria and anaemia among pregnant women at first antenatal clinic visit in Kisumu, 
western Kenya. Tropical Medicine & International Health, 12(12), 1515–1523.  
32. Piper, R., Lebras, J., Wentworth, L., Hunt-Cooke, A., Houzé, S., Chiodini, P., & Makler, M. 
(1999). Immunocapture diagnostic assays for malaria using Plasmodium lactate dehydrogenase 
(pLDH). The American Journal of Tropical Medicine and Hygiene, 60(1), 109–118.  
33. Poungvarin, N., Viriyavejakul, A., & Komontri, C. (1991). Siriraj stroke score and validation 
study to distinguish supratentorial intracerebral haemorrhage from infarction. BMJ (Clinical 
Research Ed.), 302(6792), 1565–7.  
34. Rogerson, S. J., van den Broek, N. R., Chaluluka, E., Qongwane, C., Mhango, C. G., & 
Molyneux, M. E. (2000). Malaria and anemia in antenatal women in Blantyre, Malawi: a twelve-
Chapter	5	
120	
month survey. The American Journal of Tropical Medicine and Hygiene, 62(3), 335–40.  
35. Ryan, C. M., Schoenfeld, D. a, Thorpe, W. P., Sheridan, R. L., Cassem, E. H., & Tompkins, R. G. 
(1998). Objective estimates of the probability of death from burn injuries. The New England 
Journal of Medicine, 338(6), 362–6.  
36. Samuels, A. M., Matey, E., Mwinzi, P. N. M., Wiegand, R. E., Muchiri, G., Ireri, E., … Secor, W. 
E. (2012). Schistosoma mansoni Morbidity among School-Aged Children: A SCORE Project in 
Kenya. The American Journal of Tropical Medicine and Hygiene, 87(5), 874–882.  
37. Silamut, K., Molunto, P., Ho, M., Davis, T., & White, N. (1991). Alpha 1-acid glycoprotein 
(orosomucoid) and plasma protein binding of quinine in falciparum malaria. British Journal of 
Clinical Pharmacology, 32(3), 311–315.  
38. Steketee, R. W., Wirima, J. J., Bloland, P. B., Chilima, B., Mermin, J. H., Chitsulo, L., & 
Breman, J. G. (1996). Impairment of a pregnant woman’s acquired ability to limit Plasmodium 
falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg, 
55(1_Suppl), 42–49.  
39. Stevens, P. (2004). Diseases of poverty and the 10/90 gap. London, United Kingdom: 
International Policy Network. 
40. Tako, E. a, Zhou, A., Lohoue, J., Leke, R., Taylor, D. W., & Leke, R. F. G. (2005). Risk factors 
for placental malaria and its effect on pregnancy outcome in Yaounde, Cameroon. The American 
Journal of Tropical Medicine and Hygiene, 72(3), 236–42.  
41. Thiam, S., Kimotho, V., & Gatonga, P. (2013). Why are IPTp coverage targets so elusive in sub-
Saharan Africa? A systematic review of health system barriers. Malaria Journal, 12(1), 353.  
42. Van Eijk, A. M., Hill, J., Alegana, V. A., Kirui, V., Gething, P. W., ter Kuile, F. O., & Snow, R. 
W. (2011). Coverage of malaria protection in pregnant women in sub-Saharan Africa: a synthesis 
and analysis of national survey data. The Lancet Infectious Diseases, 11(3), 190–207.  
43. Walker-abbey, A., Djokam, R. R. T., Eno, A., Leke, R. F. G., Titanji, V. P. K., Fogako, J., … 
Taylor, D. W. (2005). Malaria in pregnant Cameroonian women: the effect of age and gravidity 
on submicroscopic and mixed-species infections and multiple parasite genotypes. American 
Journal of Tropical Medicine and Hygiene, 72(3), 229–235. 
44. WHO. (2010). Guidelines for the treatment of malaria (2nd ed., pp. 1–194). Geneva, Switzerland: 
World Health Organization. 
45. WHO. (2011a). Haemoglobin concentrations for the diagnosis of anaemia and assessment of 
severity (WHO/NMH/NHD/MNM/11.1). Vitamin and Mineral Nutrition Information System (pp. 
1–6). Geneva, Switzerland: World Health Organization.  
46. WHO. (2011b). Serum ferritin concentrations for the assessment of iron status and iron deficiency 
in populations (WHO/NMH/NHD/MNM/11.2). Vitamin and Mineral Nutrition Information 
System (Vol. WHO/NMH/NH, pp. 1–5). Geneva, Switzerland.  
47. WHO Global Malaria Programme. (2010). Global report on antimalarial drug efficacy and drug 
resistance: 2000 - 2010. Geneva, Switzerland: World Health Organization. 
48. WHO Global Malaria Programme. (2011). Global plan for artemisinin resistance containment 
(GPARC). Geneva, Switzerland: World Health Organization. 
49. Wilson, C., Heath, D. I., & Imrie, C. W. (1990). Prediction of outcome in acute pancreatitis: A 
comparative study of APACHE II, clinical assessment and multiple factor scoring systems. 
British Journal of Surgery, 77(11), 1260–1264. 
 
	121	
Chapter	6	
Early	identification	of	pregnant	women	
at	high	risk	of	giving	birth	to	a	neonate	
with	low	birth	weight	5	
	
Introduction 
Approximately 16.5% of infants in developing countries, or 20 million infants, are born 
annually with a birth weight <2,500g. Epidemiological evidence indicates that such 
neonates die at a 20 times faster rate than heavier babies (UNICEF/WHO 2004), but low 
birth weight has also been associated, among others, with increased morbidity in the 
neonatal and post-neonatal period. Mortality rates can vary 100-fold across the range of 
birth weight, and rises continuously with decreasing weight (UNICEF/WHO 2004). 
A better understanding of the etiology of low birth weight may provide clues for its 
prevention. In a randomised controlled trial among Kenyan women, we have recently 
shown that daily iron supplementation in the second and third pregnancy trimesters can 
reduce the risk of low birth weight by 65%, whilst correction of iron deficiency resulted in 
an increase in birth weight by 250g (Mwangi et al., submitted). Data that were collected as 
part of this trial at baseline and at delivery may allow for a further analysis of factors 
associated with birth weight. 
In the period 2005–2012, 43% of pregnant African women attended the minimum four 
times antenatal care as recommended by the World Health Organization (WHO). Yet, many 
continue to deliver outside health facilities. For example, in western Kenya, in an area 
adjacent to where we conducted our trial, 80% of women delivered outside a health facility; 
among these, traditional birth attendants assisted 42%, laypersons assisted 36%, while 22% 
received no assistance (Van Eijk et al. 2006). Thus it would be important to develop 
methods that allow for identification of women at an early stage of pregnancy who need 
specific care to prevent low birth weight or who need urgent referral for safe delivery in a 
health care facility. 
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Thus we aimed a) to identify factors associated with birth weight; b) to develop a 
methodology to predict cases of low birth weight, using a single risk score that is based on 
prognostic variables collected at the second trimester of pregnancy. 
Subjects and Methods 
Population 
This study used samples collected for a double blind, randomized controlled trial to 
investigate the safety and efficacy of iron supplementation in Kenyan pregnant women 
(Mwangi et al. submitted). The study (www.ClinicalTrials.gov: NCT01308112) was 
conducted from October 2011 to April 2013 in western Kenya (South-West Kisumu). 
Ethical clearance was received in Kenya and England. All participants gave written 
informed consent. Pregnant women in the late stage of the first trimester to early stage of 
second trimester were screened and assessed for eligibility into the study.  
The study area was rural and highly endemic for malaria. The participants were recruited 
from married (or cohabiting) local women aged 15 – 45 years. If a woman missed her 
menstrual period for 10 weeks, she was invited for a pregnancy test. Women who were not 
in stable relationships were invited for a free pregnancy test every 12 weeks. Pregnant 
women received preventive chemotherapy with albendazole and praziquantel against 
helminth infections and intestinal schistosomiasis to prevent severe anemia. Gestation age 
was determined by ultrasound examination. 
The population consists mainly of poor families from the Luo tribe.  Their diet is mostly 
based on maize with a low content of animal products. Sorghum, millet, and cassava are 
consumed in smaller quantities. In the study area, anaemia is highly prevalent (69%) (Ouma 
et al., 2007) and intestinal schistosomiasis is common (Samuels et al., 2012).  
We included pregnant women who:  gave informed consent; were aged 15─45 years; likely 
to be available for study until 1 month after delivery and planning to deliver in the pre-
designated health facility. We excluded women who had:  obvious mental retardation; a 
metabolic disorder; a medical history of sickle cell anemia, epilepsy, diabetes; an obstetric 
history suggestive of eclampsia or pre-eclampsia; carrying multiples; gestational age at the 
second visit was <13weeks or >23weeks; no venous blood was collected, or haemoglobin 
concentration was <90g/L. 
As part of the main trial, the flour from the homesteads of all participants was fortified with 
NaFeEDTA at the local mill level from screening until women left the study. The mill 
operators added fortificant iron (target dose: 20mg/kg as NaFeEDTA) (WHO et al., 2009) 
to grain routinely brought by a member of a participating homestead. Based on weighed 
intake studies, we estimate that fortification supplied on average 5.7mg fortificant iron 
daily in pregnant women (unpublished data). 
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The baseline data and blood samples were collected 14─21 days after the initial screening 
visit. Blood pressure was assessed during the first and second visits to the research clinic. 
We did not assess smoking in the population studied as very few women smoke. 
Consumption of alcohol and coffee is also probably very low. We collected venous blood in 
K2EDTA tubes, and measured haemoglobin concentration (HemoCue301, Ängelholm, 
Sweden) and zinc protoporphyrin (Aviv 206d, Lakewood, NJ). Buffy coat and erythrocyte 
sediment were stored separately in DNA-stabilizing buffer (AS1, Qiagen, Valencia, CA) at 
2–8˚C in the field and subsequently at–80˚C until PCR assays. Plasma was stored at –
196˚C in the field and subsequently at–80˚C until analysis. 
Randomization and blinding 
Pregnant women were randomly allocated to 60 mg iron as ferrous fumarate (Dr. Paul 
Lohmann®, CAT No.500005025200) or to placebo group. The supplements comprised 
capsules with starch as filler that were identical in appearance except that the shell for each 
type was into two colors (blue and dark green for iron, white and buff for placebo). The 
code linking each color to the type of supplement was kept in sealed, opaque envelopes. 
One of us (HV) not involved in the fieldwork used tables with random numbers to produce 
sequentially numbered envelopes containing the code. Eligible women were allocated in 
order of enrolment to the color indicated in the next available envelope. Participants and 
field staff were blinded to intervention until data analysis.  
Laboratory analysis 
Haemoglobin concentrations were measured using a photometer (HemoCue model 301, 
Ängelholm, Sweden). Iron markers (plasma concentrations of ferritin, soluble transferrin 
receptor, transferrin), vitamins (plasma vitamin B12 and folate concentration), and 
inflammation markers (plasma concentrations of C-reactive protein [CRP] and α1-acid 
glycoprotein) were measured on a Beckman Coulter UniCel DxC 880i analyser as per 
manufacturer’s instructions. ZPP content in whole blood was measured by 
hematofluorometer (Aviv 206D, Lakewood Township, NJ, USA). Control samples at low, 
medium, and high levels (AVIV) were run after every 30 readings while two level 
calibration (Aviv; low, high) samples were run twice per year. 
ZPP was also measured in the washed erythrocytes. To wash erythrocytes, blood samples 
were centrifuged (8min, 600xg), plasma was removed and replaced with an equal volume 
of phosphate buffered saline (Medicago, Uppsala, Sweden; catalogue no. 09-2051-100) in 
100 mL deionized water. Following renewed centrifugation (8min, 600×g), the supernatant 
and buffy coat were discarded.  
HIV infection was determined using rapid antibody tests (Alere Determine™, Alere™, 
Waltham, Massachusetts, USA); a positive result was confirmed using other antibody tests 
(Unigold™, Trinity Biotech PLC™, Co Wicklow, Ireland, and/or Bioline™, Pantech, 
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Umhlanga, Kwazulu-Natal, South Africa). 
Plasmodium antigenaemia was assayed by dipstick tests (Access Bio Inc., Somerset, NJ, 
USA; CareStart, catalogue G0151 and G0171) that can detect P. falciparum-specific 
histidine-rich protein-2 (HRP2), Plasmodium lactate dehydrogenase (pLDH) specific to 
either P. falciparum or to non-falciparum species, i.e. P. ovale, P. malariae or P. vivax. 
Whereas HRP2-based tests detect current or recent P. falciparum infection, pLDH-based 
tests only indicate current infection. (Makler, Piper, & Milhous, 1998) (Piper et al., 1999) 
(Moody, 2002) HIV infection was assayed using antibody tests (Alere, Waltham, MA; 
confirmed by Unigold; Trinity Biotech, Bray, Ireland and/or Bioline; Pantech, Umhlanga, 
South Africa). 
We determined α+-thalassaemia genotype by polymerase chain reaction; (Veenemans et al., 
2008) (Veenemans et al., 2011) because of practical reasons, we could perform this analysis 
only in the first 213 successively recruited women. 
Supervised daily administration of the study supplement was ensured for all the randomized 
participants. At delivery, we recorded the date of birth and the neonatal data (gender, 
anthropometric data). Maternal blood (6 mL) was collected by venipuncture within 1 hour 
after delivery. All blood samples were collected in tubes with K2EDTA (Becton 
Dickinson). In addition, placental biopsies were collected and stored in 40% formaldehyde 
solution with PBS at pH 7.2 for subsequent histological examination.  
Definitions 
Hypertension is usually defined as diastolic blood pressure ≥ 90 mmHg or systolic blood 
pressure ≥ 140 mmHg. Because blood pressure is reduced in the first half of pregnancy by 
25 mmHg,(WHO 1987) however, were defined hypertension as diastolic blood pressure ≥ 
75 mmHg or systolic blood pressure ≥ 125 mmHg, each determined as the average of two 
measurements taken on different days. 
Plasmodium infection status in placental biopsies was classified as non-infected, active 
infection, active-chronic infection and past-chronic infection.(Bulmer et al. 1993) 
Low vitamin B12 status was defined by plasma cobalamin concentrations <200 ng/L (148 
pmol/L). (Carmel et al. 2003) 
Statistical analysis 
Objective 1: First, we used one-way ANOVA and univariate linear regression analysis to 
identify factors possibly associated with birth weight. In this analysis, we used variables 
collected at recruitment into the trial, as well as data collected at delivery. We used dummy-
coded categorised explanatory variables because several factors have been reported to be 
associated with birth weight of fetal growth in a non-linear fashion (e.g. maternal age, 
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gravidity, haemoglobin concentration). We subsequently developed a multivariate linear 
regression model with backward elimination to identify factors that were independently 
associated with birth weight. Gestational age at delivery was not included in this model, 
because its inclusion would adjust and thus eliminate effects on birth weight by factors that 
affect gestational duration. For iron deficiency and iron supplementation, we assumed 
interaction because pre-planned subgroup analysis of the randomisation trial had confirmed 
our expectation that women with initial iron deficiency had a greater response in birth 
weight to iron supplementation than their peers who were initially iron-replete (Mwangi et 
al., submitted). We found no support for effect modification between iron supplementation 
and other baseline factors assessed in the present paper (not shown). 
Objective 2: We modelled low birth weight using multivariate logistic discriminant analysis 
with a stepped forward selection procedure to examine the added prognostic value of 
variables collected at baseline (second trimester of pregnancy). We started the model with 
the variable iron supplementation, then also entered variables that could easily be obtained 
from an interview and a routine medical examination, subsequently added laboratory data 
that can be collected using point-of-care tests that are commercially available (haemoglobin 
concentration, Plasmodium antigenaemia, HIV antibodies, C-reactive protein 
concentration), and lastly data that would require measurement in a tertiary care facility or 
reference laboratory. Thus variables were categorised into four types, depending on the 
practical ease of performing each test and the inputs required for their assessment (Table 
1).  
Table 1: Categorisation of prognostic variables assessed at 2 trimester of pregnancy 
Variable Measure 1 
Type 1 (routinely assessed at most rural care facilities, or could be added at 
no cost) 
Iron supplementation Binary 
Maternal age Nominal 
Marital status Nominal 
Gravidity Ordinal 
Height  Nominal 
Body mass index Nominal 
Hypertension Binary 
Category 2 (not assessed at all rural care facilities, but can be added at with 
relatively small inputs) 
Haemoglobin concentration Nominal 
Plasmodium dipstick test (any test positive) Nominal 
Type 3 (can be assessed at rural care facilities with relatively large added 
inputs) 
Inflammation (plasma C-reactive protein concentration >10 mg/L) Binary 
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Table 1: Categorisation of prognostic variables assessed at 2 trimester of pregnancy 
Erythrocyte ZPP content Ordinal 
Type 4 (requires assaying in reference laboratory) 3 
Inflammation (plasma α1-acid glycoprotein concentration >10 mg/L) Binary 
Iron status (plasma ferritin concentration and inflammation 2) Nominal 
Folate status Binary 
1As analysed in the present paper; 2Elevated plasma concentrations of both C-reactive protein 
concentration and α1-acid glycoprotein concentration; 
3α+-thalassaemia genotype was not 
considered because of its relatively high cost, practical problems in its measurement (e.g. DNA 
isolation in a DNA-free environment), and because it probably will never be used because it is 
not informative about other health conditions. 
 
Type 1 and Type 2 variables include variables that are routinely assessed in most rural care 
facilities in developing countries, or that can be assessed with relatively small inputs; Type 
3 variables concern point-of-care tests that can also be performed in such facilities, but this 
would require substantial inputs in the form of capital investments, recurrent costs, training, 
supervision or a reliable supply of consumables. Type 4 variables need to be assessed in a 
reference laboratory. The prognostic value of added variables was evaluated using 
likelihood ratio tests, and variables were rejected if p>0.15.  
The coefficients obtained by multiple logistic regression analysis were used to produce a 
linear predictor (LP) that was converted into a predicted probability (P) of low birth weight 
for each mother, based on the logistic regression equation. By allowing the variable P to 
vary in the range [0 1], we produced Receiver Operating Characteristics (ROC) curves, 
which were used to assess the ability of various models to discriminate between women 
who gave birth to a neonate with or without low birth weight. This discriminating ability 
can be expressed by the area-under-the-curve (AUC). We predefined AUC values in the 
ranges 0.50 0.60, 0.60 0.70, 0.70 0.80, 0.80 0.90 and 0.90 1 to indicate failed, poor, 
fair, good and excellent performance. 
Results 
Table 2 show results of the analyses to identify factors associated with birth weight. 
Teenage pregnancy, short stature (<155cm), being not married hypertension, inflammation 
and active-chronic placental infection with malarial parasites were associated reductions in 
birth weight. On the other hand, birth weight increased with gravidity, iron 
supplementation, body mass index and gestational age. There was weak evidence that birth 
weight was associated with haemoglobin concentration class at baseline, and there was no 
consistent monotonous trend in this association. 
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Associations with low vitamin B12 status are not reported because we found only 3 women 
(0.6%) to have low vitamin B12 status. There was no evidence of an associated between 
plasma cobalamin concentrations and birth weight (not shown). 
Table 3 shows associations with birth weight obtained by multivariate regression analysis. 
Being never married, presence of inflammation, being a girl and presence of iron deficiency 
were independently associated with reductions in birth weight, whereas being overweight 
(body mass index ≥ 25 kg/m2) was associated with increased birth weight. 
Evidence that markers of Plasmodium infection were associated with birth weight was 
weak. Results of dipstick tests from blood collected from the antecubital vein were not 
associated with birth weight, and these were rejected in the multivariate analysis.  
We nonetheless retained placental markers of infection in the multivariate model because 
there is strong evidence from randomised trials that malaria causes a reduced birth weight 
that can be reversed by control measures, (Garner and Gulmezoglu 2006, Eisele et al. 2012, 
Kayentao et al. 2013) and our data indicated that active-chronic placental infection is 
independently associated with a reduction in birth weight by 213g (Table 3). Our reduced 
multivariate logistic regression model (‘Model 1’) of low birth weight only contained iron 
supplementation, maternal height and HIV infection from the Type 1 and Type 2 variables 
(Table 4). 
Because the other Type 1 and Type 2 variables can be relatively easily assessed, we also 
added the full model (‘Model 2’); however, there was no statistical evidence that this model 
performed better (p=0.72). For Type 3 and Type 4 variables, only inflammation as 
indicated by plasma α1-acid glycoprotein concentration ≥ 1 mg/L (‘Model 3’) had added 
prognostic value (p=0.02). 
The results from the logistic regression analyses shown in Table 4 were used to calculate 
the predicted probability of low birth weight. For example, for Model 1, P was computed as 
follows: P=1⁄((1+e^(-LP) ) ), where LP = 1.059 [Iron supplementation] + 2.108 [Height1] + 
0.490 [Height2] + 1.096 [Height3] + 1.783 [Height4] – 0.870[HIV infection] – 4.092 
(variable names indicated between straight brackets; [Height1 4] indicate binary dummy 
variables indicating categories 155–159.9cm, 160–164.9cm, 165–169.9cm and ≥ 170 cm, 
respectively). 
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Table 2: Factors associated with birth weight (g) 
Factor n Birth 
weight, g 
(SD) p-value Effect (95% CI) 
Determined at baseline or in samples collected at baseline       
Maternal age    0.05   
<20 years 67 3,008 (459)  –141 (–255 to –27) 
20–34.99 years 290 3,149 (423)  Reference 
≥35 years 36 3,085 (416)  –64 (–213 to 85) 
Maternal height    0.11   
< 155 cm 45 2,999 (481)  –169 (–313 to –26) 
155–159.9 cm 75 3,071 (390)  –97 (–217 to 23) 
160–164.9 cm 146 3,169 (449)  Reference 
165–169.9 cm 75 3,099 (436)  –69 (–189 to 51) 
≥ 170 cm 52 3,183 (361)  14 (–122 to 150) 
Marital status    0.004   
Married or living together 341 3,146 (431)  Reference 
Never married 39 2,908 (391)  –238 (–379 to –96) 
Divorced or separated 13 3,059 (386)  –87 (–23 to –150) 
Body mass index    0.001   
≤ 18.5 kg/m2 30 3,072 (436)  –20 (–179 to 139) 
18.5–25 kg/m2 321 3,093 (405)  Reference 
≥ 25.0 kg/m2 42 3,357 (542)  264 (–128 to 401) 
Hypertension    0.56   
Absent 358 3,123 (432)  Reference 
Present 1 35 3,078 (424)  –45 (–195 to 105) 
Gravidity    0.003   
Primigravida 54 2,932 (437)  Reference 
Secundigravida 76 3,126 (413)  194 (45 to 343) 
Multigravida 263 3,156 (426)  224 (99 to 349) 
Haemoglobin concentration    0.06   
< 100 g/L 60 2,996 (443)  –99 (–230 to 32) 
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Table 2: Factors associated with birth weight (g) 
100–100.9 g/L 83 3,149 (437)  54 (–64 to 171) 
110–119.9 g/L 134 3,095 (401)  Reference 
120–129.9 g/L 98 3,180 (447)  85 (–27 to 196) 
≥ 130 g/L 18 3,238 (425)  142 (–69 to 354) 
Inflammation    0.001   
Absent 275 3,165 (418)  Reference 
Plasma CRP concentration ≥10mg/L and AGP concentration <1.0 
g/L 53 3,105 (395) 
 
–59 (–184 to 66) 
Plasma CRP concentration <10mg/L and AGP concentration ≥1.0 
g/L 21 3,012 (433) 
 
–153 (–341 to 36) 
Plasma CRP concentration ≥10mg/L and AGP concentration ≥1.0 
g/L 44 2,905 (483) 
 
–260 (–395 to –125) 
Iron status    0.02   
Deficient (plasma ferritin concentration <15μg/L) 211 3,145 (433)  7 (–91 to 105) 
Replete (ferritin concentration ≥15μg/L; inflammation absent) 113 3,152 (417)  Reference 
Uncertain (ferritin concentration ≥15μg/L; inflammation present) 69 2,988 (428)  –163 (–290 to –36) 
Iron supplementation    0.001   
No 199 3,050 (410)  Reference 
Yes 194 3,191 (441)  141 (56 to 225) 
Erythrocyte ZPP content    0.34   
≤40 μmol/mol haem 203 3,107 (411)    
40–70 μmol/mol haem 94 3,175 (481)  67 (–38 to 173) 
> 70 μmol/mol haem 96 3,090 (419)  –17 (–122 to 88) 
Folate status    0.66   
Plasma folate concentration <5 μg/L 322 3,115 (436)  25 (–87 to 138) 
Plasma folate concentration ≥5 μg/L 69 3,140 (404)  Reference 
Plasmodium infection 3    0.19   
Absent 247 3,136 (443)  Reference 
Sub-patent 68 3,150 (421)  14 (–102 to 130) 
Patent 78 3,040 (396)  –95 (–205 to 14) 
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Table 2: Factors associated with birth weight (g) 
HIV infection    0.12   
Absent 304 3,137 (431)  Reference 
Present  87 3,055 (425)  –82 (–185 to 21) 
α+-thalassaemia genotype    1.00   
Normal (αα/αα) 94 3,147 (471)  Reference 
Heterozygote (α–/αα) 79 3,143 (396)  –4 (–133 to 125) 
Homozygote(α–/α–) 14 3,154 (256)  7 (–235 to 248) 
Determined at delivery or in samples collected at delivery       
Infant sex    0.03   
Boys 196 3,167 (427)  Reference 
Girls 197 3,072 (430)  –96 (–181 to –11) 
Gestational age    <0.001   
≤ 37.99 weeks 131 2,952 (409)  –233 (–321 to –144) 
38–41 weeks 234 3,185 (401)  Reference 
≥ 41.00 weeks 25 3,392 (517)  207 (37 to 377) 
Haemoglobin concentration    0.18   
< 100 g/L 70 3,050 (417)  –124 (–260 to 13) 
100–100.9 g/L 64 3,079 (410)  –95 (–235 to 45) 
110–119.9 g/L 71 3,074 (402)  –100 (–236 to 36) 
120–129.9 g/L 84 3,174 (424)  Reference 
≥ 130 g/L 101 3,177 (471)  4 (–121 to 129) 
Plasmodium infection 3       
Assessed in circulating venous blood    0.43   
Absent 278 3,137 (451)  Reference 
Sub-patent 45 3,077 (333)  –60 (–196 to 76) 
Patent 68 3,073 (400)  –64 (–179 to 50) 
Assessed in placental biopsies    0.05   
Absent 192 3,188 (440)  Reference 
Active 8 3,138 (429)  –50 (–353 to 252) 
Active-chronic 28 2,975 (398)  –213 (–383 to –44) 
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Table 2: Factors associated with birth weight (g) 
Past-chronic 88 3,089 (403)  –98 (–206 to 10) 
CRP: C-reactive protein; AGP: α1-acid glycoprotein 
 
1 Diastolic blood pressure ≥ 75 mmHg or systolic blood pressure ≥ 125 mmHg, each determined as the average of two measurements taken on 
different days; 2 p-value for interaction between initial iron status and iron supplementation; 2 Categories defined as follows:  deficient: plasma 
ferritin concentration <12 μg/L, regardless of the presence or absence of inflammation; replete: plasma ferritin concentration ≥12 μg/L in the 
absence of inflammation (plasma concentrations of C-reactive protein <10 mg/L or α1-acid glycoprotein <1.0 g/L); uncertain: plasma ferritin 
concentration ≥12 μg/L in the presence of inflammation; 3 Mutually exclusive categories defined as follows: absent: negative results for any dipstick 
test or PCR test; sub-patent: positive result for P. falciparum-specific PCR test but negative result for any dipstick test; patent: at least one positive 
dipstick test result (i.e. presence of either HRP2, P. falciparum-specific pLDH, or pLDH specific human Plasmodium species other than P. 
falciparum), regardless of PCR test result. 
 
	
Table 3: Factors independently associated with birth weight (g), multivariate linear regression analysis 
 Effect on birth weight, g (95% CI) p 
Marital status   0.02 
Married or living together Reference   
Never married –207 (–358 to –55)  
Divorced or separated –90 (–344 to 165)  
Body mass index   0.001 
≤ 18.5 kg/m2 –22 (–210 to 167)  
18.5–25 kg/m2 Reference   
≥ 25.0 kg/m2 264 (124 to 404)  
Inflammation at baseline   0.06 
Absent Reference   
Plasma CRP concentration ≥10mg/L and AGP 
concentration <1.0 g/L 
–129 (–289 to 32)  
Plasma CRP concentration <10mg/L and AGP 
concentration ≥1.0 g/L 
–150 (–385 to 85)  
Plasma CRP concentration ≥10mg/L and AGP –235 (–406 to –63)  
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Table 3: Factors independently associated with birth weight (g), multivariate linear regression analysis 
concentration ≥1.0 g/L 
Infant sex   0.02 
Boy Reference   
Girl –110 (–199 to –20)  
Iron status at baseline 1   0.001 2 
Iron-deficient –158 (–309 to –6)  
Iron-replete Reference   
Uncertain –11 (–248 to 227)  
Placental infection status by Plasmodium spp.    
No infection Reference  0.283 
Active –12 (–298 to 275)  
Active-chronic  –158 (–324 to 9)  
Past –55 (–162 to 51)  
AGP: α1-acid glycoprotein; CRP: C-reactive protein 
 
1 Iron status categories: iron-deficient: plasma ferritin <15 μg/L regardless of inflammation status; iron replete: plasma ferritin ≥15 μg/L 
without inflammation (both plasma CRP concentration ≥10mg/L and AGP concentration <1.0 g/L); iron status uncertain (either plasma 
CRP concentration ≥10mg/L or  AGP concentration <1.0 g/L). The associations reported for iron-deficiency and uncertain iron status 
apply to women who did not receive supplementation. The model also included effects for iron supplementation and its interaction terms 
with iron status categories, but these effects will be reported elsewhere. 2 P-interaction 
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Table 4: Prognostic factors for low birth weight (g), based on multivariate logistic 
regression analysis 
 Model 1 
(Type 1 2 variables; 
reduced model) 
Model 2 
(Type 1 2 
variables; 
full model) 
Model 3 
(Type 3 4 variables; 
Reduced model) 
Type 1 variables    
Constant 4.092 –3.895 –3.572 
Iron supplementation 1.059 0.961 0.942 
Maternal height    
155–159.9 cm 2.108 2.276 2.162 
160–164.9 cm 0.490 0.512 0.53 
165–169.9 cm 1.096 1.142 1.036 
≥ 170 cm 1.783 1.734 1.721 
HIV –0.870 –1.209 –1.016 
Maternal age    
20–34.99 years – –0.351 –0.503 
≥35 years – –0.640 –0.769 
Marital status    
Never married – 0.061 0.119 
Divorced or separated – –0.530 –0.268 
Gravidity    
Secundipara – 1.043 0.871 
Multipara – 0.609 0.716 
Body mass index    
18.5–25 kg/m2 – 0.100 0.128 
≥ 25.0 kg/m2 – –0.583 –0.41 
Hypertension – 1.068 1.211 
Type 2 variables    
Hb concentration    
100–100.9 g/L – 0.411 0.38 
110–119.9 g/L – –0.521 –0.509 
120–129.9 g/L – –0.177 0.025 
≥ 130 g/L – –0.915 –0.812 
Plasmodium infection 3    
Sub-patent – –0.015 0.431 
Patent – –0.352 –0.26 
Type 3-4 variables    
Inflammation (plasma α1-acid 
glycoprotein ≥ 1 mg/L) 
  –1.288 
Values indicate coefficient estimates associated with each factor. 
Figure 1
women who would deliver a neonate with low or normal birth weight was fair for Model 1, 
and good for Model 3. Under Model 1, the decision rule of P > 0.0360 would have 90% 
sensitivit
Under Models 2 and 3, this 90% sensitivity is attained with P > 0.0375 and P > 0.0348, 
respectively, yielding specificity values of 58% and 63%.
Figure 1:
collected at second trimester of pregnancy to discriminate between women who will or 
will not given birth to a neonate with low birth weight (<2,500g)
 
AUC: Area
4), respectively). For explanation of variables included in each model, see Table 
diagonal line represents the theoretically worst test with no discrimination between groups. 
Diagonal segments in curves are produced by ties.
 
When the decision rule of P > 0.0360 under Model 1 (see preceding paragraph) were 
applied to Keny
2004) a predicted outcome of normal birth weight would be correct with a probability of 
97%, whilst a predicted outcome of low birth weight would be correct with a probability of 
17% (
y in predicting low birth weight, and the corresponding specificity would be 46%. 
Tab
 shows the ROC curves for Models 1
 ROC curve showing the ability of various combinations of variables 
-under
le 5). The decision rules P > 0.0375 and P > 0.0348 under Models 2 and 3, 
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respectively, would give virtually identical probabilities of correctly predicting normal birth 
weight, and yield only small improvements in the probability of correctly predicting low 
birth weight (21% and 23%, respectively; table 5). 
Table 5: Performance of decision rules obtained with Models 1, 2 and 3 in predicting 
low birth weight with 90% sensitivity in pregnant women, at a prevalence of low birth 
weight reported for Kenya (11%) 
Model 1. Decision rule to predict low birth weight: P > 0.0360 1 
Predicted Birth weight     
 <2,500g ≥2,500g     
Low birth weight 0.10 0.48 0.58  Specificity 46% 
Normal birth 
weight 0.01 0.41 0.42  PPV 17% 
 0.11 0.89 1.00  NPV 97% 
       
Model 2. Decision rule to predict low birth weight: P > 0.0375 1 
Predicted Birth weight     
 <2,500g ≥2,500g     
Low birth weight 0.10 0.37 0.47  Specificity 58% 
Normal birth weight 0.01 0.52 0.53  PPV 21% 
 0.11 0.89 1.00  NPV 98% 
       
Model 3. Decision rule to predict low birth weight: P > 0.0348 1 
Predicted Birth weight     
 <2,500g ≥2,500g     
Low birth weight 0.10 0.33 0.43  Specificity 63% 
Normal birth weight 0.01 0.56 0.57  PPV 23% 
 0.11 0.89 1.00  NPV 98% 
PPV: positive predictive value, i.e. the probability of correctly predicting low birth weight; 
NPV: negative predictive value, i.e. the probability of correctly predicting the absence of low 
birth weight. 
 
1   =   (  +     )⁄ ; model-specific LPs can be derived from Table 4 (see text). 
	
Discussion 
Our data showed that being never married, inflammation, being a girl and iron deficiency 
were independently associated with reduced birth weight, whereas being overweight was 
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associated with increased birth weight. We have also shown that methods can be developed 
with fair accuracy in discriminating between women due to give birth to neonates with low 
birth weight versus normal birth weight, using a single risk score that is based on a 
combination of prognostic variables collected at the second trimester of pregnancy. 
Our two research questions have driven separate approaches to data analysis, with different 
results. First, we considered an etiological question about the causal factors that determine 
birth weight. In this part of the research, we used birth weight as a continuous outcome 
variable, because dichotomisation into a derived variable ‘low/normal birth weight’ 
inevitably results in a loss of information and statistical precision, (e.g. MacCallum et al. 
2002) and mortality rates are believed to rise continuously with decreasing birth weight 
(UNICEF/WHO 2004). In addition, etiological research requires the exclusion of 
confounders, i.e. external factors that form an alternative explanation for an apparent 
association between a potential determinant of birth weight) and consideration of effect 
modification, i.e. the measure of association between a potential determinant and birth 
weight depends on an external factor. A backward elimination procedure, as we applied, is 
commonly used and recommended to eliminate confounding between factors, and to 
identify factors that are independently associated with outcome. In this analysis, we also did 
not include gestational age because it is likely in the causal pathway between other factors 
and birth weight. A separate analysis would be required to identify factors that are 
independent determinants of gestational duration but this was outside the scope of the 
present paper. 
Second, we considered a prognostic question about factors that predict the risk of low birth 
weight. In this analysis, we dichotomised birth weight, mimicking the decision eventually 
to be made by care providers as to whether or not to take special precautions to prevent low 
birth weight or to ensure safe delivery. The objective of this part of our analysis is not to 
explain the occurrence of low birth weight, so confounding and effect modification are 
irrelevant, and the factors included in the statistical model do not necessarily have to be 
causally related to low birth weight. A stepped forward approach allows the assessment of 
the predictive value of each factor when sequentially added to those factors already 
included. From a practical point of view, it is logical to start with those factors that can be 
easily measured under field conditions. For these reasons, the factors included the models 
thus generated (Table 4) are different from those included in the first part of this paper 
(Table 3). 
A problem that is often encountered in prognostic (and diagnostic) research is that 
associations are reported between single factors and outcome. In medical care, however, 
one is usually interested in the added value of a factor over and above the prognostic 
information that is already contained in other variables. One strength of our paper is the 
multivariate approach that allowed us to overcome this problem, and that produced a single 
risk score (P) to predict the risk of low birth weight based on the predictive information 
contained in a combination of variables. A limitation of the present paper, however, is that 
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it used a randomised trial as the vehicle for research. As a consequence, we may have failed 
to collect key variables that could be helpful in the prediction of low birth weight, and 
generalizability of our results may be limited by the eligibility criteria used in the trial. We 
have nonetheless developed a promising methodology that can be further advanced in 
future studies. Another issue that may be raised concerns the question whether the 
prognostic factors were influenced by our experimental intervention, i.e. iron 
supplementation. We believe that we have accounted for this by including iron 
supplementation as a separate variable in the analysis. A last limitation is that our decision 
rules should be considered with caution, because they need to be validated in other settings. 
Several of the risk factors identified in univariate analysis (Table 3) were similarly 
associated with birth weight as reported elsewhere. For example, it has been described that 
girls weigh less than boys, neonates from single mothers and divorced mothers have an 
increased risk of low birth weight, and second and third children are heavier than first 
children (Kramer 1987, Valero De Bernabé et al. 2004). We did not find an inverted U-
shaped association between haemoglobin concentration at delivery and birth weight, 
(Valero De Bernabé et al. 2004) but this may be in part because we collected blood 
immediately after birth, which may not properly reflect haemoglobin status and iron stores 
immediately before birth. We also found limited evidence for an association between 
markers of Plasmodium infection and birth weight, despite strong evidence from 
randomised trials that malaria can cause a reduced birth weight that is reversed by control 
measures. (Garner and Gulmezoglu 2006, Kayentao et al. 2013)  However, blood markers 
of Plasmodium infection measured in our samples collected at baseline and at delivery may 
not have captured the entire history of exposure to infection during pregnancy, particularly 
in this population of women who, due to frequent exposure to infection, presumably have 
developed considerable protective immunity to suppress parasitaemia. 
A notable finding in the univariate and multivariate analyses presented in Tables 3 and 4, as 
well as the results presented in Table 5, is the marked reduction in birth weight associated 
with inflammation, particularly as indicated by elevated plasma concentrations of α1-acid 
glycoprotein. Contrary to C-reactive protein concentration, which increases rapidly after an 
inflammatory stimulus and drops rapidly after the cessation of such a stimulus, α1-acid 
glycoprotein may indicate more chronic inflammation because it rises slowly and also 
drops slowly. (e.g.Thurnham et al. 2010) Pregnancy is characterised by a low-grade 
systemic inflammatory response, but infection-induced inflammation is also a common 
cause of preterm birth. (Romero et al. 2007, Genc and Ford 2010, Mor et al. 2011) Further 
work would be needed to assess the cause of inflammation in our study population; 
considering that the absence of an associations between birth weight with either 
Plasmodium infection or HIV infection, it seems likely that the cause of inflammation was 
due to other causes. 
Lastly, our prediction models (Table 4, Figure 1) show that measurement of plasma α1-acid 
glycoprotein concentration overall has added value in predicting low birth weight. 
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However, this added benefit leads to only small gains in predictive performance when 
applied to screen women with a view to better management (table 5). In such conditions, 
one wishes to have a high specificity to ensure that the majority of women at high risk of 
giving birth to a neonate with low birth weight are detected, and to rule out cases of low 
birth weight on the basis of the prediction. When applied with a sensitivity of 90% and an 
11% risk of low birth weight as extant in Kenya (table 5), the addition of α1 acid-
glycoprotein concentration leads to only a small reduction in the proportion of women who 
are falsely indicated as being at high risk. On this basis, it may be better to base decision 
rules on Models 1 or 2, which were equally effective in correctly ruling out cases of low 
birth weight. 
Conclusion 
We conclude that it is technically feasible to predict with fair accuracy women at high risk 
of giving birth to a neonate with low birth weight, based on variables that can be collected 
rapidly at relatively low cost and ease in the second trimester of pregnancy. 
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Chapter	7	
General	discussion	6	
	
The aim of this thesis was to assess the effect of iron supplementation on safety indicators, 
and on iron status, in pregnant women and their neonates. The main study  was 
implemented against the backdrop of new fortification regulations in  Kenya that required 
all industrially milled flour to be fortified with micronutrients including iron in the form of 
NaFeEDTA. (Government of Kenya, 2012) We hypothesized that consumption of food 
products fortified with iron combined with intake of iron supplements especially in 
pregnancy, could increase malaria rates, with adverse health consequences for pregnant 
women and their neonates. The specific aims of the thesis were as follows: 1) To compare 
the presence of malarial infection in parturient women who received a combination of iron-
fortified foods with iron supplements versus iron-fortified foods only [chapter 2]; 2) to 
assess intervention effects on the maternal prevalence of iron deficiency anaemia at 1 
month after delivery [chapter 2]; 3) to assess intervention effects on neonatal iron stores at 
1 month of age [chapter 2]; 4) to assess the diagnostic utility of Zinc protoporphyrin in 
diagnosing iron deficiency in malaria endemic regions [chapter 3]; 5) to identify baseline 
factors that are prognostic for the NTBI response to consumption of a single iron 
supplement [chapter 4]; 6) to determine the factors that predict Plasmodium infection in 
pregnancy [chapter 5]; 7) to identify factors associated with birth weight [chapter 6]; 8) to 
develop a methodology to predict cases of low birth weight, using a single prognostic score 
that is based on prognostic variables collected at the second trimester of pregnancy 
[chapter 6]; 9) to develop methods for community-based flour fortification with iron; 10) 
to assess intervention effects on maternal intestinal pathogens at 1 month after delivery. At 
the time of completion of this thesis, data analysis on maternal intestinal pathogens was 
ongoing; these findings will be reported elsewhere. 
Main findings of this thesis 
Figure 1 is a summary of the main findings, outlined sequentially from safety issues 
regarding iron supplementation, beneficial aspects of iron supplementation, main 
conclusions of all chapters, and finally, policy implications of the thesis findings. Contrary 
to our hypothesis, iron supplementation did not result in an increased risk of Plasmodium  
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	Figure 1: Overview 
 
of main findings 
143	
 
	144	
infection. We did not find evidence that the effect of iron on Plasmodium infection 
depended on the use of Intermittent Preventive Treatment (IPTp). We nonetheless agree 
with the current World Health Organisation recommendation that “in malaria-endemic 
areas, provision of iron and folic acid supplements should be implemented in conjunction 
with measures to prevent, diagnose and treat malaria”. (WHO, 2012a)   
Although this recommendation has obvious benefits for the target population, programme 
implementers and governments in resource-poor settings are held-back by the increased 
cost of malaria control, iron deficiency, and anaemia control programmes. Usually, the end 
result is a poorly implemented programme with low coverage. This exacerbates the 
problem of malaria and iron deficiency anaemia control in malaria-endemic countries. 
Considering the upper limit of the 95% CI of the main effect of iron supplementation 
(─9.3% to 9.3%), we cannot exclude the possibility that iron supplementation may have led 
to a 9% increase in Plasmodium infection, which may have reduced birth weight. (Desai et 
al. 2007) Overall, however, iron supplementation led to large increase in birth weight 
(143g). Particularly in women who were initially iron deficient, iron supplementation 
increased birth weight by 249 g. Although it is theoretically possible to screen and treat 
only those who are iron deficient, this is difficult to achieve in developing countries 
because of practical and financial constraints. For these reasons, we recommend universal 
iron supplementation in pregnant women, even in areas with poor coverage of IPTp. 
The results reported in this thesis have tremendous implications for neonatal health. We 
showed that iron supplementation reduced the risk of low birth weight, which is the primary 
determinant of neonatal and post-neonatal mortality. Low birth weight is also an important 
cause of neonatal morbidity, inhibited infant growth, and cognitive development (chapter 
2). Our calculations indicate that if our results are applied to all women in developing 
countries in order to eliminate iron deficiency, we could avoid 3 million births with low 
birth weight annually and save the lives of more than half a million neonates. These figures 
should be treated with caution, however, because they are based on many assumptions. 
The effect of iron on birth weight was achieved at least in part through increased fetal 
growth (effect: 0.27 SD, 95%CI: 0.04 to 0.50). In this analysis, we assessed fetal growth by 
z-scores. Compared to dichotomised indicators of fetal growth such as small-for-gestational 
age, z-scores have the advantage that dichotomising of continuous outcomes leads to loss of 
information and reduced statistical precision when comparing groups. (MacCallum, Zhang, 
Preacher, & Rucker, 2002)  
Our study also showed improved neonatal iron stores one month post-partum as indicated 
by an increase in plasma ferritin concentration by 17.1% (95% CI: 2.0% to 34.3%) in 
neonates of mothers who received high-dose iron compared to those who received low-dose 
iron.  It is a common belief that the fetus obtains and stores normal amounts of iron even 
when its mother is mildly to moderately iron deficient. (Allen, 1997).  
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Most studies that failed to show an association between maternal and infant iron status 
examined the relationships between iron status in late pregnancy and iron markers in cord 
blood in women who were not iron deficient. (Allen, 1997) (Ajayi, 1988; Doyle, Crawford, 
Wynn, & Wynn, 2009; Okuyama, Tawada, Furuya, & Villee, 1985; Rios, Lipschitz, Cook, 
& Smith, 1975). In areas where anaemia is prevalent, however, cord blood iron markers 
were closely associated with maternal concentrations. (Agrawal, Tripathi, & Agarwal, 
1983; Gaspar, Ortega, & Moreiras, 1993) The findings of this thesis provide more impetus 
to the need to offer iron supplements to pregnant women with an aim of boosting infant 
iron stores. Although infants born at term are not usually iron deficient, neonatal stores are 
important because they probably delay the time until infants develop iron deficiency. 
We also assessed whether zinc protoporphyrin is accurate when used to assess iron 
deficiency in malaria endemic regions (Chapter 3). After comparisons with other iron 
indicators such as plasma ferritin concentrations it was found that zinc protoporphyrin is of 
unreliable diagnostic utility when discriminating between pregnant women with and 
without iron deficiency. Whole blood ZPP content overestimated the proportion of iron 
deficient population. Erythrocyte ZPP content performed slightly better but still over-
estimated the proportion of iron deficient population. Further research is required to explain 
the factors that influence ZPP synthesis in patients with chronic diseases. In addition, there 
is need for a review of the guidelines on the diagnosis and management of iron deficiency 
as assessed by ZPP in pregnancy in regions where chronic diseases are prevalent. Our 
results indicate that whole blood ZPP should have no role as a screening marker to manage 
iron deficiency in pregnant women. Erythrocyte ZPP may have limited value to rule out 
iron deficiency in populations with low prevalence of iron deficiency, but a positive test 
result should be followed by other, more specific diagnostic tests such as plasma ferritin 
concentration. Haemoglobin concentration is not suitable for this purpose. 
Non-transferrin bound iron has been the subject of many scientific discussions especially 
after the publication of the Pemba trial results. (Sazawal et al., 2006) The appearance of 
NTBI in circulation after oral ingestion of iron supplements has been thought to aid the 
growth and multiplication of Plasmodium parasites thereby increasing malaria induced 
morbidity and mortality. We conclude that oral ingestion of 60mg of ferrous fumarate will 
not lead to a detectable increase in NTBI concentrations provided that it is taken with 
food(Chapter 4). The absence of an effect is consistent with the lack of an effect of iron on 
Plasmodium infection (Chapter 2). 
In chapter 5 of this thesis, we aimed to develop a field friendly tool that can be used to 
predict asymptomatic Plasmodium infection. This was motivated by the fact that most 
point-of-care dipstick tests used to detect Plasmodium infection are not able to detect 100% 
of all the infection present yet asymptomatic infections are increasingly associated with 
adverse maternal and neonatal outcomes. In addition, with the observed reduction in 
malaria prevalence rates, focus is probably going to shift towards methods to detect 
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asymptomatic Plasmodium infection. Although many likely predictive factors were 
assessed individually or in combination with others, we did not get a reliable tool that is 
easy to apply in resource-poor malaria endemic settings.  
Low birth weight neonates die at a 20 times faster rate than heavier babies (UNICEF/WHO 
2004).  We postulate that a better understanding of the aetiology of low birth weight can 
provide clues for its prevention. In chapter 6, we aimed to identify factors associated with 
birth weight and then to develop a methodology to predict cases of low birth weight, using 
a single prognostic score that is based on variables collected at the second trimester of 
pregnancy. We used data collected as part of the trial presented in Chapter 2 and undertook 
further analyses. We show that being never married, inflammation, being a girl and iron 
deficiency were independently associated with reduced birth weight, whereas being 
overweight was associated with increased birth weight. Our findings indicate that methods 
can be developed with fair accuracy in discriminating between women due to give birth to 
neonates with low birth weight versus normal birth weight, using a single risk score that is 
based on a combination of prognostic variables collected at the second trimester of 
pregnancy. 
Methodological issues: study design, implementation, and analysis 
Selection of study area and participants 
A prudent selection of study area and participants is key to measuring effects in randomised 
controlled trials. The population under study must be “at-risk” of the outcome studied. In 
our case, we selected an area that is highly malaria endemic. We confirmed this by 
analysing not only the available literature about the area, but also by visiting research 
institutions in the area and discussing their raw data, surveys and observations. Key 
institutions that were visited included Kenya Medical Research Institute/US Centres for 
Disease Control and Prevention (KEMRI/CDC Kisumu), and the Walter Reed Project in 
Kombewa. We also held meetings with the Director of the Kenya national malaria control 
programme who confirmed that the selected area was a “malaria hot spot”. In addition, 
there was also a high prevalence of anaemia, iron deficiency, helminth infections, and 
schistosomiasis.   
Participants were recruited over a long time period stretching over a year. Because of the 
envisaged long duration of follow-up, and to avoid attrition, we carefully selected 
participants who were most likely to cooperate until the end of the intervention. We 
therefore strictly observed our inclusion and exclusion criteria. We engaged community 
volunteers to help in identification and recruitment of study participants, and recruited 
research assistants who would help in supervised administration of the iron supplements. 
These were respected members of the study population who had participated in health 
interventions in the study area in the past. We coupled every participant with a community 
volunteer and a research assistant, and also ensured that participants could call the study 
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personnel any time of day or night. In the end, we learnt that building a trust system with 
participants was key to realising our study objectives.  
We achieved very high compliance rates in our study. Only two women failed to meet our 
compliance criteria which was measured as the proportion of women who consumed >90% 
of the scheduled supplements. We attributed the success rates in compliance to supervised 
administration of iron supplements. To our knowledge, there are no other studies that have 
ensured supervised administration of iron supplements during pregnancy in a malaria-
endemic region. A recent Cochrane review highlighted compliance and attrition as major 
problems that affected studies that investigated the relationship between iron 
supplementation and maternal and neonatal outcomes. (Peña-Rosas et al., 2012) 
Justification of inclusion of fortification plus supplementation group 
In the study design, we compared supplementation with iron versus placebo in women who 
all received fortification. We could instead have chosen to compare fortification and 
supplementation versus supplementation only. However, this would have several 
disadvantages. First, this comparison would result in a relatively small contrast in iron 
intake, so that intervention effects could have been too small to measure with sufficient 
precision. Iron supplementation, on the other hand, leads to a larger contrast in iron intake, 
so that in the absence of evidence of effects on infection, we can be more confident that 
lower iron intakes of iron as supplied by fortification is safe. 
Second, if a combination of fortification and supplementation increased malarial infection 
among pregnant women, then governments would be asked to reconsider universal iron 
supplementation programmes rather than iron fortification. Universal iron supplementation 
in pregnancy has been controversial because of the uncertainty about the functional 
improvements that can be achieved, poor adherence by women, and the poor performance 
of supplementation programmes. In addition, fortification benefits not only pregnant 
women but also other population groups.  
Assessment of malarial parasitaemia in pregnancy 
Various studies have used different methods to assess malarial parasitaemia in pregnancy 
(Table 1). This not only makes it difficult to compare results from different studies but also 
poses a dilemma regarding the most appropriate method to use. To accurately detect 
asymptomatic parasitaemia, we used combinations of methods of assessment, namely 
dipstick tests, PCR, and histopathology of placental biopsies. The last two methods are not 
feasible in remote field conditions. 
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Table 1: Studies that assessed malarial parasitaemia in pregnancy in Kenyan women using different methods 
Reference Year; place Study population Prevalence (outcome) 
Perrault et al. 
2009 
Year not reported; 
New Nyanza Provincial General 
Hospital, Kisumu (urban; n=92) 
 
Siaya District Hospital (rural; n=65) 
Parturient women aged 15-40 y, apparently 
healthy, with singleton pregnancy 
35.7% (placental blood; rt-PCR) 
17.2% (placental blood; microscopy) 
33.1% (peripheral blood; rt-PCR) 
15.9% (peripheral blood; microscopy) 
10.8% (cord blood; rt-PCR) 
Siaya: 52.3% (peripheral blood; by rt-PCR) 
 
Van Eijk, Ayisi 
et al. 2004 
 
June 1999 – June 2000; 
NNPGH 
 
All women who delivered at NNPGH with 
uncomplicated pregnancy of a gestational 
age ≥ 32 weeks, residing in Kisumu 
municipality, willing to be tested for HIV 
and who attended ANCs 
 
13.9% (peripheral blood; microscopy)  
SP lead to 46% reduction in prevalence of placental 
malaria, but was only taken by 38% of women. 19% 
of women reported having used iron/folic acid 
supplements. 
 
Ter Kuile et al. 
2003 
 
1996-99; 
Rarieda Division, Siaya District 
 
Pregnant women in the cohort area 
 
19.6% in ITN villages vs 26.1% in control villages 
(maternal placental or peripheral blood; microscopy)  
Cord blood parasitaemia: 2.8% vs 4.1% 
 
Van Eijk et al. 
2003 
 
1996-99; 
NNPGH, Kisumu 
 
Pregnant women, no known underlying 
disease, attending ANC with uncomplicated 
singleton pregnancy ≥ 32 weeks’ gestation, 
residing in the Kisumu area 
 
21.9% (15.2% in peripheral blood and 19.0% in 
placental blood; microscopy) 
 
Schulman et al. 
2001 
 
January 1996-July 1997; 
Kilifi District Hospital 
 
Parturient women with singleton 
pregnancies 
 
Primigravidae: 24%, 23%, 34% 
Secundigravidae: 18%, 13%, 24% 
3,4-gravidae: 8%, 7%, 13% 
>4: 10%, 7%, 12% 
(peripheral blood, placental blood and placental 
biopsies; microscopy) 
 
Parise et al. 
 
5 clinics in Kisumu District and 4 
 
Parturient women 
 
Kisumu: 27.1% and 23.8% 
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Table 1: Studies that assessed malarial parasitaemia in pregnancy in Kenyan women using different methods 
Reference Year; place Study population Prevalence (outcome) 
2003 clinics in Mombasa District Kilifi: 24.5% and 19.5% 
(peripheral and placental blood; microscopy) 
 
Parise et al. 
1998 
 
1994-96; 
NNPGH and Kisumu District 
Hospital, Kisumu 
 
Women in their 1st and 2nd pregnancies 
attending antenatal clinics with 16-26 weeks 
gestation 
 
Case management: 27.0% and 27.1% : 2-dose SP: 
9.8% and 11.5% 
Monthly SP: 6.7% and 8.9% 
(peripheral and placental blood; microscopy) 
 
Shulman et al. 
1998 
 
September 1994-November 1995 
Women attending ANC at Kilifi 
District Hospital 
 
Primigravidae or women with a previous 
history of a pregnancy <12 weeks, with a 
singleton pregnancy 
 
Control: 5.8% and 35.8% 
ITNs: 12.7% vs 41.3 
(peripheral and placental blood; microscopy) 
NNPGH, New Nyanza Provincial General Hospital-Kisumu; ANC, Antenatal clinic; ITN, Insecticide treated net     
 
Table 2: Case definitions of Plasmodium infection 
 HRP2-
based 
dipstick 
test 
LDH-based 
dipstick test 
Microscopy 
of 
peripheral 
blood 1 
Placental biopsy PCR, peripheral 
blood 
PCR, maternal 
placental blood 
P. 
falciparum 
Other 
spp. 
Pigment Parasites 
1 
P. 
falciparum 
Other 
spp. 
P. 
falciparum 
Other 
spp. 
Case 1 (primary 
outcome) 2 
   ○  ○     
Case 2 (patent)    ○  ○ ○ ○ ○ ○ 
Case 3 (sub-patent) ○ ○ ○ ○ ○ ○     
Case 4 (current or 
recent) 
   ○ ○ ○     
Diagnostic tests are included () or excluded (○) in each case definition, and are linked through ‘OR’ Boolean operators. 
1 Regardless of parasite stage (i.e. asexual or sexual stages). 
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Histological examination of placental biopsies is often considered the ‘gold standard’ of 
malaria diagnosis in pregnancy, and results in infection status being classified into four 
categories depending on the presence and distribution of Plasmodium parasites and 
haemozoin (Bulmer, Rasheed, Francis, Morrison, & Greenwoods, 1993): 
1. Active infection: parasites are present in maternal erythrocytes the intervillous 
spaces with or without pigment in intervillous erythrocytes or monocytes; 
2. Active-chronic infection: parasites are present in the intervillous spaces along with 
pigment as deposits in fibrin or in macrophages within fibrin;  
3. Past infection: pigment is present in fibrin or in macrophages within fibrin but not 
in parasites; and  
4. Not infected. 
Although placental histopathology is expensive, laborious and requires highly skilled 
manpower, it provides a unique opportunity for researchers to study past Plasmodium 
infections retrospectively. For ethical reasons, it is not feasible to assess Plasmodium 
infection during the intervention period without providing chemotherapy to those found to 
be infected. Investigators would like to quantify the presence of Plasmodium infections 
during pregnancy in a way that does not compromise ethical standards. Placental 
histopathology provided an opportunity to study the occurrence of past infections during 
pregnancy without compromising ethics.  
Any form of Plasmodium infection that is associated with adverse maternal or pregnancy 
outcomes is bad for the pregnant mother and her new-born baby. We formulated the 
primary outcome as the presence of maternal Plasmodium infection in samples collected at 
delivery, regardless of species, as indicated by one or more positive results for the presence 
of Plasmodium-derived LDH or HRP2 in plasma (dipstick tests), past placental infections, 
or Plasmodium DNA (any species, by PCR test). Although we assessed the presence and 
density of Plasmodium parasites in microscopical examination of blood films, we excluded 
these results from our case definition because results from microscopy would be considered 
incorrect if discordant with results from PCR tests. Table 1 shows the case definitions used 
in this study.  
Pigment deposition has generally been found to be associated with low birth weight, 
particularly in the presence of parasites in the intervillous spaces (Menendez et al., 2000). 
There is uncertainty, however, about the effect of past infections (i.e. with pigment 
deposition but without parasitaemia), on neonatal outcomes: such infections have been 
found to be associated with reduced birth weight in several studies Walter, Garin, Blot, & 
Philippe, 1981, Watkinson & Rushton, 1983, Rogerson et al., 2003, but not in others  
(Matteelli et al., 1996, Menendez et al., 2000, Muehlenbachs, Mutabingwa, Fried, & Duffy, 
2007, Muehlenbachs et al., 2010).  
PCR is considerably more sensitive in detecting maternal infection than either microscopy 
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or rapid dipstick tests that assay the presence of Plasmodium-specific proteins (e.g. HRP2 
or LDH). (Kattenberg et al., 2011) Several studies have found that sub-patent infections 
(i.e. low parasitaemias that are detected by PCR but not by microscopy or dipstick tests) are 
associated with reduced birth weight ((Malhotra, Dent, Mungai, Muchiri, & King, 2005),  
(Adegnika et al., 2006), (Arango, Maestre, & Carmona-Fonseca, 2010), (Mohammed et al., 
2013)) but others have not (Mankhambo, Kanjala, Rudman, Lema, & Rogerson, 2002, 
Mockenhaupt et al., 2006,Rantala et al., 2010)).  
We are not aware of studies on the maternal or pregnancy outcome of P. malariae or P. 
ovale infection during pregnancy in Africa. P. vivax is associated with low birth weight 
((Luxemburger et al., 2001), (Nosten, ter Kuile, Maelankirri, Decludt, & White, 1991), 
(Nosten et al., 1999)) but this species rarely occurs in Africa. 
Various studies targeting placental malaria have been done in Kenya. Table 3 shows the 
prevalence of placental malaria as reported by some studies that used combinations of the 
methods discussed above. 
Selection bias 
Selection bias is unlikely to occur in a trial if participants are individually and properly 
randomised and sample size is large. In all the chapters of this thesis, we present results 
after comparing the full population sample, thus ensuring that group similarity at baseline is 
maintained. We also assessed for possible confounding by comparing crude and adjusted 
prevalence ratios. The latter was obtained by including baseline covariates that could be 
prognostic for outcome. These covariates were either likely to be prognostic for the primary 
outcome, as predefined on the basis of the literature review or simply possibly prognostic 
for the primary outcome. They included: gravidity (M. Desai et al., 2007), maternal age (M. 
Desai et al., 2007) (Tako et al., 2005), HIV infection status (Kuile et al., 2004), 
Plasmodium infection status, iron status, and gestational age at delivery. When the potential 
value of the adjustment was in doubt, we considered the unadjusted analysis as the one of 
primary attention, and the adjusted analysis as supportive. 
Throughout this thesis, various sub-group analyses have been reported. It is possible that 
subgroup analysis could distort the balance achieved by randomisation of participants at 
baseline. We interpreted the results of subgroup analysis cautiously. (Assmann, Pocock, 
Enos, & Kasten, 2000), (Wang, Lagakos, Ware, Hunter, & Drazen, 2007), (Fletcher, 2007; 
Oxman, 1992; Sun, Briel, Walter, & Guyatt, 2010; Yusuf, 1991) 
Effect modification 
We expected the relationship between iron supplementation and malaria parasitaemia at 
parturition to be modified by various factors as discussed below. 
a. Gravidity: In highly endemic areas, primigravidae are at greater risk of malarial 
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infection (Nosten et al., 1991) (A. M. Greenwood et al., 1992), probably because they 
have reduced immunity. Thus, we expected that their ability to suppress a possible 
increase in parasitaemia resulting from iron would be reduced. 
b. Age: Plasmodium infection was expected to be higher in women ≤20 years old. Young 
primigravidae and multigravidae are at greater risk of malaria and its adverse effects 
than older primigravidae or multigravidae, respectively (Espinoza et al., 2005; Leenstra 
et al., 2003; Marques et al., 2005) (S J Rogerson et al., 2000) (Walker-abbey et al., 
2005). This is probably because age-associated immunity plays a role in controlling 
malaria infection during pregnancy in highly endemic areas. We expected that women 
≤20 years old had a reduced ability to suppress a possible increase in parasitaemia 
resulting from iron. 
c. HIV infection: HIV infection compromises malarial immunity such that HIV infected 
multigravidae have at least as high a risk of placental infection as non-HIV-infected 
primigravidae (M. Desai et al., 2007). HIV exacerbates the burden of malaria and 
increases the degree to which malaria is associated with maternal severe anaemia. We 
expected that due to compromised malarial immunity, women that were HIV infected 
would be more susceptible to iron-induced infection. 
d. Maternal iron status at baseline: Low iron status at baseline would be protective against 
malaria infection but would also result in increased absorption of the supplemented iron. 
The vice versa was also true thus we expected the effect of iron supplementation on 
malaria parasitaemia to be influenced by iron status at baseline. 
Adverse outcomes 
We defined adverse outcomes as “any untoward medical occurrence in a study participant”. 
The most serious adverse events (unrelated to study treatment) that occurred were deaths of 
two mothers and eight neonates (see participant flowchart in Chapter 2). One of the mothers 
died soon after delivery due to post-partum haemorrhage while the other mother died three 
weeks after delivery due to pneumonia and cardiac complications. The cause of death of 
most neonates as reported by attending nurses was neonatal sepsis. All adverse events were 
reported to the principal investigator within 24 hours and then to the data safety monitoring 
committee. The data safety committee was independent, blinded, and periodically reviewed 
cumulative trial data and advised on safety issues. 
There were two cases of neural tube defects which were referred to Bethany kids – Kijabe 
mission hospital, a specialised hospital dealing with spina bifida and neural tube defects 
(http://kijabehospital.org/). Both babies had classic wounds on their spine and 
hydrocephalus. After extensive surgery and close follow-up, both babies survived. 
Intermittent preventive treatment (IPT) 
Intermittent preventive treatment data were obtained retrospectively from the participants 
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antenatal clinic attendance booklets. In Kenya, nurses fill in the information in these 
booklets during the antenatal clinic visits. This is standard practice countrywide and it has 
major benefits. In situations where there are virtually no existent hospital records regarding 
a pregnant mother, the antenatal booklets serve as a key source of information for medical 
practitioners. All clinical and non-clinical interventions received by the pregnant mother are 
recorded in these booklets.  
We examined whether intermittent preventive treatment had an effect on malaria 
parasitaemia at birth. Because IPT data was recorded after randomisation, theoretically, it 
could have been influenced by the intervention and thus it was considered separately in the 
analysis. Contrary to our expectations, mothers who had two recorded IPT interventions 
had the highest rates of Plasmodium infection at parturition compared to mothers who had 
one or three IPT interventions (preliminary data, not shown). Most mothers received two 
IPT doses. It is possible that mothers came for a follow-up antenatal visit because they were 
experiencing malaria-related symptoms. Although the clinic attendance booklets provide a 
wealth of information, interpretation of data there-in deserves critical and logical thought. 
Important pre-trial procedures 
This section of the discussion highlights important issues related to implementation of 
studies of similar nature in resource poor settings. This is arguably a “mine-field” for most 
researchers and successful navigation of critical aspects of trial implementation determines 
to a great extent, the success of the research. Reference is made to experiences gathered 
during fieldwork in Kenya. 
Legal requirements and issues regarding ethical clearance 
Implementation of a study in humans in developing countries is not as straight-forward as 
often perceived. There are complex networks of government regulations, institutional 
collaborations, finance obligations, and often, conflicting bureaucracies. Planning for a 
study must take into account time spent on the vital but necessary pre-trial registrations and 
legal issues.  
The first step in launching the study in Kenya involved applying for research permits for 
the main researchers. This application is submitted to the Kenya National Council for 
Science and Technology. The procedure involves submitting the study proposal and 
detailed field wok implementation plans. These are legal requirements without which no 
research can be undertaken in Kenya. Once research permits are granted, the process of 
obtaining ethical review permits can begin. It is prudent to apply for these documents as 
early as possible to avoid delays. In addition, with research permits, certain activities are 
permitted e.g. holding meetings with community leaders etc. This can be useful as the 
researcher awaits final ethical clearance. Though the national council for science and 
technology does not require annual reports of trial implementation progress, it does require 
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the researcher to deposit two copies of the final report of findings at its depository. If a 
researcher applies for a new research license and yet he/ she did not submit reports of past 
research, a denial of license could be imposed. 
Ethical clearances were obtained from two Ethical Review Committees (ERCs): Kenyatta 
National Hospital/University of Nairobi ERC (Kenya), and the London School of Hygiene 
and Tropical Medicine ERC (United Kingdom). Obtaining ethical clearance in the United 
Kingdom was vital because London School of Hygiene and Tropical Medicine was the 
legal trial sponsor and was thus responsible for insurance of all trial participants etc. To 
conduct the research in Kenya, local ethical clearance was mandatory hence the reason for 
obtaining the second ethical clearance in Kenya. 
Unlike the research license requirements, most ethical committees in Kenya require 
submission of an annual progress report. Adverse events and serious adverse events are also 
required to be reported “as they occur – based on a pre-specified criteria”. The process of 
obtaining ethical clearance is usually slow and proper planning of field activities is vital so 
as to maximise utility of available resources. Figure 2 shows the administrative process 
prior to, and during trial implementation. Since there are several institutions from which 
ethical clearance can be obtained, it is important to carefully select the institution that has 
the quickest processing times etc. This information can be obtained by gathering 
information from fellow researchers in the target study area. 
The success of many research projects hinges on goodwill not only from study participants 
but also from the governance framework in the target study area. Before start of the trial, 
we approached key government departments and briefed the lead persons verbally and in 
writing, about the impending research work. It was hoped that this would provide a 
platform upon which dissemination of the trial findings would be done i.e. after trial 
completion and publication of findings. Because of the envisaged policy implications upon 
completion of the study, we expanded the list of “contacted” key authorities at national 
level to include the Division of Malaria Control, Division of Reproductive Health, and the 
Ministry of Public Health and Sanitation. Officials at Provincial and District levels 
responsible for health in the target area, especially those from the Ministry of Medical 
Services and the Ministry of Public Health and Sanitation, were visited to explain study 
aims and procedures, and to obtain their approval. We were lucky that the available trial 
funding enabled us to do all these preparatory activities. While we recognise that funding 
limitations curtail the extent to which researchers can do preparatory work prior to trial 
commencement, we emphasize the benefits and good will derived from these efforts. A 
notable example was when we were experiencing clinical staff shortages. A visit to the 
provincial medical officer of health solved the problem as he was already aware and in 
support of our work, thus he immediately approved the appointment of 3 extra nurses at our 
research station. 
 
Figure 2: Decision tree prior to, and during trial implementation
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Numerous meetings were held with community members, community health workers, 
provincial administrators and local leaders to sensitise and inform them about study aims 
and procedures. Local health facilities (including local dispensaries, District, and Provincial 
Hospitals) were visited to learn about standard clinical procedures (including HIV testing) 
and to coordinate our study with on-going health activities in the area. Although virtually 
all women in the study area currently accept HIV testing, we still took time to demystify the 
HIV testing procedures that we were going to use and to assure all the interested persons 
that the results of the tests would be completely confidential. This paid off in the 
implementation phase of our study as all our study participants accepted HIV testing 
despite the cultural myths surrounding this procedure. 
The census 
In order to implement the trial effectively, it was necessary that we know approximately 
how many people were resident in the study area. This was especially because we intended 
to fortify with NaFeEDTA, all the flour in all the participating households and their 
homesteads, for the entire duration of follow-up of the index subject. The only estimates of 
population size available to us were from the previous Kenya Demographic and Health 
Survey 2008-2009.(Kenya National Bureau of Statistics (KNBS) & ICF Macro, 2010) 
Unfortunately, detailed data regarding the target area were not available and thus the 
solution was to conduct a census.   
The area selected for study consisted of three administrative units (‘sub-locations’) in 
South-West Kisumu location. Enumeration of all persons, and households in this area 
involved careful planning, recruitment of personnel, training, and closely monitored data 
collection. The first step was obtaining the necessary legal permissions from the provincial 
administration. We then developed a five-page census questionnaire that was aimed at 
collecting vital information necessary for implementation of our research work.  
For efficient census data collection, we coupled each census enumerator with a village 
elder. The elders were key to obtaining community support to our efforts. Enumerators 
were much more likely to be accepted by the community when accompanied by the elders. 
In addition, the data was more correct and trustworthy because the elders usually had very 
good insight of the family situations of the visited households. By equipping the elders and 
enumerators with key information regarding our intended study, community mobilisation 
and support was obtained.   
Global Positioning System (GPS) data of each household was collected in addition to the 
regular census data. This aided follow-up of study participants as there are no person-
specific location/ home addresses in this area. In addition, we enquired about grain milling 
procedures and patterns. This information proved very useful when planning for the 
community based flour fortification programme.  
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Vital fieldwork collaborations before trial launch 
The term “independent researchers” in this section refers to researchers who are formally 
not staff of local research institutions such as Kenya Medical Research Institute or US 
Centers for Disease Control and Prevention, Kisumu. Some PhD fellows venture out as 
independent researchers without support by local institutions. Institutions ensure that the 
research infrastructure (offices, laboratories, vehicles etc.) is ready for use when needed. 
Usually, they also map out areas where they implement their trials. The studies presented in 
this thesis were done within the framework of an “independent researcher”.  
Unlike researchers who are part of local institutions, independent researchers have to set up 
the research infrastructure from scratch. We identified our “partner” health clinic after an 
extensive tour of the proposed study area. This clinic (Ober Kamoth health centre) was 
favoured because it was centrally located in the research area. Furthermore, there were 
referral hospitals within a radius of 10-15 km from the health centre. Although it had 
facilities that could be converted to research offices, they were in dilapidated conditions 
and needed extensive renovations before research work could commence. The health centre 
was also severely under-staffed. The community had very little confidence in its ability to 
deliver quality health services. We decided to transform this health centre into a beacon of 
health services delivery in the area as part of our contribution to better health services in the 
area.  
The first step was undertaking extensive discussions with the Department of Health 
Services, Kisumu municipality, as it was the owner and manager of the health centre. A 
Memorandum of Understanding (MoU) was signed between all parties. The MoU 
recognised our presence in the study area and gave permission to not only work from the 
health centre, but to also under-take extensive repairs of the health facility. Periodic 
meetings would be held to discuss and approve plans before major work was done to the 
existing buildings. As part of the MoU, we requested for additional nurses from the 
Ministry of Health and from the Health Department, Kisumu. Luckily, following 
recommendations from leaders we had met in the initial planning meetings, we received 
additional staff.   
It is important for independent researchers to secure support by other research institutions 
in their target area. This is necessary for many reasons e.g. emergency laboratory support or 
when demarcating geographical research areas to avoid “crossing-over” of study 
participants from one study to another. In our study area, three other research institutions 
were identified. These were:  
1. Kenya medical Research Institute/ US Centers for Disease Control (KEMRI/ 
CDC) – Kisumu 
2. Walter Reed Programme – Kisumu and Kombewa field sites 
3. Maseno University – Maseno 
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We held meetings with the institutions above and explained our research aims and 
objectives. We then mapped out our proposed study area and sought to find out whether 
there were any active studies involving human subjects ongoing in the area. In return, the 
representatives of the research organisations explained to us their research interests, focus, 
capabilities, and geographical area of operation. They also gave us their commitment to 
support us during the implementation of the research project. Some of them even visited 
our field research offices and offered valuable advice on how to transform the site for 
research purposes.  
Conflict of interests with humanitarian aid organisations based in the study area 
In the preparatory period before trial commencement, a new humanitarian aid project – the 
Output-Based Approach (OBA) project begun in parts of our target area (www.output-
based-aid.net). This project aimed at promoting hospital delivery of newborn children (as 
opposed to the practice of unsafe home deliveries in rural villages). The project had 
collaborated with World Food Programme, which would provide iron-fortified flour (7 
kg/month) to the recruited women. The OBA project thus indirectly led to delays in our 
procedures as we evaluated the probability of participants in our study receiving additional 
fortified flour from the Output-Based Approach project.  
We carried out a survey to determine how many women in the study area were in the OBA 
project. We interviewed 40 pregnant women. Out of these, only 17% were in the OBA 
project. As such, in order to avoid iron overload, we decided to avoid recruiting women 
who were already in the OBA project. Women in our study were given instructions about 
the repercussions of obtaining fortified flour from other sources. The antenatal clinic books 
of all our participants were clearly stamped on the front-page with information pertaining to 
the fact that the subject was part of an ongoing study and thus giving additional iron as 
either fortification or supplementation would possibly be injurious to the health of the 
mother.  
Community mobilization and incorporation of traditional birth attendants into 
research activities 
The success of a research project based in a remote place depends largely on the level of 
support given by the local community. African communities are organised in complex 
ways. There are multiple factors that determine if a community will support a research 
study. In Western societies, an individuals’ decision to participate is based on written 
information, mass media, and probably ones assessment of the perceived benefits. In 
Kenya, the decision to participate depends also on other additional factors such as advice 
from community elders, opinion leaders, religious leaders, and health advocates such as 
community health workers.  
We embarked on a community mobilisation campaign in order to garner support by all 
parties involved. Initially, we gave key information to census enumerators and their 
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accompanying elders. We also held meetings with the local administration (chief, sub-
chiefs, and elders of the community). We explained in detail what the study was about, the 
stages that the study would go through, how long it would take, who would participate, 
participants’ benefits, and compensation mechanisms in-case of harm to participants. It was 
very important that the administrative team gives their support to the project otherwise the 
study would probably not be allowed to start. In addition, we made sure that we did not 
over-state the benefits that individual participants or the community would get so as to 
avoid future misunderstandings. Written meeting minutes proved useful during periodic 
evaluation meetings. 
 
Following advice by the administrative team, we held more meetings with opinion leaders, 
religious leaders, millers, and community health workers. The objective was to provide a 
platform for them to ask as many questions as possible and for us to provide answers to 
their questions and clarifications whenever necessary. This was vital in view of the fact that 
our participants were a highly vulnerable group. The millers were also interested in 
knowing whether the fortification of locally-sourced flour would change the taste of the 
flour product and whether they would be required to charge more money to customers. We 
assured everyone that all our activities would not require a financial investment from their 
side and that participants would not be required to pay extra for the fortificant. 
 
One of the outcomes of the community mobilisation activities was the realisation that we 
needed to also target the traditional birth attendants (popularly known as TBAs). TBAs are 
highly respected amongst the women folk in rural Africa not only because they provide a 
service that the government sometimes cannot, but also because their work is deeply rooted 
in the local culture and customs. Although the government health officials had made a point 
that they were not in support of the work of TBAs due to health risks to the pregnant 
women, it turned out that a lot of women still sought the services of traditional birth 
attendants. Modern hospitals are not many in the area considering the geographical expanse 
of the region. It was not a surprise to us that women in labour went to the nearest help 
(TBA) available. The TBAs brought up an issue that we had not anticipated. Our project 
was going to cut-off their revenue source. In addition, government was not supporting them 
so they could not officially be seconded to the project. Following extensive discussions 
with the TBAs, it was agreed that we train and then engage them as community health 
workers in the project. This way, when women went to them to give birth, they would 
immediately call the project ambulance and the woman would be moved to the hospital 
where she would deliver under skilled attendance. This was a win-win solution for all and it 
proved to be one of the key success pillars of the project.  
 
Global position system (GPS)-aided research project administration 
Modern technology is increasingly becoming the tool that resource-poor countries use to 
circumvent problems. Global position system (GPS) has been recognised as a unique 
research tool in remote research locations. Unlike in developed countries, most research 
areas in developing countries have no formal address codes. Usually, the population relies 
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on post office boxes that are centrally located in the nearest mid-size town for their mail. 
GPS has enabled easier follow-up of study participants in such areas. 
As part of the census, we collected GPS data of 2,564 households. The GPS data was 
entered into an electronic database, and linked to the census data. With a view to assist in 
locating homes of the women in the study area, a high-resolution photographic satellite map 
was produced of the study area, and integrated with GPS data so that individual households 
were visible and indicated. 
 
Figure 3 is a map generated from Google maps and overlaid with the GPS coordinates of 
the study participants who were randomised into the study. It also shows the location of the 
research health centre relative to the whole study area. From the map, we could easily 
locate the home of a participant especially in times of emergencies such as during delivery. 
Women would call for the project ambulance as soon as they went into labour. Using the 
GPS coordinates of the home of the woman (or sometimes just relying on local knowledge 
of the area), we would rush to the home of the woman and bring her to the research hospital 
where skilled staff would ensure a smooth delivery of her baby. In addition, GPS data 
enabled us to know if a woman came from within the boundaries of our research project. 
Furthermore, as randomisation of trial participants progressed, we were able to see from the 
map whether we were randomising from only one side of the area or from the whole area. 
 
The success of the community based flour fortification programme 
a) Estimating flour intake and milling practices in the area:  
In 2010-11, we conducted studies in the study area to assess flour intake and grain milling 
practices of the target population.  Dietary assessment was done to quantify flour intake and 
to identify sources of flour. Methods used to collect this data included food frequency 
questionnaires (n=50; conveniently selected households), weighed food records (n=18 
households; in duplicate), and field observations of all posho mills in the area. The results 
indicated that 93% of households in the target population obtained their flour by milling 
grain at local hammer (posho) mills, whilst only 2% of households reported to obtain their 
flour exclusively from the shops (centrally processed flour). The mean daily per capita 
intake of flour was 252 g (SD: 41 g). Out of the 45 posho mills in the area, 24 run on diesel 
and 21 on electricity. Most flour was produced from maize only, or maize together with 
sorghum or cassava. The smallest amount of flour milled was 1 kg. Many households also 
used flour as animal feed.  
 
From these data, we concluded that flour fortification at hammer mill level was plausible; 
maize/ corn was obviously the target food vehicle though other foods such as cassava, 
millet, and sorghum could also be fortified; the target client would be the pregnant mother 
though the whole homestead would have to benefit from the fortification. The latter point 
was motivated by the observation that food was shared between household members and it 
was not uncommon for the mother to serve everyone else and serve herself last. This is 
typical of most African communities.    
	Figure 3: Visualization of the GPS coordinates of the geo
GPS coordinates visualized using GPS visualizer 
	
- www.gpsvisualizer.com
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-locations of the study participants (map courtesy of Google maps. 
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b) Field-testing of a protocol for community-based fortification:  
Fortificant  iron (as NaFeEDTA;  ±13%  iron), in premix form,    was  obtained  from  
Fortitech  (Fortitech  Europe  ApS, Gadstrup,  Denmark).  The  target  fortification  level 
(20mg  iron as  NaFeEDTA per kg of flour)  was  based  on guidelines  from  the  Flour  
Fortification  Initiative  that  were  adopted  by  the  World  Health Organization (WHO, 
2009) and by the Kenya Bureau of Standards (KEBS 2010, GoK 2008), and based on an 
estimated per capita consumption of flour of 225g of flour per day.  
The premix contained iron in highly concentrated form.  The manufacturers prefer to ship it 
in this form in order to reduce shipping and storage costs. It is therefore not possible to 
achieve a homogenous mixture of the premix in flour when adding directly to the grains 
being milled. For this reason, an additional step was required whereby premix was diluted 
into a preblend, which was suitable for addition to the grains being milled.  
We diluted premix into three preblend master batches at a ratio of 1:100. During trial runs 
in the Netherlands, we used an electric cement mixer (new) to mix the flour and the premix 
so as to obtain a preblend. However, contrary to expectations, it proved impossible to 
procure an electrical cement mixer in Kenya. Available mixers were all diesel-powered, 
which are unsuitable for food preparation purposes due to the risk to carcinogenic 
compounds from the petroleum products.  
The problem was solved by using an “ODJOB” home cement mixer procured from the 
USA. This drum-like mixer works by being rolled on the ground. Since it has specially 
designed grooves on the inside, the manufacturers claim that cement is adequately mixed 
within 10 seconds of continuous rolling. We decided to apply this principle in the 
production of fortificant premix albeit with a few additional tests.   
Two “ODJOB” cement mixers were obtained and thoroughly cleaned before being used 
exclusively for fortification work. To improve efficiency and reduce human workload, the 
“ODJOB” mixer was mounted on a stand that was locally designed and assembled (Figure 
4). The stand had a mounting section for the “ODJOB” drum and a handle used to rotate it 
while standing or sitting on a high chair. It was also specially designed to give a tilt to the 
angle of rotation so that the flour not only mixed because of the irregular form of the 
“ODJOB” mixer but also because the drum was tilted at various angles. This increased 
efficiency of the assembly. Figure 4 shows the “ODJOB” mixer, mounted on a locally-
made stand. 
We assessed the effect on homogeneity of preblend iron content after various mixing times. 
Each of the batches was mixed for 60 minutes; 6 preblend samples (25 g) were collected 
according to a pre-established plan from various locations in the mixer at 20, 40 and 60 
minutes. We similarly assessed the effect of producing preblend in batches of various 
volumes (8 kg, 10 kg and 12 kg). Lastly, we diluted preblend into flour in 10 different 
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mills, at a ratio of 1:100. The fortificant iron content was determined for all samples in 
duplicate. 
There was no demonstrated effect of preblend mixing volume on fortificant iron 
homogeneity. With a mixing time of 20 minutes, the iron concentration of preblend was 
2.01 g/kg (co-efficient of variation: 2%) (Target: 2 g/kg); there was no evidence that a 
longer mixing time resulted in a more homogenous sample. Fortification at the mill resulted 
in an average level of fortification of 18.0 mg iron per kg flour, SD: 2.2 mg/kg (target: 20.0 
mg/kg). The difference could be explained by losses due to the retention of flour in the mill 
after the first run. Thus we were confident that our fortification procedure resulted in 
adequate levels and adequate homogeneity of fortificant iron in flour, and that our target 
level (20 mg/kg) in the final fortified product was appropriate in view of the per-capita 
amount of flour consumed by the participating women. 45 local millers were trained in 
fortification procedures and all but three participated in the study. The three were excluded 
because their mills had porous sieves thus the iron in the fortified flour product was not 
homogenously mixed. 
	
Figure 4: “ODJOB” mixer, mounted on a locally-made stand 
Issues related to the manufacture of trial supplements 
We  had  originally  foreseen  that  the  iron  supplements  in  our  trial  would  contain  
dried  ferrous sulphate, the compound that is conventionally used in iron tablets. To mask 
the metallic taste, we decided to have this formulated into capsules. When conducting 
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laboratory tests for stability of the iron supplements, we became aware that ferrous sulphate 
is hydrophilic, withdrawing water from gelatine capsules that naturally contain 16% water. 
As a result, there was a serious threat that the capsules would eventually crack and its 
contents would leak. This would also allow the study participants to taste the contents of 
the iron capsules and to distinguish between capsules containing iron and placebo. Thus we 
decided to switch to ferrous fumarate, which is not hydrophilic but which has a similar 
molecular weight (thus not requiring bigger capsules, which may be hard to swallow for 
pregnant women) and similar fractional absorption of iron as in ferrous sulphate. 
Issues of study administration 
Implementation of a research project with multiple research partners can exert a lot of 
pressure on the implementation team. Some major decisions are so urgent that there is no 
time to wait for consultations to take place up and down the management ladder. It is vital 
that the implementation team is given a leeway in situations that demand urgent action.  
Staff administration is a key component of successful project implementation. However, it 
rarely gets the appraisal necessary because some projects are short-term. In long-term 
projects such as the one described in this thesis, the ability of the project team to deliver the 
expected results depends largely on the interrelationships between various team members. 
Figure 5 is the organisational structure of the human resource in the research project.  
Researchers in poor, remote communities sometimes result to borrowing from the research 
budget due to humanitarian demands. Pregnancy is a period full of surprises for most 
couples including those that participated in our project. Despite our repeated messages 
about the extent of our mandate, most project participants were of the idea that the project 
team could sort out any of the pregnancy-related issues that arose. We were very careful not 
to overstep our mandate while at the same time keeping within ethical boundaries.   
Although we intended to hold regular technical meetings with the project management team 
spread out in Africa and Europe, we quickly realised that teleconferences and video 
conferences were the way forward. Every team member has to be up-to-date with current 
events and procedures in the field. It is challenging to call for meetings when field 
procedures such as the birth of children are not predictable. Sometimes, we had to 
participate in teleconferences while at the same time driving through the bush to locate a 
woman in labour.  
Another interesting realisation was that data is not only closely guarded by researchers but 
also by the participating individuals and communities. The last two quickly realised that we 
would accumulate quite a lot of health-related information about them. We explained 
clearly what information would be collected, who would see it, how it would be stored, and 
how the results would be disseminated to them. Trial planners and implementers should 
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never take it for granted that the community is at ease with collection of health related 
information.  
We ensured that there was a framework for data back-up, archiving, and protection from 
theft or loss of data or samples. The trial sponsor (London School of Hygiene and Tropical 
Medicine) ensured that all collected information was kept in encrypted memory sticks and 
could be regularly sent to the principal investigator for back-up. These sticks were virtually 
indestructible, can survive very harsh weather conditions, and most importantly, can be 
remotely wiped-off all data. 
A minor but nevertheless important extra point was the number of staff members involved 
in this project. Since the principle investigator (HV) was based in the Netherlands, the PhD 
fellow had to manage more than 84 members of staff on a daily basis. The roles of these 
people are indicated in the organisational structure – figure 5. In addition, there was the 
usual handling of suppliers, part-time workers etc. As such, the research work inevitably 
went beyond the realms of research and demanded good management and leadership skills. 
Community based pregnancy testing and surveillance 
Pregnant women in the study area delay making their first antenatal clinic visit to the 
hospital sometimes till the third trimester. As such, we decided to deploy a community-
based pregnancy surveillance programme aimed at identifying and encouraging pregnant 
women to make the visit earlier i.e. before 20 weeks of gestation. Pregnancy testing was 
necessary in order to identify pregnancies at an early stage. However, excessive testing is 
expensive, puts an unnecessary burden on field staff and women, and may lead to false 
positive test results. In addition, very early testing is unethical because 60% of pregnancies 
are lost due to natural causes before the end of the first trimester is reached. In view of 
these issues, we developed a Standard Operating Protocol (SOP) for surveillance and 
detection of early pregnancy (see annex II). This SOP reviewed outlined strategies and 
appropriate procedures for early detection of pregnancies in the study area.  
Because unmarried women may initially ‘hide’ their pregnancies, we invited them for 
regular urine testing. Married women were questioned monthly about the occurrence of 
their menstrual periods.  A nurse administered urine tests at the research clinic to: 
a) All women who had never been married, or who were divorced, separated, or 
widowed: at 12-weekly intervals;  
b) All women who were married or living together: when women reported not to 
have had a menstrual period for 10 weeks since the date of the onset of the last 
menstrual period. 
  
	Figure 5: Organisational structure 
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Confirmation by obstetric ultrasound was done if the time since the onset of the last 
menstrual period exceeded 10 weeks.  A nurse conducted an ultrasound examination 
immediately after pregnancy had been confirmed by urine test, or as shortly as possible 
thereafter.   
Ultrasound techniques served to confirm pregnancy, determine if the pregnancy concerned 
a singleton, and determine the gestational age. Five nurses from the research clinic were 
trained on ultrasonography. These nurses actively participated in the screening and 
recruitment of pregnant women and also in conducting successful deliveries of babies from 
the project mothers. However, only one nurse did most of the ultrasound scans. During a 
period when this particular nurse was on pregnancy leave, a stand in nurse failed to identify 
two twin pregnancies. These mothers were followed up until the end to be included in the 
full analysis set, but they were excluded from the per protocol analysis. 
Pregnancy surveillance: the use of common electronic tools  
Pregnancy surveillance and testing in the source population (approximately 4,025 women 
of childbearing age (15-45 years) was a challenging task that could easily have become 
inefficient and chaotic. We aimed to detect all pregnancies in the source population within 
the first trimester. An electronic MS-Excel based pregnancy surveillance and detection 
database was designed and used to help detect potentially pregnant women. Its key features 
were:  
1. Resident women in the study area within the eligible age range (15-45 years) were listed 
in the ‘Source population’, together with information about their date of birth, marital 
status, village of residence, GPS coordinates, and parity.   
2. Information  about  community health workers,  including  their  village  of  residence,  
and  contact details.  
3. For each woman, pregnancy surveillance was assigned to a community health worker or 
a study nurse, who also supervised the community health workers. If a woman was 
married, she was assigned to a community health worker. Unmarried women were 
assigned to the study nurses. This criterion for assigning women to a community health 
worker or study nurse was based on previous experience in an adjacent area, which 
indicated that married women were generally open about  their  pregnancies i.e. their  
reported  history  of  menstrual periods  was  largely  reliable.  By contrast, unmarried 
women tended to initially hide their pregnancies, because these pregnancies are often 
unplanned or unwanted (Mrs. Joyce Nduku, formerly Kenya Medical Research Institute; 
personal communication). For these reasons, pregnancy monitoring in women who were 
married or living together was done by community health workers and traditional birth 
attendants (through questioning, with follow-up by a nurse in case of missing menstrual 
periods), whereas in women who were unmarried, divorced, separated, or widowed), it 
was done by a study nurse (through urine testing).  
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4. The database had summary sheet that automatically provided summary real-time 
information on the total number of women in the database, the total under surveillance 
by community health workers and the study nurse, etc. It also warned automatically if 
there were women in the database that were not accounted for, and provided a 
breakdown of the reasons for not being under surveillance (e.g. current pregnancy).  
The surveillance database was dynamic in the sense that it automatically included 
registered young women when becoming of childbearing age (based on their birth dates) 
and automatically excluded others when exceeding our cut-off age of 45 years. We updated 
the database every month with data from participating households brought by community 
health workers. The achieved efficiency of pregnancy detection was a key milestone in the 
fieldwork. 
Sustaining a high recruitment rate 
In the study protocol, we assumed a crude birth rate of 43 per 1,000 population (Kisumu 
District, 1999 census data(Central Bureau of Statistics, Ministry of Finance and Planning, 
2002), which allowed us to recruit and attain the minimal target  sample size of 300 women 
within a 1.5-year period. We thus needed to conduct the study in a population of 
approximately 7,000 people. In our study proposal, however, we had asked for permission 
to include 450 women if allowed by available resources. To improve the rate of 
recruitment, we expanded the study area to cover a population of approximately 12,000 
people. 
The projected end of recruitment and end of follow-up of project participants was based on 
an average recruitment rate of 1.21 pregnant women per day. This rate improved as the 
fieldwork teams became more efficient. Mobilization and awareness meetings were held 
regularly with community leaders and elders to improve the recruitment rate. A progress 
graph of the rate of recruitment is shown below.  
Between the 70th and 95th day since the start of recruitment, we observed a plateau in the 
recruitment progress. At the time, there was a severe drought (and food shortage) in our 
study area. Most pregnant women who had been scheduled to come for randomisation visits 
did not honour the appointment. To remedy the situation, we sourced for maize grain and 
gave some grain to the mothers who came for recruitment as motivation to join the study. 
The recruitment progress then continued according to plan. 
Strategies to promote hospital delivery and to minimise attrition 
In Western Kenya, 80% of rural women deliver outside a health facility; among these, 
traditional birth attendants assisted 42%, laypersons assisted 36%, while 22% received no 
assistance. (Van Eijk et al. 2006) These statistics coupled with information obtained from 
resource persons familiar with health related practices in our study area prompted us to 
General	discussion	
169	
develop a comprehensive strategy aimed at retaining recruited participants in the study and 
hence minimising attrition.  
	
Figure 6: Recruitment progress based on actual rate of recruitment 
We offered various incentives to participants and devised strategies aimed at promoting the 
overall good will among our participants. These strategies included  the following:  
1. Building a trust system with the local community: we quickly realised that the local 
community had very little trust in the health care system around them. We intensified 
efforts aimed at boosting the trust and confidence of the local community (especially 
pregnant women) thus we ensured that when they approached us for help, we responded 
promptly and helped in whatever way we could. We also developed a working 
philosophy that “the (pregnant) mother is the queen”. This made all our members of 
staff treat the patients with care and respect thereby promoting the confidence of the 
locals with our service delivery. 
2. Transportation of pregnant women to and from the hospital: we sent the project 
ambulance to transport our participants to and from the hospital for all their pregnancy 
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related appointments. Bearing in mind that the homes of some participants were over 
15km away, the transportation service was highly appreciated by the participants. 
3. Ambulance services (24hr) during labour: when women went into labour, they called 
the project ambulance and were then transported free of charge to the health centre 
where the study staff were waiting to help in delivery of the baby. We ensured that for 
all participating women, we were available continuously on all days of the week 
including public  holidays.  
4. Hospital delivery at no cost: no fees were charged for delivery of babies of our study 
participants. If a mother was referred to a bigger hospital, the project paid all fees 
related to the delivery.  
5. General assistance in referrals to specialised health institutions: we acted as 
intermediaries for our clients whose babies had medical conditions that were outside the 
scope of our research. For example, when two babies were born with spina bifida, we 
contacted a specialised hospital near Nairobi (340km away) and assisted in transporting 
the babies to the hospital for specialised care. Further, we managed to negotiate with the 
hospital administration so that the babies were treated free of charge. This level of 
assistance was deeply appreciated by the surrounding community. 
6. Recruitment of research assistants and community volunteers from the study area: in 
order to secure support and good will from members of the community, we recruited 
local people with health related training as staff in our project. 
7. Regular meetings with spouses of pregnant women: we recognised that the spouses of 
the pregnant women played a big role especially when the women went into labour. 
Usually, the spouses are the ones who would call us and ask us to send the ambulance. 
We therefore held regular meetings with the spouses to make sure that they not only 
supported our efforts but also that they got an opportunity to clear any doubts that they 
had about the project. 
8. Visiting participants (and their new born babies): we made it a practice to visit as many 
already current and already graduated participants as possible. This was not only to 
ensure that we maintained a good rapport with our present and past participants but also 
to check on the welfare of the new born babies and their mothers. We later realised that 
these women referred a lot of their friends to our study. 
9. Training of traditional birth attendants (TBAs) and engaging them in our project as 
community health workers: TBAs are respected members of the community. When 
women realised that the TBAs supported our project, they accepted to participate. 
10. Other motivations: 
a. Maize grain – during times of food scarcity and drought, we gave some maize grain 
to the participating mothers. This grain was obtained locally and was distributed “as 
is” i.e. without milling or value addition. Women would then take it to the mill and 
have it fortified as they would have done with their own grain. We did not supply a 
lot of grain. Further, we calculated the amount of grain given to a woman based on 
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her stage of pregnancy. For example, a woman who was eight months pregnant 
received slightly more grain than a woman who was 4 months pregnant. It is worth 
mentioning that this grain was consumed by all members of the household thus we 
did not measure exactly what the woman consumed.  
b. Delivery gift-pack: when women came to give birth, our staff gave them a standard 
gift pack that comprised of antiseptic, soap, cotton wool, glycerine, baby oil, a 
nappy and baby powder. The idea to prepare a small gift pack was arrived at after 
we realised that most mothers would need a hygiene pack soon after delivery of their 
baby. Unlike in Western countries, mothers in our study area did not attend formal 
antenatal lessons where they were instructed about preparing for the delivery of their 
babies. They also got little or no support from their husbands.  
c. Fortification of flour at the mills: most mothers liked the idea that micronutrients 
were added to their flour products.      
A lot of wisdom is required in deciding what sort of incentives to offer participants in a 
study. Usually, a financial compensation is worked out and offered to all participants. This 
is normally calculated based on established formulas which vary from institution to 
institution. However, researchers working in resource poor settings must ensure that the 
motivational incentives should not influence the decision of the potential participant i.e. in 
making their decision to participate. We devised direct and indirect motivational strategies 
that would not unnecessarily impair the independent decision of potential participants.  
Judging from the fact that our study had very high compliance rates and very low attrition, 
we can conclude that our strategies worked.  
Future research 
Researchers may not be able to repeat the study described in this thesis due to ethical 
dilemmas especially in light of the described benefits of iron supplementation during 
pregnancy.  However, there are questions that still need answers. Below are potential 
research areas that need further understanding: 
1. Although we did not observe an effect of oral ingestion of 60mg ferrous fumarate on 
non-transferrin bound iron (NTBI) three hours after ingestion, it is possible that the 
meal consumed by the participants hindered NTBI expression. Further research would 
be needed to assess the NTBI response to consumption of different types and amounts 
of oral iron supplements. 
2. As per national and international guidelines, the daily supplementation dose for 
pregnant women should be doubled to 120 mg iron if they are anaemic or if 6 months 
duration cannot be achieved in pregnancy (Chapter 2). Further studies would be needed 
to establish whether such high iron doses are safe. 
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3. Further studies are needed to assess the diagnostic performance of zinc protoporphyrin 
in children. 
4. Although the rates of malaria are declining, and despite the implementation of IPTp in 
the study area, we still found the risk of asymptomatic infections to be unacceptably 
high (45%) in our population. The detrimental effects of asymptomatic infections are 
already well documented as outlined in this thesis. There is urgent need for diagnostic 
tools that can be used in resource-poor settings to diagnose asymptomatic infections. 
5. In developed countries, it may be possible to screen women at an early stage of 
pregnancy, with the aim to identify women who need iron supplementation to prevent 
anaemia and low birth weight. Our studies suggest that screening based on haemoglobin 
concentration, as now practiced in many countries, is inaccurate in discriminating 
between women at high and low risk of delivering neonates with low birth weight. 
Further studies are needed to identify appropriate markers and cutpoints that are suited 
to this purpose. 
Policy implications 
The findings presented in this thesis should eliminate doubts about the safety of daily 
antenatal supplementation with 60 mg iron as ferrous salts in malaria endemic areas. Our 
findings show that universal iron supplementation should be strongly encouraged, also in 
malaria-endemic regions.  
Most developing countries already have iron supplementation policies that are well aligned 
to the policies by the World Health Organization. (WHO, 2012a, 2012b) Information about 
coverage of antenatal supplementation is scarce and difficult to interpret, because it does 
not routinely include estimates of adherence to supplementation throughout pregnancy. 
What is available suggests that it can be drastically scaled up. In Kenya, pregnant women 
should receive iron supplements during antenatal visits, as per national guidelines (Chapter 
2). The vast majority of rural women who obtain antenatal care go to government care 
facilities (85%; (KNBS/ICF Macro 2010), at least in part because these facilities provide 
antenatal care free of charge. Only 60% of rural pregnant women receive their first 
antenatal care before the third trimester (Figure 7). Thus women do not benefit fully from 
iron supplementation because they start attending antenatal services late in pregnancy. A 
survey conducted in 2002 among rural women in western Kenya found that only 53% 
women who had recently delivered had received any iron supplements during pregnancy. 
(Anna M Van Eijk et al., 2006)  Because care facilities are of out of stock or low in stock, 
the supply of supplements provided per visit, if any, will provide cover for only small 
periods. Only 44% of rural pregnant Kenyan women make four or more antenatal visits 
(Figure 7), and this number seems to be declining. (Kenya National Bureau of Statistics 
(KNBS) & ICF Macro, 2010) Although supply problems have been a major constraint, 
adherence to supplementation is also problematic. (Galloway & McGuire, 1994) Thus even 
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women who report to have received iron supplements are likely to have been covered for 
only a small proportion of their pregnancy.   
	
	
Figure 7: Frequency distribution of number of antenatal care visits during the most 
recent live birth (top) and the timing of the first visit (bottom). 
The survey was representative for rural Kenyan women aged 15-49 years with a live birth 
in the five years preceding the survey. (KNBS/ICF Macro 2010) 
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The pattern of visits of antenatal care shown in Figure 7 varies widely between countries, 
but is worse in many other countries in sub-Saharan Africa and South Asia. (WHO, 2003) 
A review of implementation and progress of national programmes to control micronutrient 
deficiencies concluded that the supply of iron tablets procured from the UN Children’s 
Fund and external sources is very low relative to the need, calculated on the basis of the 
birth rate and the number of iron tablets to fully cover a 40-week pregnancy. (Mason et al., 
2001) Although the distribution framework for iron supplementation is in place in most 
resource-poor countries, the pharmaceutical supply chain could be improved by elimination 
of key systemic barriers. (Thiam, Kimotho, & Gatonga, 2013)   
The evidence provided by this thesis is only applicable to pregnant women and cannot be 
extrapolated to children, for whom there is substantial evidence that iron supplementation 
can increase malaria rates. (Sazawal et al., 2006) As per current WHO policy, children 
should be screened for iron status, and iron supplementation should be restricted to those 
with iron deficiency. (WHO/CDC, 2007; WHO, 2004) 
Conclusions 
We found no evidence that antenatal iron supplementation increases the risk of Plasmodium 
infection, but it leads to substantial improvements in birth weight, fetal growth and infant 
iron stores, with potentially immense benefits for infant survival and health that should 
outweigh any possible concerns about risks of malaria. Scaling up universal iron 
supplementation in pregnancy in developing countries is likely to generate major public 
health gains.  
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Abbreviations and Definitions 
A list of the abbreviations and acronyms used in the Statistical Analysis Plan (SAP) and 
their definitions are shown here below in alphabetical order. 
AE Adverse Event 
AGP Alpha-1 acid glycoprotein 
BMI Body Mass Index 
CRP C-reactive protein 
Hb Haemoglobin 
HIV Human Immunodeficiency virus 
IPT Intermittent preventive treatment 
IUGR Intra uterine growth restriction 
NaFeEDTA sodium ethylenediaminetetraacetate 
NTBI Non Transferrin Bound Iron 
PCR Polymerase Chain Reaction 
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
sTfR Serum transferrin 
WHO World Health Organization 
ZPP:Heme ratio Zinc protoporphyrin to haemoglobin ratio 
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Introduction 
A recent trial in children reinforced earlier concerns that supplemental iron can lead to an 
increased burden of malaria, perhaps through the transient production in plasma of non-
transferrin bound iron (NTBI). An expert group convened by the World Health 
Organization (WHO) recently recommended that iron supplementation in children should 
be restricted in malaria-endemic areas, but that these restrictions are not to be applied to 
food fortification with iron. The Kenyan government has recently made mandatory iron 
fortification of industrially milled flour a legal requirement. Universal iron supplementation 
continues to be recommended for women during pregnancy and 3 months postpartum. 
Potential effects of iron on infection are likely to be most pronounced in pregnancy, when 
iron absorption is very high. This seems to be confirmed by observational studies, which 
indicate that iron deficiency in parturient women is associated with a marked reduction in 
the prevalence and density of malarial parasites in the placenta. Such infections have 
devastating effects on the foetus and neonate, causing low birth weight, intrauterine growth 
retardation, preterm delivery, spontaneous abortion, stillbirth and neonatal mortality. This 
study was designed to compare daily high-dose iron (i.e. iron-fortified foods plus iron 
supplements) versus low-dose iron (i.e. iron-fortified foods only) during pregnancy 
regarding the presence of Plasmodium infection at delivery.  
 
Definitions 
1. Plasmodium infection: see Table 4. 
2. Patent infection: an infection that results in detectable parasites or parasite antigens 
based on HRP2 and/ or pLDH dipstick tests. 
3. Sub-patent infection: an infection with a negative result upon blood examination by 
microscopy or Plasmodium antigen dipstick test (HRP2 and/ or pLDH) but with a 
positive result for a PCR test. 
4. Gravidity: the number of times a woman reports to have been pregnant, regardless of 
the outcome of these pregnancies, with twins and other multiple births counted as 1, 
and including the current pregnancy. 
5. Presence of intrauterine growth restriction(IUGR): a fetus whose weight is below the 
10th percentile based on a reference population with similar gestational age, or whose 
birth weight at term is less than 2500g (Galan, Ferrazzi, & Hobbins, 2002); 
6. Fever: axillary temperature ≥ 37.5 °C; 
7. Anaemia: haemoglobin concentration <110 g/L (WHO, 2011a); 
8. Iron deficiency: plasma ferritin concentration <15 µg/L (WHO, 2011b); 
9. Iron deficiency anaemia: presence of both anaemia and iron deficiency; 
10. Inflammation: either C-reactive protein (CRP) >10 mg/L(Nielsen et al., 1990) or alpha-
1-acid glycoprotein (AGP) >1 g/L(Filteau et al., 1993); 
Parasite density was calculated as the median of four counts by microscopic examination of 
thick blood films (duplicate counts by each of two laboratory technicians).  
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Haemoglobin concentration was calculated as the mean of duplicate measurements or 
median values if more than two recordings were available. 
Purpose of the analyses 
This plan is restricted to the statistical analysis of the primary study objective as formulated 
in the original study proposal, i.e. to compare the presence of Plasmodium infection in 
parturient women who received a combination of iron-fortified foods with iron supplements 
versus iron-fortified foods only. The plan is based on the original proposal, and has been 
finalised before the treatment code was known/revealed. No interim analyses were planned 
or done. 
 
Analyses populations 
1. Full Analysis Population 
All subjects who were randomised and who a) received at least one dose of the 
experimental supplements (iron or placebo); b) Plasmodium infection status could be 
ascertained from blood or placental samples collected at birth or within 48 h after 
birth. In case of maternal or (unborn) child death, a study subject contributes only to 
the full analysis population when meeting both criteria (a) and (b) above.  
 
2. Per Protocol Population 
The per-protocol population comprises the full analysis set but restricted to 
participants who a) consumed >90% of scheduled supplements; and b) had singleton 
pregnancies. 
 
3. Safety Population 
All subjects who received the study treatment (including control) and are confirmed as 
providing complete follow-up data (including information on adverse events). 
 
General information 
In the univariate analysis, variables will be checked for distribution (normal, binomial etc.), 
central tendency (mean, median, mode), dispersion of the values (standard deviation, 
variance, range, and quartiles), and the presence of outliers/ extreme values. Similar 
variables will be compared by use of bar graphs, box plots and by comparing their means 
and distributions. In case the intervention was stopped before its prescheduled end, whether 
by decision of the trial participant or the field team, we will report reasons for this 
withdrawal. 
 
In case data or samples were collected after stopping the intervention, we will include these 
data or information derived from these samples in the full analysis set. Missing data for 
haemoglobin concentration at the end of the intervention will be imputed blindly, before 
starting primary analysis, as the mean, geometric mean or median values obtained from 
participants without missing values in the same intervention group. 
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Reporting conventions: We will report confidence intervals when possible. P-values ≥0.01 
will be reported to two decimal places; p-values less than 0.001 will be reported as 
“<0.001”. Means, standard deviations and any other statistics other than quartiles will be 
reported to one decimal place greater than the original data. Quartiles, such as median, or 
minimum and maximum will use the same number of decimal places as the original data. 
Estimated parameters, not on the same scale as raw observations (e.g. regression 
coefficients) will be reported to three significant figures. 
Baseline descriptions  
Data will be summarised by intervention group as n, mean, SD (symmetrically distributed 
continuous variables); n, median and IQR (skewed continuous variables); or numbers and 
percentage (categorical variables). Means for non-normally distributed variables will be 
reported as geometric mean. 
The following tables will show the study participants’ characteristics per intervention 
group. 
Table 1: Demographic and biochemical characteristics at baseline 
Characteristics 
Height, cm 
Weight, kg 
BMI, kg/m2 
Marital status 
Married or living together 
Divorced or separated 
Never married 
Age, y1 
Gestational age, weeks 1 
Gestational age 
1st trimester 
2nd trimester 
Gravidity 
Primigravidae 
Secundigravidae 
Multigravidae 
Current fever (axillary temperature ≥ 37.5 °C) 
Plasmodium infection, Table 4 
Current or recent P. falciparum infection, by either HRP2- or LDH-based dipstick 
P. falciparum, by PCR 
P. falciparum, by HRP2- or LDH-based dipstick or PCR 
Plasmodium spp. other than P. falciparum, by LDH-based dipstick or PCR 
Any Plasmodium spp., by dipstick or PCR 
HIV infection 
Haemoglobin concentration, g/L 
Anaemia, haemoglobin concentration <110g/L 
Plasma transferrin concentration, g/L 
Plasma sTfR concentration, µg/L 
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Table 1: Demographic and biochemical characteristics at baseline 
Plasma ferritin concentration, µg/L 
Iron deficiency, plasma ferritin concentration <15µg/L 
All 
Restricted to those with CRP<10mg/L 
Restricted to those with alpha-1- acid glycoprotein<1.0g/L 
Restricted to those with CRP<10mg/L or alpha-1- acid glycoprotein<1.0g/L 
Whole blood ZPP:haem ratio, µmol/mol 
Erythrocyte ZPP:haem ratio, µmol/mol  
Erythrocyte FEP concentration , µg/L 
 
Study endpoints 
1. Primary outcome:  
The primary outcome is defined as the presence of maternal Plasmodium infection in 
samples collected at parturition, regardless of species, as indicated by one or more positive 
results for the presence of parasite-derived LDH or HRP2 in plasma (dipstick tests), past 
infections (as indicated by Plasmodium pigment upon histological examination of placental 
biopsies), or Plasmodium DNA (any species, by PCR test) (Table 2, case 1). We excluded 
the results of microscopy from this case definition because these results would be 
considered incorrect if discordant with results from PCR tests. 
 
2. Secondary outcomes   
As secondary outcomes, we will consider the following indicators: 
 Patent and sub-patent Plasmodium infection (Table 2, cases 2 and 3 respectively); 
 Current or recent Plasmodium infection (Table 2, case 4); 
 Birth weight (g); 
 Gestational age at delivery (weeks); 
 The presence of intrauterine growth restriction (IUGR);    
 Maternal and neonatal iron status at 1 month after delivery, assessed by haemoglobin 
concentrations, iron deficiency anaemia and iron stores (ratio of ferritin: transferrin 
receptor concentrations); with and without restriction to those with inflammation. 
 
Justification 
When formulating our outcome definitions, we considered Plasmodium infections in 
pregnant women to be important in so far as they are associated with adverse maternal or 
pregnancy outcomes. However, the pathological consequences of maternal infection likely 
depends on population-specific factors such as immunity (and thus transmission intensity, 
parity and maternal age), access to treatment, coverage and quality of antenatal services and 
drug resistance. Discordant results between studies in the association between maternal 
Plasmodium infection and adverse maternal or pregnancy outcomes are also likely due to 
differences in the sensitivity and interpretation of diagnostic tests(Uneke, 2007).  
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Histological examination of placental biopsies is often considered the ‘gold standard’ of 
malaria diagnosis in pregnancy, and results in infection status being classified into four 
categories depending on the presence and distribution of Plasmodium parasites and 
haemozoin (Bulmer, Rasheed, Francis, et al., 1993):  
a) Current infection: parasites are present in the intervillous spaces with or without pigment in 
intervillous monocytes;  
b) Chronic infection: parasites are present in the intervillous spaces along with pigment as deposits 
or in macrophages within fibrin;  
c) Past infection: pigment is present in the absence of parasites; and  
d) Not infected.   
Pigment deposition has generally been found to be associated with low birth weight, 
particularly in the presence of parasites in the intervillous spaces (C Menendez et al., 2000). 
There is uncertainty, however, about the effect of past infections (i.e. with pigment 
deposition but without parasitaemia), on neonatal outcomes: such infections have been 
found to be associated with reduced birth weight in several studies Walter, Garin, Blot, & 
Philippe, 1981, Watkinson & Rushton, 1983, Rogerson et al., 2003, but not in others 
(Matteelli et al., 1996, Menendez et al., 2000, Muehlenbachs, Mutabingwa, Fried, & Duffy, 
2007, Muehlenbachs et al., 2010).  
PCR is considerably more sensitive in detecting maternal infection than either microscopy 
or rapid dipstick tests that assay the presence of Plasmodium-specific proteins (e.g. HRP2 
or LDH). Several studies have found that sub-patent infections (i.e. low parasitaemias that 
are detected by PCR but not by microscopy or dipstick tests) are associated with reduced 
birth weight ((Malhotra et al., 2005), (Adegnika et al., 2006), (Arango et al., 
2010),(Mohammed et al., 2013)) but others have not ((Mankhambo, Kanjala, Rudman, 
Lema, & Rogerson, 2002), (Mockenhaupt et al., 2006),(Rantala et al., 2010)). With regards 
to Plasmodium species other than P. falciparum, we are not aware of studies on the 
maternal or pregnancy outcome of P. malariae or P. ovale infection during pregnancy. P. 
vivax is also associated with low birth weight but most of these infections cause symptoms 
((Luxemburger et al., 2001), (Nosten et al., 1991),(Nosten et al., 1999)) and this species 
rarely occurs in Africa. 
1. Primary analysis 
The primary measure of intervention efficacy will be the difference in prevalence between 
intervention groups, calculated using Newcombe’s method (Altman, Machin, Bryant, & 
Gardner, 2000) in the per protocol population (see section 3.2.). We will also report the 
prevalence difference as a percentage relative to the placebo group, as well as the 
prevalence ratio. 
 
2. Secondary analyses 
Adjustment for baseline covariates 
Annex	1	
184	
We will assess possible confounding by comparing crude and adjust prevalence ratios, the 
latter being obtained by including baseline covariates that may be prognostic for outcome in 
a Cox regression analysis with constant time at risk (Lee & Chia, 1993), (Lee, 1994; 
Osborn & Cattaruzza, 1995), (Barros & Hirakata, 2003). These covariates are divided into 
two groups: 
a) Variables that are likely to be prognostic for the primary outcome, as predefined on the 
basis of the literature review: 
• Gravidity (M. Desai et al., 2007)): entered as a dummy-coded categorical 
variable with 3 classes:  primigravidae, secundigravidae, multigravida; 
• Maternal age (M. Desai et al., 2007) (Tako et al., 2005): dummy-coded 
categorical variable with 2 classes: < 20 years and ≥ 20 years; 
• HIV infection status (Kuile et al., 2004) : binary variable. 
b) Variables that are possibly prognostic for the primary outcome:  
• Plasmodium infection status (any Plasmodium spp., by dipstick or PCR): 
binary variable; 
• Iron status: haemoglobin concentration as continuous variable centred around 
the mean as well as plasma ferritin concentration as a binary variable (<12 
μg/L or ≥ 12 μg/L); 
• Gestational age at delivery (continuous variable, centred around the mean). 
We will examine the influence of these factors using a backward elimination procedure 
from a full model that includes all of the above variables. When judging the degree of 
confounding, a diversion of >15% of the crude prevalence ratio will be considered to be of 
public health importance. When the potential value of this adjustment is in doubt, we will 
consider the unadjusted analysis as the one of primary attention, and the adjusted analysis 
being supportive. 
 
Full analysis set 
An exploratory analysis will be conducted on the full analysis set.  
Subgroup analyses  
As a first step, we will use stratified analysis to assess to what extent the effect of iron on 
Plasmodium infection is influenced by gravidity, age, HIV infection and iron status, 
indicated by anaemia and iron deficiency (Table 3). In this analysis, we will consider 
variables with the following categories: gravidity: primigravidae, secundigravidae and 
multigravidae; age: ≤20 years, >20 years; HIV infection: infected, non-infected.  
In a second step, we will assess such effect modification directly using multivariate logistic 
regression analysis. 	
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Table 2: Case definitions of Plasmodium infection 
 HRP2-
based 
dipstic
k test 
LDH-based 
dipstick test 
Microsc
opy of 
peripher
al blood 
1 
Placental biopsy PCR, peripheral 
blood 
PCR, maternal 
placental blood 
P. 
falcipar
um 
Other 
spp. 
Pigment Parasite
s 1 
P. 
falcipar
um 
Other 
spp. 
P. 
falcipar
um 
Other 
spp. 
Case 1 (primary 
outcome) 2 
   ○  ○     
Case 2 (patent)    ○  ○ ○ ○ ○ ○ 
Case 3 (sub-patent) ○ ○ ○ ○ ○ ○     
Case 4 (current or 
recent) 
   ○ ○ ○     
Test with positive () or negative (○) results are linked through ‘OR’ Boolean operators. 
1 Regardless of parasite stage (i.e. asexual or sexual stages). 
 
We will interpret the results of subgroup analysis cautiously (Assmann et al., 2000), (Wang et al., 2007),(Fletcher, 2007; Oxman, 
1992; Sun et al., 2010; Yusuf, 1991). 
In the analysis of haemoglobin concentrations in maternal blood at 1 month post-partum, we expect little or no treatment effect in 
individuals who are iron replete, because iron absorption is known to decrease with the magnitude of the iron stores (L Hallberg, 
2001).  
	186	
Intermittent preventive treatment (IPT) 
Intermittent preventive treatment data was obtained retrospectively from the participants 
ante-natal clinic attendance booklets. The information in these booklets is filled in by 
nurses during the antenatal clinic visits. Because IPT data was recorded after 
randomisation, theoretically, it could be influenced by the intervention and thus it is 
considered separately in the analysis. We will examine whether intermittent preventive 
treatment has an effect on malaria parasitaemia at birth. 
 Intermittent preventive treatment will be a categorical variable with 5 classes: no dose 
(participants whose booklets were available but had no data on IPT thus no IPT dose 
received), single dose, two doses, three doses, unknown (participants whose booklets were 
not available). 
Table 3: Justification of effect modifiers to be assessed  
Effect modifier Justification 
a. Gravidity In highly endemic areas, primigravidae are at greater risk of malarial 
infection (Nosten et al., 1991) (A. M. Greenwood et al., 1992), 
probably because they have a reduced immunity. Thus we expect 
that their ability to suppress a possible increase in parasitaemia 
resulting from iron to be reduced. 
b. Age Plasmodium infection is expected to be higher in women ≤20 years 
old. Young primigravidae and multigravidae are at greater risk of 
malaria and its adverse effects than older primigravidae or 
multigravidae, respectively(Espinoza et al., 2005; Leenstra et al., 
2003; Marques et al., 2005)(S J Rogerson et al., 2000)(Walker-
abbey et al., 2005). This is probably because age-associated 
immunity plays a role in controlling malaria infection during 
pregnancy in highly endemic areas. We expect that women ≤20 
years old have a reduced ability to suppress a possible increase in 
parasitaemia resulting from iron. 
c. HIV infection HIV infection compromises malarial immunity such that HIV 
infected multigravidae have at least as high a risk of placental 
infection as non-HIV-infected primigravidae (M. Desai et al., 2007). 
HIV exacerbates the burden of malaria and increases the degree to 
which malaria is associated with maternal severe anaemia. We 
expect that due to compromised malarial immunity, women that are 
HIV infected will be more susceptible to iron-induced Plasmodium 
infection.  
d. Iron status at 
baseline 
Low iron status at baseline may be protective against malaria 
infection but will result in increased absorption of supplemented 
iron. The vice versa is also true thus we expect the effect of iron 
supplementation on malaria parasitaemia to be influenced by iron 
status at baseline.  
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Efficacy Analyses 
The most important indicator for evaluating intervention benefits will be haemoglobin 
concentration at 1 month post-delivery. Group differences in haemoglobin concentration 
will measured by linear regression analysis, adjusting for possible group differences in time 
between delivery and blood collection (centred on 30 days post-partum). We will assess 
possible confounding of the intervention effect by comparing the difference in mean 
haemoglobin concentration with and without adjustment for baseline haemoglobin 
concentration (continuous variable). We will also assess the influence of haemoglobin 
concentration at baseline (continuous variable) on the haemoglobin response to the iron 
intervention, using multivariate linear regression analysis. 
We will use similar procedures to assess intervention effects on plasma ferritin 
concentration at 1 month post-delivery. 
All analyses of the continuous efficacy variables will be performed as analysis of variance 
with treatment group adjusting for inflammation etc. All assumptions for regression models 
will be assessed by viewing plots of the residual values. Dependent variables will be log-
transformed as appropriate.  
Safety Analyses 
Summary statistics per intervention group will be produced for deaths and serious adverse 
events that are judged to be related to the treatment. Each subject will only be counted once 
and any repetitions of adverse events will be ignored; the denominator will be the total 
population size. 
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Annex	II	
Surveillance	for	and	detection	of	early	
pregnancy	
	
	
	
Prenatal	Iron	and	Malaria	(PIMAL)	Study	
	
STANDARD	OPERATING	PROCEDURE	
	
	
Terminology 
Amenorrhoea    The absence of a menstrual period in a woman of reproductive age 
Embryo A fertilised egg in its earliest stage of development, from the time of 
first cell division until about eight weeks after fertilisation (thereafter 
called a foetus) 
Fallopian tubes   Two fine tubes leading from the ovaries into the uterus 
Fertilisation     Fusion of sperm cell and egg 
Gestational age The age of an embryo, foetus or new-born infant, usually calculated 
from the first day of the woman's last menstrual period 
Implantation An event that occurs early in pregnancy in which the embryo adheres to 
the wall of uterus 
Menopause The end of the fertile phase of a woman's life as a natural consequence 
of aging (defined in this document by the absence of a menstrual period 
for 6 months in women who are neither pregnant nor have postpartum 
amenorrhoea) 
Ovary       The egg-producing reproductive organ in women 
Ovulation The process in a female's menstrual cycle by which a mature ovarian 
follicle ruptures and discharges an ovum (egg) 
Postpartum - 
Amenorrhoea: The period between childbirth and the return of menstruation following 
childbirth 
Source-  
Population: All resident women of fertile age in the study area who meet the 
eligibility criteria for randomisation 
Stillbirth  Occurs when a foetus has died in the uterus, after 20 weeks gestation or 
the baby weighs more than 400 grams 
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Aim 
This protocol describes our methods to detect pregnancies occurring in the source 
population at an early stage, but in any case before or at 20 weeks of gestation. Please note 
that gestational age is calculated as per convention from the first day of the woman's last 
menstrual period (see ‘Terminology’), assuming that conception occurs 14 days later. 
 
Background 
Kenyan women potentially become exposed to pregnancy at a relatively young age. In 
2003, 15% of girls aged 15-19 years reported to have had sexual intercourse by the age of 
15 years, whilst 17% in the same age range reported to have had intercourse within the 
previous 4 weeks (Central Bureau of Statistics 2004). The onset of menopause increases 
with age from around age 30, but increases sharply after the age of 45 years. Thus in the 
age range 46-47 years, 32% of women reported to be menopausal; in the age range 48-49 
years, this had increased to 53% (Central Bureau of Statistics 2004). Thus in our study, we 
consider that women may be exposed to pregnancy in the age range 15-45 years. 
 
Our methods used to detect pregnancies within this age range include a) questioning 
women, i.e. asking them whether they have missed their menstrual period, b) urine testing 
and c) confirmation by obstetric ultrasound. 
 
 Questioning: Questioning has the advantage of being a relatively low-cost method to 
detect pregnancies. Previous experience in an adjacent area (Mrs. Joyce Nduku, KEMRI, 
personal communication, October 2010) indicates that women who are currently married 
are generally open about their pregnancies: their reported history of periods is by and large 
reliable. By contrast, unmarried women tend to initially hide their pregnancies. With these 
women, community health volunteers and traditional birth attendants may be helpful in 
eliciting correct responses. 
 
When do we consider a menstrual period to be missing? Although the average cycle is 28 
days, there is considerable variation in cycle length within and between women. Most 
menstrual cycles have a length below 40 days (e.g. McKeown et al. 1954, Jeyaseelan et al. 
1992, Münster et al. 1992, Fehring et al. 2006, Das and Das 2010). Even though there are 
uncertainties about the validity of extrapolating these data, we define in our study a missed 
menstrual period as the reported absence of menstruation within 6 weeks from the onset of 
the last period. 
 
In most postpartum women, there is for a limited time after birth no need to check for 
pregnancy: in women who are fully breastfeeding and amenorrhoeic but not using any 
contraceptive method, the probability of pregnancy in the first 6 months post-partum is 
below 2% (Labbok et al. 1994, Kennedy and Kotelchuck 1998, Queenan 2004, Van der 
Weijden et al. 2003). Postpartum amenorrhoea is largely defined, however, by the duration 
and intensity of breastfeeding. In 2003, only 29% of Kenyan children aged below 2 months 
were exclusively breastfed; at 2-3 months, almost half of all children were reported to be 
given complementary foods. 91% of Kenyan women reported to be amenorrhoeic or 
abstaining from sex in the first 3 months post-partum; the proportion reporting to be 
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amenorrhoeic thereafter declined rapidly (Central Bureau of Statistics 2004). For this 
reason, in breastfeeding women, we will consider the probability of pregnancy to be low in 
the first 3 months postpartum, and we will not check for pregnancy in this time period. It is 
also reasonably certain that the woman is not pregnant if she is within 4 weeks postpartum 
for non-lactating women, or within the first 7 days post-abortion or miscarriage (WHO 
2004). 
 
 Urine testing: To confirm pregnancy, we will use a urine test to detect the presence of the 
beta subunit of human chorionic gonadotropin (hCG). This hormone is produced by the 
developing embryo after conception and later by the syncytiotrophoblast (part of the 
placenta). It can be detected in urine or blood after implantation, which occurs 6–12 days 
after fertilization (Wilcox et al. 1999). Home pregnancy test kits, when used by 
experienced technicians, are almost as accurate as professional laboratory testing (97%). 
When used by consumers, however, the accuracy can drop to as low as 75%, probably 
because many users misunderstand or fail to follow the instructions included in the kits 
(Bastian et al. 1998). To avoid errors, it is important to understand the reasons for their 
occurrence: 
a. False negative readings can occur when testing is done too early. The most sensitive 
urine tests usually can detect hCG shortly after implantation (see Figure 1 for an 
overview of the menstrual cycle); less sensitive urine tests may not detect pregnancy 
until 3–4 days after implantation. Menstruation occurs on average 14 days after 
ovulation, so the likelihood of a false negative is low once a menstrual period is late. 
 
However, ovulation may not occur at a predictable time in the menstrual cycle. A 
number of factors may cause an unexpectedly early or late ovulation, even for women 
with a history of regular menstrual cycles. The accuracy of a pregnancy test is most 
closely related to the day of ovulation, not of the act of intercourse or insemination 
that caused the pregnancy. It is normal for sperm to live up to 5 days (Weschler 2002) 
in the fallopian tubes, waiting for ovulation to occur. It could take up to 12 further 
days for implantation to occur, meaning even the most sensitive pregnancy tests may 
give false negatives up to 17 days after the act that caused the pregnancy. Because 
some home pregnancy tests have high hCG detection thresholds (up to 100 IU/L), it 
may take an additional 3–4 days for hCG to rise to levels detectable by these tests — 
meaning false negatives may occur up to 3 weeks after the intercourse that causes 
pregnancy. 
 
Note that few cycles are exactly average! Menstrual cycles are counted from the first 
day of menstrual bleeding. Under optimum circumstances, some sperm cells can live 
up to about 5 days. Once released through ovulation, the egg is capable of being 
fertilised for 12-48 hours before it begins to disintegrate. Thus the fertilisation period 
starts 5 days before ovulation, and ends 1-2 days afterwards. Fertilisation usually 
takes place in the ampulla, the widest section of the fallopian tubes. It usually takes 6 
days for a fertilized egg to reach the uterus and to implant into the endometrium. 
 
Annex	II
	
Figure
 
b.
Another factor that makes it undesirable to administer urine tests too frequently or too early 
is that many pregnancies are lost early. This is particularly important for young, unmarried 
women, who may wish such lost pregnancies to remain confidential. St
tests have shown that approximately 60% of all fertilised eggs are lost due to natural causes 
before the end of the first trimester is reached (Goldstein 1994). Such miscarriages usually 
Early in pregnancy, more accurate results may be obtained by using the first urine of 
the morning when hCG levels are highest. When the urine is dilute, the hCG 
concentration may not be representative of the blood concentration, and the test may
be falsely negative.
 False positive readings
appear on many home pregnancy tests if read after the suggested 3
or reaction time, independent of an actual pregnancy. False positives may also appear 
on tests used past their 
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occur without the knowledge of the once pregnant woman, and may be interpreted as a 
menstrual cycle of abnormal length (e.g. Edmonds et al. 1982, Kolstad et al. 1999). Even in 
recognised pregnancies, about 25% are lost in the first trimester. Most early pregnancy 
losses occur in the first month after conception, and are uncommon after the end of the 
embryonic period, i.e. 10 weeks after the onset of the last menstrual period (Goldstein 
1994). 
 
Obstetric ultrasound: We will use diagnostic ultrasound to confirm pregnancy and to 
estimate gestational age. Because gestational age probably is prognostic for many of 
outcome indicators considered in our trial, its estimation will allow for adjustment of 
intervention effects. Thus estimation of gestational age is not merely done to determine the 
expected date of delivery, although this is useful to plan the delivery in the predesignated 
health facility. 
 
The starting day of the Last Menstrual Period, quickening, first audible foetal heart tones, 
uterine fundus at the umbilicus, and measurements of the fundal height are also commonly 
used as indicators of gestational age, but these have limited value because of inaccuracies 
in recall, lactation, and the subjective nature of some of these measurements. 
 
The earlier in pregnancy verification of gestational age with ultrasound is done, the more 
accurate and precise that estimate will be. In the first trimester of pregnancy, foetal crown-
rump length is the most important technique employed (Hohler 1984). When done 
properly, it allows for estimation of gestational age between 9 and 13 weeks within 5 days 
with 95% confidence (Hohler 1984; gestational age in days, measured from the first day of 
the LMP = 51.008 + 0.6 × crown-rump length in mm). Earlier than 9 weeks, the anatomical 
landmarks are somewhat obscure, and it is not possible to examine a single picture and be 
certain that the maximum longitudinal diameter of the foetus has actually been measured. 
Before 12 weeks gestation, one should measure the crown-rump length; after 12 weeks, one 
should rely on determination of the biparietal diameter (i.e. the transverse diameter of the 
foetal skull), ideally in combination with femur length, head circumference and abdominal 
circumference. The accuracy of pregnancy dating from 12 to 20 weeks is probably just as 
good as that done earlier in pregnancy using the crown-rump length. 
 
Procedures 
Our procedures (Figure 2) for detection of pregnancy follow a strategy that is outlined in 
the table below. An ultrasound examination is to be conducted immediately after pregnancy 
has been confirmed by urine test, or as shortly as possible thereafter. 
	
Roles and responsibilities 
 
 Community volunteers: It is the role of community volunteers, including traditional birth 
attendants, to question women about their history of menstrual periods. The Field 
Coordinator in close consultation with local authorities and village elders will appoint 
volunteers. Each volunteer will do the pregnancy surveillance in a pre-allocated, fixed 
number of households.	
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Figure 2: Illustration of measurement locations (panels A-D) for foetal growth 
indicators. Crown-rump length (CRL), biparietal diameter (BPD), abdominal 
anteroposterior diameter (APD), abdominal transverse diameter (ATD), placental 
diameter (PD), and placental thickness (PT); panels (E-H) obtained ex vivo by light 
microscopy. 
	
Volunteers are identified and trained in surveillance procedures. The volunteers will have 
the following responsibilities: 
• To identify all eligible women within the allocated households by listing their name, 
date of birth, marital status, pregnancy status; 
• To ensure that all eligible women mark their menstrual periods on a calendar; 
• To conduct a monthly survey by visiting women within the allocated households who 
are currently married or living together on a monthly basis, and by questioning them 
carefully about their history of menstrual periods; 
• To record findings on a standard, predefined form (Annex 1), and to submit this report 
to the study nurse during a monthly meeting.  
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Target group Action required Comments 
1. Women who delivered a child 
during the surveillance period, 
or within 6 months before the 
start of the surveillance period, 
regardless of their marital status 
(Depending on time of delivery 
– see below) 
 
 a. Delivery occurred less than 3 
months ago 
No questioning or urine testing 
required 
 
 b. Delivery occurred more than 
3 months ago 
Urine tests to be done by nurse 
at 12-weekly intervals until 
menstrual periods have 
recurred; pregnancy detection 
thereafter as indicated below 
 
c. Unmarried women (never been 
married, divorced, separated, or 
widowed) 
Urine testing to be done by 
nurse strictly every 12 weeks 
At such intervals, the gestational age of pregnancies 
detected will likely be within the eligible range, whilst 
in the vast majority of pregnancies, gestational age can 
be established simply by obstetric ultrasound on the 
basis of estimated crown-rump length (accurate in the 
first 13 weeks of gestation) 
d. Married women (currently 
married,  or living together with 
a man) 
Questioning to be done by nurse 
every month (4 weeks) by 
community volunteers 
 
Urine testing to be done 
whenever women report the 
start of their menstrual period to 
have occurred 10 weeks earlier 2 
Urine tests should not be normally be administered 
earlier: 
a. In the first 7 days after menstruation, the probability 
of pregnancy is very low; 
b. In the subsequent time period until the time of the 
next expected menstruation, there is a high risk of 
false negative test results; 
c. In the subsequent time period until 10 weeks after the 
onset of the Last Menstrual Period, a woman may 
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Target group Action required Comments 
be pregnant but there is a high risk of her 
pregnancy being lost. 
	
Please note: 
• Volunteers must make every effort to notify a study nurse immediately when a woman reports her menstruation to be absent 
for 6 weeks or more from the onset of the last period (missed menstrual period), so that the nurse can set a date for a urine 
test at 10 weeks after the onset of the last period. 
• Women who have never been married, or who are divorced, separated or widowed will be under direct surveillance by the 
study nurse (see preceding sections). 
 
Study nurse 
A study nurse, based at the research clinic, will have the following responsibilities: 
• Ensure that all households in the study area have been assigned to a Community Volunteer; 
• Keep record of all Community Volunteers, and women who have been assigned to them; 
• Ensure that Community Volunteers collect data at 4-weekly intervals among women who are married or living together; 
• Enter data collected by Community Volunteers daily into an electronic database, and make daily backups of this database; 
• Ensure that urine tests are administered at the research clinic to: 
• All women who never have been married, or who are divorced, separated, or widows: at 12-weekly intervals; 
• All women who are married or living together: when women report not to have had a menstrual period for 10 weeks since the 
date of the onset of the Last Menstrual Period; 
• Coordinate the follow-up of problem cases as and when required; 
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Woman is currently 
pregnant, or has delivered 
within the previous 3 months
Yes
No
No action required until 3 
months after delivery 
(breastfeeding women) *
Urine testing at 12-weekly 
intervals until menstrual 
period recurs
Check marital status
Woman is currently married, 
or is living together
Question monthly; record 
date of last menstrual period 
(LMP)
Question again in 4 weeks 
time
Make booking for a urine 
test to be conducted at 10 
weeks after LMP
Woman has never been been
married, or she is divorced, 
separated or widowed
LMP  occurred more than 6 
weeks ago
LMP  occurred less than 6 
weeks ago
* All others: see text 	
Figure 2: Decision tree for early detection of pregnancy 
• Conduct an ultrasound examination immediately after pregnancy has been confirmed by 
urine test, or as shortly as possible thereafter; 
• Organise a monthly group meeting with Community Volunteers to a) check their 
records; b) to identify women who missed their menstrual periods and to set dates for 
urine testing as needed; c) to assess and discuss the performance of the Volunteers; and 
d) to hand out incentives to Volunteers as appropriate; 
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• Keep petty cash for handing out incentives to Community Volunteers, and to keep up-
to-date financial records accordingly; 
• Keep an up-to-date monthly log book on surveillance activities (Annex 2); 
• Prepare and submit a monthly progress report (Annex 3) to the Field Coordinator 
(Martin Mwangi). 
Even though the nurse may delegate some duties to a data entry clerk or a student, (s)he 
will ultimately remain responsible. 
 Field Coordinator (Martin Mwangi) 
• To take part in monthly meetings with Community Volunteers and the study nurse;  
• To supervise and check the study nurse in all surveillance activities; 
• To prepare and submit quarterly progress reports to his supervisors (Drs. Pauline 
Andang’o and Hans Verhoef). 
All information shared by women, as well as the results of urine tests, are to remain 
confidential. This information may be shared with family members only after 
agreement has been reached with the woman concerned. Community volunteers as 
well as the study nurse must ensure that unauthorised persons do not have access to 
study records. The study nurse may disclose the pregnancy status of women with the 
Field Coordinator but not with other members of the Study Team, unless authorised 
by the Field Coordinator. 
In our study, most ultrasound examinations will be conducted at a gestational age that 
is too early to (reliably) determine the sex of the foetus. Even if the sex of the foetus 
can be established, however, the study nurse is under no circumstance allowed to 
disclose this information to the parents. 
Number of tests required for the study 
Based on a total population in our study area of 12,202 people, a crude birth rate of 35.3 per 
1000 population in rural areas in Kenya (Kenya Demographic and Health Survey 2008-09), 
and 10% of pregnancies being undetected in our surveillance system, we would expect to 
detect 388 births per year, so that the target number of 450 women would be attained in 14 
months. Because a substantial proportion of women will already be pregnant at the start of 
our surveillance activities, however, we expect that the detection rate of pregnant women 
will initially exceed the rate at which they become pregnant. Thus we expect to be able to 
attain our target number within 1 year. 
Based on a census in the study area that we conducted in 2010 (unpublished results), we 
expect that our source population includes 2,806 women of child-bearing age. Of these, we 
expect 1,686 to be married (or living together), and 1,120 to be single (never married, 
divorced, separated or widowed) (Table 1). Assuming that urine tests will be administered 
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monthly to 5% of women who are married (or living together), and every 12 weeks for 
single women, this would amount to a daily workload for the study nurse of 4 married 
women and 19 single women. We expect to administer 5,863 tests over a recruitment 
period of 1 year (Table 2);  with an extra safety margin of 15%, this would amount to 6,750 
tests. 
Table 1: Distribution of women aged 15-50 years by marital status 
Marital status Relative distribution 1 Absolute number 
Currently married   54.5% 1,529 
Never-married 2  29.8% 836 
Living together  5.6% 157 
Divorced/separated 2  5.9% 166 
Widowed 2  4.2% 118 
Total  100% 2,806 
1 Based on data from 2003 (Anonymous 2004); 2 women in this category may not be open 
about their pregnancy (see text). 
	
Table 2: Testing frequency and test requirements for the study 
Married Single Total 
Testing frequency 
5% of 
women/month 
Every 12 
weeks 
n 1,686 1,120 2,806 
No. of tests to be administered per working 
day 4 19 23 
No. of tests to be administered per month 84 404 489 
No. of tests to be administered per year 1,012 4,852 5,863 
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Summary	
Since the British doctor Ronald Ross received the 1902 Nobel Prize in medicine for his 
work on malaria, more people have died from the disease than all world wars combined. 
This is in spite of the fact that the French chemists Pierre Joseph Pelletier and Joseph 
Bienaimé Caventou made quinine available from as early as 1820. According to the World 
Health Organisation (WHO), there were about 219 million cases of malaria in 2010 and an 
estimated 660,000 deaths majority of which (80% of cases and 90% of deaths) were in 
Africa.  
Of almost two billion people who are anaemic globally, 41.8% are pregnant women. Iron 
supplements are used to prevent anaemia. There are concerns that iron given in high doses 
may increase malaria rates. Uncertainties regarding the safety of iron supplementation in 
malaria endemic regions were propelled by a randomized controlled trial that evaluated the 
effects of iron and folic acid supplementation in 32,155 children in Pemba, Tanzania. This 
study found that children who received iron and folic acid supplements were more likely to 
die or to need hospitalisation for an adverse event. At the same time, malaria is known to 
exacerbate anaemia; an almost inevitable consequence of malarial infection. As such, the 
safety of daily oral use of iron supplements by pregnant women, as a public health 
intervention is still not clearly established; at least not until publication of our main 
findings. 
This thesis assessed the effects of iron supplementation on safety indicators, and on iron 
status, in pregnant women and their neonates. Several preparatory activities were carried 
out, including a census of the population in the study area and a pilot study to check the 
operability of the study protocols. A main study was designed with the hypothesis that 
consumption of food products fortified with iron combined with intake of iron supplements 
especially in pregnancy, would be detrimental to the health of pregnant women and their 
neonates. 
The objectives of the study were: 1) to compare the presence of malarial infection in 
parturient women who received a combination of iron-fortified foods with iron supplements 
versus iron-fortified foods only; 2) to assess intervention effects on the maternal prevalence 
of iron deficiency anaemia at 1 month after delivery; 3) to assess intervention effects on 
neonatal iron stores at 1 month of age; 4) to assess the diagnostic utility of Zinc 
protoporphyrin (ZPP) in diagnosing iron deficiency in malaria endemic regions; 5) to 
identify baseline factors that are prognostic for the Non-Transferrin Bound Iron (NTBI) 
response to consumption of a single iron supplement; 6) to determine the factors that 
predict Plasmodium infection in pregnancy; 7) to identify factors associated with birth 
weight; 8) to develop a methodology to predict cases of low birth weight, using a single 
prognostic score that is based on prognostic variables collected at the second trimester of 
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pregnancy; and 9) to develop methods for community-based flour fortification with iron. 
Most countries have enacted, or are in the process of enacting legislation for mandatory 
fortification of flour with iron. Thus pregnant women may receive iron from fortified foods 
and from universal iron supplementation programmes. This thesis provides answers to 
pertinent questions regarding the safety and efficacy of iron supplementation by comparing 
daily high-dose iron (i.e. iron-fortified foods plus iron supplements) versus low-dose iron 
(i.e. iron-fortified foods only) during pregnancy. The main outcome measure was the 
presence of maternal Plasmodium infection at birth, regardless of species. Chapter 1 is a 
detailed introduction of the background to the study and the design of the study. 
This thesis presents concrete evidence that iron supplementation to pregnant women in a 
highly malaria endemic region does not result in increased risk of malarial infection; 
percent difference (95%CI) = 0.0% (─9.3% to 9.3%). Programme implementers and 
governments in malaria endemic regions should not be held back by previous 
recommendations that cautioned against issuing iron supplements to pregnant women. In 
light of these findings, there is no need to first screen for malaria before giving iron 
supplements.  
Iron supplementation had major benefits for mothers and their neonates (chapter 2). The 
findings reported in this thesis showed a mean increase in birth weight of 143 g relative to 
the low-dose iron group. The effects of iron were influenced by the participants initial iron 
status. Correction of iron deficiency increased birth weight by 249 g, even though we 
cannot exclude the possibility that this may have increased malarial infection by 10%. 
There was no evidence that effects of iron on birth weight were influenced by intermittent 
preventive treatment against malaria. Iron supplementation also increased fetal growth by 
0.27 SD, 95%CI: (0.04 to 0.50) probably as a result of gains in length and weight for 
gestation age.  
We also showed improved neonatal iron stores one month post-partum as indicated by a 
17.1 % (95% CI: 2.0% to 34.3%) increase in plasma ferritin concentration in neonates of 
mothers who received high-dose iron compared to those who received low-dose iron.  This 
provides more impetus to the need to offer iron supplements to pregnant women with the 
aim of boosting infant iron stores (chapter 2).  
ZPP was found to be of unreliable diagnostic utility when discriminating between pregnant 
women with and without iron deficiency in regions where chronic diseases are prevalent 
(chapter 3). The current conventional cut off points for whole blood ZPP e.g. >70 μmol/mol 
heme, can result in gross estimates of the prevalence of iron deficiency especially if the true 
prevalence is low.    
The appearance of non-transferrin bound iron (NTBI) in circulation after oral ingestion of 
iron supplements has been thought to aid the growth and multiplication of Plasmodium 
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parasites thereby increasing malaria induced morbidity and mortality. We did not observe 
any increase in NTBI concentrations three hours after oral ingestion of 60 mg of ferrous 
fumarate (Chapter 4). We cannot exclude the possibility that iron supplementation leads to 
NTBI production when supplements are not consumed with food, because the lunch meal 
consumed by majority of our participants during the 3-hour waiting period probably 
contained natural compounds (phytates) that may have limited an NTBI response.  
In chapter 5 of this thesis, we aimed to develop a field friendly tool that can be used to 
predict asymptomatic Plasmodium infection. This was motivated by the fact that most 
point-of-care dipstick tests used to detect Plasmodium infection are not able to detect 100% 
of all the infection present yet asymptomatic infections are increasingly associated with 
adverse maternal and neonatal outcomes. Although many likely predictive factors were 
assessed individually or in combination with others, we did not succeed in developing a 
reliable tool that is easy to apply in resource-poor malaria endemic settings.  
In Chapter 6, we aimed to identify factors associated with birth weight and to develop a 
methodology to predict cases of low birth weight using a single prognostic score that is 
based on prognostic variables collected at the second trimester of pregnancy. Factors that 
were found to be independently associated with reduced birth weight were being never 
married, inflammation, being a girl, and iron deficiency. Being overweight was associated 
with increased birth weight. The results indicate that we can use variables collected rapidly 
and at relatively low cost and ease to identify with fair accuracy  women in the second 
trimester of pregnancy who are at high risk of giving birth to a neonate with low birth 
weight. 
The various aspects of the work presented in this thesis including the implications for 
policy makers are discussed in chapter 7. For policy makers, the findings of this thesis are a 
welcome relief. The findings therein eliminate all doubt that has hitherto been associated 
with antenatal iron supplementation in malaria endemic areas. Most countries already have 
iron supplementation policies that are well aligned to the World Health Organisation 
policies. Efforts to widen the coverage of antenatal iron supplementation especially in 
malaria endemic regions should be urgently scaled up. However, the evidence provided in 
this thesis is only applicable to pregnant women and cannot be extrapolated to children in 
malaria endemic regions. For this population, the current WHO policy must be used thus 
before iron supplementation, children must first be screened for malaria.  
Although this thesis provides answers to key scientific questions that have hitherto baffled 
the scientific community, there are still research questions that can be clarified further. The 
effects of a high iron dose in pregnancy (as per national and international guidelines, the 
daily supplementation dose for pregnant women should be doubled to 120 mg iron if they 
are anaemic or if 6 months duration cannot be achieved in pregnancy (Chapter 2)) on 
maternal and neonatal outcomes need to be elucidated. Further research is needed in order 
to describe fully, the NTBI response to consumption different types and amounts of oral 
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iron supplements. There is urgent need for diagnostic tools that can be used in resource-
poor settings to diagnose asymptomatic infections. Further research in children is needed to 
provide evidence of the safety and efficacy of iron supplementation in malaria endemic 
regions and to assess the diagnostic performance of zinc protoporphyrin in children. In 
addition, since our studies suggest that screening based on Hb concentration as now 
practiced in many countries, is inaccurate in discriminating between women at high and 
low risk of delivering neonates with low birth weight, further studies are needed to identify 
appropriate markers and cut-off points that are suited to this purpose. 
In conclusion, this thesis has shown that there is no evidence that antenatal iron 
supplementation increases Plasmodium infection. Antenatal iron supplementation leads to 
large improvements in birth weight, fetal growth and infant iron stores, with potentially 
immense benefits for infant survival and health that should outweigh any possible concerns 
about risks of malaria. Epidemiological calculations indicate that if our results are applied 
to all women in developing countries in order to eliminate iron deficiency, we could avoid 
3 million births with low birth weight annually and save the lives of more than half a 
million neonates. Scaling up universal iron supplementation in pregnancy in developing 
countries will generate major public health gains. 
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Samenvatting	
 
Sinds de Britse arts Ronald Ross in 1902 de Nobelprijs voor de geneeskunde ontving  voor 
zijn werk over malaria, zijn er meer mensen overleden aan deze ziekte dan in alle 
wereldoorlogen samen, ook al maakten de Franse chemici Pierre Joseph Pelletier en Joseph 
Bienaime Caventou in 1820 kinine beschikbaar. Volgens de Wereldgezondheidsorganisatie 
(WHO), waren er in 2010 ongeveer 219 miljoen gevallen van malaria en naar schatting 
660.000 doden, waarvan de meerderheid (80% van de malaria-gevallen en 90% van de 
sterfgevallen) in Afrika. 
Bijna twee miljard mensen wereldwijd, en 42% van de zwangere vrouwen, lijden aan 
bloedarmoede. IJzersupplementen worden gebruikt om bloedarmoede te voorkomen. Een 
hoge dosering ijzer verhoogt echter mogelijk ook het aantal malaria-gevallen. De twijfel over 
de veiligheid van ijzersuppletie in malaria-endemische gebieden kwam voort uit de resultaten 
van een gerandomiseerde gecontroleerde studie naar de effecten van ijzer en foliumzuur 
suppletie bij 32.155 kinderen in Pemba, Tanzania. Uit deze studie bleek dat kinderen die 
supplementen met ijzer en foliumzuur kregen, meer kans hadden om te sterven of in het 
ziekenhuis terecht te komen. Daarnaast is het bekend dat malaria bloedarmoede verergert; dit 
is een bijna onvermijdelijk gevolg van een infectie met malaria. De veiligheid van het 
dagelijks gebruik van ijzersupplementen door zwangere vrouwen als 
volksgezondheidsinterventie is nog steeds niet duidelijk vastgesteld; althans niet voor de 
publicatie van onze bevindingen . 
Dit proefschrift onderzoekt de effecten van ijzersuppletie op veiligheids- indicatoren en op 
ijzerstatus bij zwangere vrouwen en hun pasgeborenen. Meerdere voorstudies zijn 
uitgevoerd, zoals een volkstelling in het studiegebied en een pilot-studie naar de 
operationalisering van de onderzoeksprotocollen. De hoofdstudie werd ontworpen met de 
hypothese dat de consumptie van met ijzer verrijkte voedingsmiddelen in combinatie met de 
inname van ijzersupplementen tijdens de zwangerschap, nadelig voor de gezondheid van 
zwangere vrouwen en hun pasgeborenen zou zijn. 
De doelstellingen van het onderzoek waren: 1) het vergelijken van de aanwezigheid van 
malaria-infectie ten tijde van de bevalling bij vrouwen die een combinatie van ijzer-verrijkte 
voedingsmiddelen en ijzersupplementen kregen ten opzichte van vrouwen die alleen ijzer-
verrijkte voedingsmiddelen kregen; 2) het bepalen van het effect van de interventie op de 
prevalentie van ijzergebreksanemie bij moeders, 1 maand na de geboorte; 3) het bepalen van 
het effect van de interventie op de ijzervoorraad van 1 maand oude babies; 4) het bepalen van 
de bruikbaarheid van zinkprotoporfyrine (ZPP) bij de diagnose van ijzergebrek in malaria-
endemische gebieden; 5) het identificeren van factoren die prognostisch zijn voor de reactie 
van non transferrin-bound iron (NTBI) op inname van één enkel ijzersupplement; 6) het 
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vaststellen van factoren die voorspellend zijn voor Plasmodium-infectie tijdens de 
zwangerschap; 7) het identificeren van factoren die geassocieerd zijn met geboortegewicht; 
8) het ontwikkelen van een methodologie om gevallen van laag geboortegewicht te 
voorspellen, met behulp van één enkele score die is gebaseerd op prognostische variabelen 
die verzameld zijn tijdens het tweede trimester van de zwangerschap; en 9) het ontwikkelen 
van methoden voor een verrijking van meel met ijzer op dorpsniveau. 
De meeste landen hebben wettelijk vastgelegd dat meel moet worden verrijkt met ijzer, of 
zijn in het proces om dit te doen. Zwangere vrouwen kunnen hierdoor ijzer binnen krijgen via 
verrijkte voedingsmiddelen, maar ook via ijzersuppletieprogramma’s. Dit proefschrift geeft 
antwoorden op dringende vragen over de veiligheid en werkzaamheid van ijzersuppletie 
tijdens de zwangerschap door het vergelijken van een hoge dosis ijzer (d.w.z. ijzer-verrijkte 
voedingsmiddelen plus ijzersupplementen) versus een lage dosis ijzer (d.w.z. alleen ijzer-
verrijkte voedingsmiddelen). De belangrijkste uitkomst was de aanwezigheid van 
Plasmodium-infectie bij de moeder ten tijde van de bevalling, ongeacht de soort. Hoofdstuk 1 
is een gedetailleerde inleiding over de achtergrond en het ontwerp van de studie . 
Dit proefschrift biedt concrete aanwijzingen dat ijzersuppletie bij zwangere vrouwen in een 
malaria-endemisch gebied niet leidt tot een verhoogd risico op malaria infectie 
(risicoverschil, 95% CI: 0.0%, ─9.3% tot 9.3%). Beleidsuitvoerders en overheden in malaria-
endemische gebieden moeten zich niet laten tegenhouden door eerdere waarschuwingen 
tegen ijzersuppletie van zwangere vrouwen. Onze bevindingen in ogenschouw nemend, is het 
niet nodig om eerst te screenen op malaria alvorens ijzersupplementen te geven. 
IJzersuppletie had belangrijke voordelen voor moeders en hun pasgeborenen (hoofdstuk 2). 
De in dit proefschrift beschreven bevindingen lieten een gemiddelde toename zien in 
geboortegewicht van 143 g ten opzichte van de groep die een lage dosis ijzer ontving. De 
grootte van het effect van ijzer werd beïnvloed door de ijzerstatus bij aanvang van de 
interventie. Bij vrouwen met ijzergebrek, leidde ijzer tot een verhoging van het 
geboortegewicht met 249 g, ondanks een mogelijke toename in malariainfectie met 10% in 
deze groep. Er waren geen aanwijzingen dat de effecten van ijzer op geboortegewicht werden 
beïnvloed door intermittent preventive treatment van malaria. IJzersuppletie verhoogde de 
groei van de foetus met 0.27 SD (95% CI: 0.04 0.50), waarschijnlijk als gevolg van een 
toename in zowel relatieve lengte als relatief gewicht ten opzichte van de leeftijd van de 
foetus. 
We toonden ook aan dat ijzersuppletie leidde tot verhoogde neonatale ijzervoorraden één 
maand na de bevalling, zoals aangeduid door een verhoging van 17.1% (95% CI: 2.0% tot 
34.3%) in de plasmaconcentratie van ferritine bij pasgeborenen van moeders die een hoge 
dosis ijzer kregen, vergeleken met degenen waarvan de moeders een lage dosis ijzer kregen. 
Dit zou een extra impuls moeten vormen om zwangere vrouwen ijzersupplementen te geven, 
met als doel het verhogen van de ijzervoorraden van de baby (hoofdstuk 2). 
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ZPP bleek onbetrouwbaar in het onderscheiden van zwangere vrouwen met en zonder 
ijzertekort in gebieden waar chronische ziekten voorkomen (hoofdstuk 3). Het gebruik van 
huidige afkapwaarden van bloedwaarden voor ZPP, namelijk > 70 μmol/mol heem, kan 
leiden tot grove overschatting van de prevalentie van ijzertekort, vooral als de werkelijke 
prevalentie laag is. 
Het is aangenomen dat het voorkomen van non-transferrin bound iron (NTBI) in de 
bloedsomloop na orale inname van ijzersupplementen de groei en vermenigvuldiging van 
Plasmodium-parasieten stimuleerden, hetgeen zou leiden tot een verhoogde morbiditeit en 
mortaliteit door malaria. Wij vonden geen toename van NTBI-concentraties drie uur na orale 
inname van 60 mg ferrofumaraat (hoofdstuk 4). We kunnen niet uitsluiten dat ijzersuppletie 
leidt tot productie van NTBI wanneer supplementen worden ingenomen zonder voedsel, 
omdat de lunch, die door de meerderheid van onze deelnemers tijdens de 3 uur wachttijd 
werd geconsumeerd, waarschijnlijk natuurlijke verbindingen (fytaten) bevatte, die mogelijk 
een NTBI-respons hebben beperkt. 
In hoofdstuk 5 van dit proefschrift, hebben we geprobeerd om een praktisch instrument te 
ontwikkelen dat in het veld kan worden gebruikt om een asymptomatische Plasmodium 
infectie te voorspellen. Onze motivatie hierbij was dat de meeste dipstick-testen die worden 
gebruikt om Plasmodium-infectie op te sporen, niet in staat zijn om 100% van alle aanwezige 
infecties te detecteren, terwijl asymptomatische infecties steeds vaker worden geassocieerd 
met nadelige gevolgen voor zowel moeder als kind. Hoewel veel mogelijk voorspellende 
factoren werden beoordeeld, zowel afzonderlijk als in combinatie, zijn we niet geslaagd in 
het ontwikkelen van een betrouwbare methode die gemakkelijk te gebruiken is in een 
omgeving waar malaria voorkomt en waar weinig hulpmiddelen beschikbaar zijn. 
In hoofdstuk 6 hebben we ons gericht op het identificeren van factoren die geassocieerd zijn 
met geboortegewicht, en met het ontwikkelen van een methodologie om gevallen van laag 
geboortegewicht te voorspellen met behulp van een prognostische score die is gebaseerd op 
verschillende variabelen verzameld tijdens het tweede trimester van de zwangerschap. De 
volgende factoren waren onafhankelijke geassocieerd met een verlaagd geboortegewicht: 
nooit getrouwd geweest, ontsteking, zwangerschap, vrouwelijk geslacht van de baby, en 
ijzertekort. Overgewicht is geassocieerd met een verhoogd geboortegewicht. De resultaten 
geven aan dat we variabelen, die snel en tegen relatief lage kosten kunnen worden verzameld, 
bruikbaar zijn om tijdens het tweede trimester van de zwangerschap vrouwen te identificeren 
met een hoog risico op de geboorte van een baby met een laag geboortegewicht. 
 
De verschillende aspecten van het werk die in dit proefschrift beschreven wordt inclusief de 
implicaties voor beleidsmakers worden bediscussieerd in hoofdstuk 7. De bevindingen van 
dit proefschrift kunnen voor beleidsmakers een opluchting zijn. Onze bevindingen nemen alle 
twijfel weg die tot op heden werd geassocieerd met prenatale ijzersuppletie in malaria 
Samenvatting	
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gebieden. De meeste landen hebben al een beleid voor ijzersuppletie dat is afgestemd op het 
beleid van de Wereldgezondheidsorganisatie. Inspanningen om het gebruik van prenatale 
ijzersuppletie te verhogen, moeten dringend worden verhoogd, vooral in malaria-endemische 
gebieden. Echter, de gegevens die in dit proefschrift worden gepresenteerd, zijn alleen van 
toepassing op zwangere vrouwen en kan niet worden geëxtrapoleerd naar kinderen in 
malaria-endemische gebieden. Voor deze populatie moet het huidige WHO-beleid worden 
gehandhaafd: alvorens tot ijzersuppletie over te gaan, moeten kinderen worden gescreend op 
ijzergebrek. 
Hoewel dit proefschrift antwoord geeft op belangrijke vragen die wetenschappers tot nu toe 
bezig hielden, zijn er nog steeds vragen die om verdere opgehelderd moeten worden. Volgens 
nationale en internationale richtlijnen moet de dagelijkse dosis voor zwangere vrouwen 
worden verdubbeld tot 120 mg ijzer als ze bloedarmoede hebben, of als het niet mogelijk is 
om gedurende 6 maanden supplementen te slikken tijdens de zwangerschap (hoofdstuk 2). 
De effecten van deze hoge ijzerdosisop maternale en neonatale uitkomsten moeten worden 
onderzocht. Verder onderzoek is nodig om de NTBI-reactie op de consumptie van 
verschillende soorten en hoeveelheden van ijzersupplementen volledig te beschrijven. Er is 
dringend behoefte aan diagnostische instrumenten die gebruikt kunnen worden in een setting 
waar weinig middelen beschikbaar zijn om asymptomatische infecties vast te stellen. Bij 
kinderen is verder onderzoek nodig om de veiligheid en werkzaamheid van 
ijzersupplementen in malaria-endemische regio’s te bepalen, en om de diagnostische 
bruikbaarheid van zinkprotoporfyrine bij kinderen te beoordelen. Omdat onze studie 
suggereert dat screening op basis van hemoglobine-gehalte, zoals nu wordt gedaan in veel 
landen, niet accuraat is voor het onderscheiden van vrouwen met een hoog en een laag risico 
op een baby met een laag geboortegewicht, zijn bovendien verdere studies nodig naar 
adequate indicatoren en afkapwaarden die geschikt zijn voor dit doel. 
Samenvattend heeft dit proefschrift aangetoond dat er geen aanwijzigingen zijn dat prenatale 
ijzersuppletie leidt tot een verhoogd risico van Plasmodium-infectie. Prenatale ijzersuppletie 
leidt daarentegen tot grote verbeteringen in geboortegewicht, groei van de foetus en de 
ijzervoorraden van de baby, met mogelijkerwijs enorme voordelen voor de gezondheid en 
overlevingskansen van de baby. Deze gegevens zouden elke mogelijke bezorgdheid over de 
risico's van malaria moeten wegnemen. Epidemiologische berekeningen geven aan dat als 
onze resultaten worden toegepast op alle vrouwen in ontwikkelingslanden om zo ijzertekort 
te elimineren, we per jaar 3 miljoen gevallen van een laag geboortegewicht kunnen 
voorkomen, en mogelijk het leven kunnen redden van ruim een half miljoen pasgeborenen. 
Opschaling van universele ijzersupplementatie tijdens de zwangerschap in 
ontwikkelingslanden zal dan ook een enorme winst opleveren voor de volksgezondheid.	
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Epilogue 
	
Effective linkages are the key to enabling a collective and sustained 
approach to addressing micronutrient malnutrition 
There is evidence that the causes of micronutrient malnutrition are multifactorial and vast in 
nature. The geographical spread of micronutrient malnutrition is mind-boggling. Like a 
spiders’ web, if the synergies of different strategies to address micronutrient malnutrition 
are harnessed, the success of interventions will be guaranteed. Different stakeholders are 
equipped with different approaches and strengths to fighting micronutrient malnutrition. 
Independently, each stakeholder can only have a minimal impact on micronutrient 
malnutrition. Stakeholders must therefore seek to utilize the synergistic advantage of their 
approaches if great results are to be realized. Similarly, because the problem of 
micronutrient malnutrition is multifactorial, the approaches to combat it must have a 
cumulative strategy that seeks to use the documented successes of different approaches in 
one carefully designed strategy. For example, provision of micronutrients can be 
streamlined with medical care, economic empowerment, and promotion of education. Food 
based interventions must be implemented alongside strategies to control infectious diseases 
such as malaria and to promote health. Collaborative projects if well managed, will realize 
the greatest impact on micronutrient malnutrition. Linkages between academia, 
governments, Non-Governmental Organizations, civil society, and humanitarian 
organizations such as the World Health Organization are bound to have positive results in 
the fight against micronutrient malnutrition. 
	
	
	
	
Affliliations,	Credits	and	Grants	obtained	
220	
The	research	presented	in	this	dissertation	was	financed	by	the	Improved	Nutrition	through	Staple	Foods	
for	 Africa	 (INSTAPA)	 project,	 which	 received	 funding	 from	 the	 European	 Union's	 Seventh	 Framework	
Programme	 (FP7/2007–2013)	 under	 grant	 agreement	 no.	 211484.	 Maseno	 University,	 Kenya,	 facilitated	
and	supported	the	research	by	granting	academic	leave	to	Martin	Ndegwa	Mwangi.	Thesis	publication	was	
partially	funded	by	the	Dr.	Judith	Zwartz	Foundation,	The	Netherlands.	Financial	support	from	Wageningen	
University	for	printing	this	thesis	is	gratefully	acknowledged.	
	
Front	cover	(and	also	back	cover):	Land	area	showing	study	area	–	South	West	Kisumu,	Kenya.	The	red	
place	 marks	 show	 the	 coordinates	 of	 the	 homes	 of	 study	 participants.	 GPS	 data	 visualized	 at	
www.GPSVisualizer.com.	Map	courtesy	of	Google	©2013.	
Bottom	left	corner	on	the	front	cover:	photo	of	Wanja	Maina,	a	pregnant	Kenyan	woman.	Use	of	photo	
permitted	by	owner.	
Bottom	middle	picture	on	the	front	cover:	ultrasound	image	of	the	fetus	of	one	of	the	study	participants.	
Use	of	photo	permitted	by	owner.	Photo	by	M.N.	Mwangi.	
Bottom	right	corner	on	the	front	cover:	photo	of	breastfeeding	baby	of	one	of	the	study	participants.	Use	
of	photo	permitted	by	owner.	The	photo	was	kindly	provided	by	Belynder	Ogone.	
Back	cover:	photo	of	the	fourteen	research	assistants	(and	one	of	the	MSc	students)	who	were	engaged	in	
daily	follow-up	of	all	study	participants.	
Cover	layout	and	graphics	design:	MN.	Mwangi	
Printed	by:	Gildeprint	Drukkerrijn,	Enschede,	The	Netherlands.	
 221	
	
